

LEUKAEMIA CARE

England & Wales · Charity number 1183890

Details

Status Registered

Legal form Charitable company

Company number [11911752](#)

Registered 2019-06-13

Register [View on the Charity Commission register](#)

Contact

Address One Birch Court
Blackpole East
Worcester
WR3 8SG

Phone 01905755977

Email communications@leukaemiacare.org.uk

Website www.leukaemiacare.org.uk

Activities

Objects: 1) THE RELIEF OF SICKNESS AND THE PROMOTION AND PROTECTION OF GOOD HEALTH AMONG PERSONS SUFFERING FROM LEUKAEMIA AND ALLIED BLOOD DISORDERS. 2) THE RELIEF OF NEED AMONG THE FAMILIES, CARERS AND FRIENDS OF PERSONS SUFFERING FROM LEUKAEMIA AND ALLIED BLOOD DISORDERS, AND IN PARTICULAR THOSE CONTEMPLATING OR SUFFERING BEREAVEMENT OR WHO MUST CONTEMPLATE THE PROSPECT OF TREATMENT WHERE THOSE NEEDS ARE ATTRIBUTABLE TO THE AFFLICTION OF LEUKAEMIA AND ALLIED BLOOD DISORDERS.

Activities: Leukaemia Care is a national blood cancer support charity. We are dedicated to ensuring that anyone affected by blood cancer receives the right information, advice and support. We provide services to patients and their families, and education and training to the healthcare professionals that look after them. We also campaign for earlier diagnosis of leukaemia and access to treatment.

Classification

- **How:** Makes Grants To Individuals, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives, Disability

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£2,821,699	£2,161,369	£3,212,118	46
2023-12-31	£2,263,249	£2,860,835	£2,573,092	54
2022-12-31	£2,139,494	£1,979,542	£3,127,406	40
2021-12-31	£1,346,169	£1,338,529	£3,032,035	31
2020-12-31	£1,185,076	£1,123,974	£2,975,178	32

Trustees

Name	Role	Appointed
Christopher Ranulph George Matthews-Maxwell	Chair	1999-02-01
Carina Patterson		2021-11-03
Dharmesh Mehta		2020-12-16
Dr Luca Sabia		2026-01-19
Dr Sarah Ann Smith		2022-02-02
Dr Suzanne Dilly		2025-06-25
Elizabeth Jane Wilson		2018-09-26
Peter Mobbs		2025-11-14
Robert Heppell		2020-12-16
Wendy Jane DAVIES		2012-10-03

LEUKAEMIA CARE

England & Wales - Charity number 1183890

Accounts

Charity Registration No. 1183890 (England and Wales)

Charity Registration No. SC049802 (Scotland)

Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

Leukaemia Care
YOUR Blood Cancer Charity

www.leukaemicare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons	Lady Penny Mountbatten Beverley Warboys
Trustees	Mr Christopher R. G. Matthews Maxwell (Chair) Mrs W J Davies (Treasurer) Mrs Elizabeth Wilson (Vice Chair) Mr Robert Heppell Mr Dharmesh Mehta Ms Carina Patterson Dr Sarah Searle
President	Dr Richard Taylor (died 26 June 2024)
Vice Presidents	Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin
Senior Management Team	
Chief Executive Officer	Colin Dyer (appointed 2 April 2024)
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Director of Patient Services	Jo Peplow (appointed 1 October 2024)
Director of Engagement	Nicole Scully (appointed 30 September 2024)
Medical Advisory Panels	As described in the Trustees' Report
Secretary	Monica Izmajlowicz
Charity number (England and Wales)	1183890
Charity number (Scotland)	SC049802
Company number	11911752
Website	www.leukaemiacare.org.uk
Registered office	One Birch Court Blackpole East Worcester WR3 8SG

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Auditor

Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Bankers

Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ

Solicitors

Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG

Investment advisors

Titan Wealth Management Limited
2 Greengate
Cardale Park
Harrogate
HG3 1GY

CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET

Brewin Dolphin
12 Smithfield Street
London
EC1A 9BD

LEUKAEMIA CARE

CONTENTS

	Page
Trustees' report	1 - 18
Statement of Trustees' responsibilities	19
Independent auditor's report	20 - 22
Statement of financial activities	23 - 24
Balance sheet	25
Statement of cash flows	26
Notes to the financial statements	27 - 45

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees present their annual report and financial statements for the year ended 31 December 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

About us

Leukaemia Care is dedicated to ensuring that everyone affected by leukaemia receives the best possible diagnosis, information, advice, treatment and support. We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Purpose

The charity's objects are set out in its Articles of Association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders.
2. The relief of need among families, carer's and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long-term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

Why our work is important

- Leukaemia is the 12th most common form of cancer and 12th biggest cancer killer.
- Every year, 10,000 people are diagnosed with leukaemia in the UK.
- Every year, 5,000 people die from leukaemia in the UK.
- Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
- Over 50,000 people are living with leukaemia in the UK.
- There are 34,000 people living with MDS or MPN in the UK.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Our Strategic Goals

Our organisational strategy sets five clear goals for our work:

1. Improving diagnosis – through awareness and early detection.
2. Ensuring everyone receives high quality information, advice and support.
3. Tackling issues that impact people's lives.
4. Advancing treatment and care.
5. Creating a narrative to better reflect the reality people experience.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Leukaemia Care provides public benefit as a charity through all the charitable information, advice and support service areas detailed above. The Trustees have complied with their duty in accordance with the Charities Act 2011 to have due regard to the Charity Commission's guidance when reviewing the charity's aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission's guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met.

As examples, our work delivers public benefit by providing information, advice and direct support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our HashtagSpot Leukaemia campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment.

Achievements and performance

Executive summary

Demand for Leukaemia Care's information and support services grew across most areas in 2024 – as shown by the Charitable Programmes Summary below – while the generosity of our supporters allowed us to exceed expectations in raising funds and, therefore, work to meet that demand and plan further ahead.

In January 2024, the charity underwent restructuring across all teams and paused or consolidated some activities pending a more in-depth review.

This allowed us to focus on our core offerings which we identified as our nurse-led advice service (Helpline, WhatsApp and email), welfare and financial support (including grants), counselling, peer-to-peer support through our support groups, Facebook groups and buddy service, advocacy on behalf of individuals, PIF Tick accredited patient information, our hospital Navigator programme, and our SpotLeukaemia campaign.

We recognised that we were not able to deliver high-quality work in such a broad way, so we either paused or consolidated programmes which included videos, webinars, podcasts, some healthcare professional education and nurse bursaries. All in-person support groups, bar those linked to a hospital hub, ceased or continued to be run by other parties with us focusing on disease specific online support groups.

Colin Dyer joined as our new CEO in April, and the charity now has an adapted organisational structure focused on delivery in our key areas of work, the resilience of the organisation, and building the resource to allow Leukaemia Care to secure the funds needed to rise to the challenge of the increases we are seeing in demand for our core services.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Charitable Programmes Summary

A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care's charitable services during the year were consistent with those goals set out in our The Future We Will Create Together strategy (published in 2022 and available at www.leukaemiacare.org.uk). Examples of the allocation of those funds and the continuing increase in demand for our patient services include:

- Demand for our Welfare Service grew by 20 per cent in 2024, with 1,068 people supported. This includes our own financial grants along with expert assistance for applications for PiP, Attendance Allowance, Employment and Support Allowance, and other key information. 118 people were also supported by our Advocacy Service with issues such as employment rights, insurance, and second opinions.
- The charity's Helpline answered 1,315 calls with more than 100,000 minutes spent giving personalised support and guidance. More than 700 WhatsApp messages were also responded to.
- Leukaemia Care continued to develop its PIF (Patient Information Forum) accredited information in 2024, publishing 36 new or revised information resources, receiving more than 10,000 orders of our printed information booklets, and more than 24,000 webpage views of our online information resources.
- Eight new Leukaemia Care Hospital Hubs were launched during the year, each hosting one of the charity's Navigators. Our Navigator team supported 675 people (583 in 2023) with 1,039 in-person appointments and 483 calls.
- Peer-to-peer support remained a crucial element of our work. Across 26 Support Groups, we held 104 meetings supporting 810 people. Alongside that, 92 new patients or carers were paired with a buddy for support, with 11 new buddies trained.
- 2.76 million people engaged with our SpotLeukaemia campaign through social media, our campaign videos were watched almost 500,000 times, and the project received 4.79 million views through our digital advertising.

Financial summary

- The total income raised during the year was £2,821,699 (£2,112,349 in 2023) with a total expenditure of £2,161,369 (£2,710,249 in 2023).
- 60.2 per cent of the charity's expenditure was allocated to our charitable services and projects in 2024.
- £911,946 of the charity's income during the year came from legacy donations – including one large legacy of £676,100.
- The cost of raising funds during the year was £231,937 lower than in the previous year.
- The charity's total assets at the end of 2024 stood at £3,212,118. This includes £223,549 of restricted funds, £1,274,302 of designated funds, and £1,714,267 of general unrestricted funds (reserves). This is consistent with the charity's Reserves Policy as shown on page 12.

Strategic update for 2024 including our plans for 2025

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our organisational strategy focuses on five clear goals for our work. This report sets out Leukaemia Care's achievements in each of these priority areas during 2024, along with the charity's goals for the year ahead.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Goal 1: Improving diagnosis – through awareness and early detection

We achieve this through our SpotLeukaemia campaign work, targeting awareness days such as World Leukemia Day, our work to influence policy affecting those diagnosed with leukaemia at national and local level, and through our education work with GPs and other healthcare professionals.

In 2024 we continued our collaboration with Leukaemia UK on the SpotLeukaemia campaign, focusing on raising awareness of the symptoms of leukaemia and the causes of delayed diagnosis. 2.76 million people engaged with our campaign online through social media, we received 4.79 million views via our digital advertising, and our campaign videos were watched almost 500,000 times. 47 pieces of press coverage helped to spread the message, and we generated 82% campaign recall.

In 2025 we will look to expand the SpotLeukaemia campaign beyond its traditional home in September's Blood Cancer Awareness Month, focus on how we can change individual's behaviour when they suspect they might have symptoms, and encourage them to see their GP. We will also look at innovative ways to advertise the campaign's message beyond press and social media.

Through our policy work, we continue to explore the role of community pharmacists in earlier diagnosis efforts. In Scotland, we met with the team behind the North Cancer Alliance's lung cancer pharmacist referral pilot scheme to learn more about the trial and what resources would be needed from us to run a similar one in leukaemia. We were informed that there are plans for a second referral pilot scheme and have been asked if we would like to collaborate with the team through offering funding, general support, and other resources. We have also secured a meeting with the Scottish Health Minister alongside Leukaemia UK and aim to raise our concerns over GP recruitment and phlebotomy service capability – and the Royal College of GPs confirmed that they are willing to support our policy call for increased investment in those areas.

In 2025 we intend to increase the number of organisations with influence into the NHS that support our early diagnosis policy goals, and work to have better input into national and local health plans.

More than 400 GPs took our acute and chronic leukaemia training in 2024 in association with NHS-funded resource Gateway C and the Royal College of GPs – with more than 90 per cent of those taking the training agreeing that their clinical decision-making changed after completing the courses. We also partnered with the National Association of Sessional GPs to deliver a webinar for GP locums which was a new audience for the charity. In 2025, we will look to assess our role in GP training and awareness and ensure we have input into the best platforms and communication to achieve this.

Goal 2: Ensuring everyone receives high quality information, advice and support

High quality information, advice and support is key for people diagnosed and living with leukaemia, and those around them. This area of work covers our core direct services for patients and their carers and families including our written information (hard copy and online), advice service (incorporating the Helpline, WhatsApp, and email), advocacy casework and welfare advice, Navigators in our Hospital Hubs, support groups and forums, one-to-one buddy support, financial grants, and counselling.

Leukaemia Care continues to provide PIF (Patient Information Forum) Tick accredited information for patients and their families and, to maintain quality and meet demand, we recruited two new Patient Information Writers during the year. We published 36 new or revised information resources in 2024 – and had more than 10,000 orders of our printed information booklets and more than 24,000 webpage views of our online leukaemia information resources. In total, 93% of people responding to our pop-up survey rated our information as helpful. In 2025, we will continue to develop materials to both update existing information and develop new resources where demand exists, while also working to improve our delivery of information using the advancing technology now available and for those harder to reach patients where, for example, language may be a barrier.

Alongside our information, we offer the opportunity to seek advice and support directly from our Clinical Nurse Specialists, trained advocates, and welfare advisors.

In 2024, we added a second Nurse to our Helpline team, and answered 1,315 calls to that service with more than 100,000 minutes spent giving personalised support, information and an essential listening ear. 700 WhatsApp messages were responded to. This essential service will continue to be developed in 2025, with demand forecast to increase as some of the charity's other outreach areas grow.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Demand for our Welfare Service grew by 20 per cent in 2024 with 1,068 people supported with financial grants along with applications for blue badges, PIP, Attendance Allowance, Employment and Support Allowance, housing support and information. We provided more than £105,000 in small financial grants from our cost-of-living fund and, in 2025, we will also look to add a small number of exceptional hardship grants for those people who are unable to access any support from elsewhere.

"I got an email from Lisa from Leukaemia Care who was very professional and friendly. At the time I felt like I couldn't talk to anyone in my life as no one was helping, and I was just locking all of my friends and family out. Lisa was the only one person that helped me and got me back on the right path. She helped me fill out forms and get disability benefits that I had applied for previously and got turned away. She was the only one that said "your lifestyle isn't what it should be and we will get you back on your feet".

Also, 118 (204 in 2023) people have been supported by the Advocacy Officer, with the most popular topics being employment rights, accessing travel insurance and second opinions. Employment queries made up more than one-fifth of all enquiries with an increase in patients seeking support due to issues with their employers, mainly coming from chronic patients who want to understand their rights at work and explore what they are entitled to, including reasonable adjustments and discrimination. In 2025 we will enable the Welfare and Advocacy teams to have more focus by adding further resource to the team focused on counselling (see below) and investigating the better use of technology to improve the speed of casework.

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2024, we supported 84 people (63 in 2023) with more than 500 counselling sessions to support with issues such as bereavement, coping with a diagnosis either as a patient, parent or child, coping with chronic leukaemia, and managing anxiety following a relapse.

The growth of the Leukaemia Care Navigator team working directly with patients in our Hospital Hubs around the UK was a priority in 2024, and will continue to be so in 2025. During the year, we secured agreements for 12 new hospital hubs, eight of which became operational during the year. The remaining four will become operational in 2025.

Our 21 hospital hubs can be found in Derriford Hospital Plymouth, Royal Gwent Hospital, Freeman Hospital Newcastle, Bournemouth Hospital, Southampton General – acute clinic and CLL clinic, Royal Sussex Hospital (Brighton), Nottingham Hospital, Great Western Hospital (Swindon), Belfast Hospital, Antrim Hospital, Beatson Hospital (Glasgow), Queen Elizabeth Hospital (Glasgow), Victoria Hospital (Glasgow), Solihull Hospital (West Midlands), Heartlands Hospital (Birmingham), St James Hospital (Leeds), University of Bristol Hospital, The Christie (Manchester), University College London Hospital, and Norfolk and Norwich Hospital.

Our Navigators provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2024, we supported 675 people (583 in 2023), with 1,039 in person appointments and 483 calls. The navigators also made 850 referrals to the charity's services.

In 2025 we will also carry out a detailed piece of research into the impact of, and demand for, the Navigator service to help inform next steps with this programme.

Peer-to-peer support remains a crucial element of the charity's portfolio of support. Across 26 groups covering different leukaemias and myeloproliferative neoplasms, we held 104 support group meetings during the year, supporting 810 people. Alongside that, 92 new patients or carers have been paired with a buddy for support, with 11 new buddies trained. Development plans for both programmes will be created in 2025.

"I can't tell you how comforting (and a relief) to talk to someone who understands exactly what having this illness means! My buddy was so lovely and very chatty which made our chat so easy. What a brilliant idea, so thank-you so much."

In addition, our CAR-T Away From Home service – supported through our much-valued partnership with the Dalata Hotels Group – provided vital help for 20 families through grants and hotel stays. This service provides patients undergoing CAR-T treatment and their families access to paid hotel rooms and a £500 grant towards increased costs.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Most of the families who apply for the service have been told about it by their CAR-T clinical nurse specialist (CNS), highlighting the importance of sharing what we do with healthcare teams so that they can continue to refer new patients into the service. In 2025, we plan to work with more clinical teams to increase the awareness of this service and, therefore, generate more referrals – especially as we are the only charity offering this specific type of support (hotels and grants) to leukaemia patients undergoing CAR-T therapy.

Goal 3: Tackling issues that impact people's lives

Ensuring that Leukaemia Care is able to understand the issues facing people with leukaemia and those caring for them (both personally and professionally) is essential to our work, allowing us to push where appropriate for improvements in care and support.

In 2024, we were successful in making a switch from MPs and Government as our main targets to influence stakeholders who deal with patient issues day-to-day at a more local level. In 2025 we will continue this and work to deepen our relationship with Cancer Alliances and local NHS bodies.

The charity continues to examine the best way for the holistic care experience of leukaemia care patients to be improved, and for there to be an accepted 'standard of care' for those patients across the UK. Work in 2024 has led to the creation of a working group within our Nurse Advisory Group to take on this project, and meetings are planned with the UK Oncology Nursing Society (we were present at their conference in 2024) and the UK Acute Oncology Society among others in 2025 with the aim of publishing a draft Standards of Care document.

In addition, we have collaborated with other charities in 2024 to raise the issue of the financial impact of a leukaemia diagnosis, and will continue to develop this work in 2025 including the problem of Sick Pay for patients.

In Scotland, we are continuing to work with other charity colleagues through the Scottish Cancer Coalition Early Diagnosis Group and the Blood Cancer Alliance on the issue of data availability in the country, and have met with the Scottish Government's Centre for Sustainable Delivery to discuss issues around new measures of early diagnosis for blood cancers.

The importance of completing high-quality research to support our work and inform our strategy was also underlined in 2024, and a detailed piece of work on the impact of, and demand for, our Navigator programme will be completed early in 2025. This project has included input from students at the University of Oxford, and will be continued across other Leukaemia Care programmes in the coming year.

Goal 4: Advancing treatment and care

The charity has continued to bring health professionals together to help inform best practice for Leukaemia Care patients, and to engage those professionals in our work to ensure we are providing care and support in the best possible way.

127 medical professionals volunteered their time during the year (116 in 2023) – joining Support Group meetings, and working with our Information Team on new or updated resources, for example. Also, our Nurse Forums continued during the year with 82 health professionals attending (126 in 2023). In 2025 we will consult with those professionals close to us to ensure that we are engaging with them in the most productive way, and to identify other areas of our work where additional input from volunteer health professionals would benefit our services.

The charity's work to ensure the best access to treatment for patients also includes our involvement in relevant Health Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. We supported 10 of these in 2024.

This includes collaborative projects – for example our work with Leukaemia UK and Anthony Nolan on a new type of CAR-T treatment being appraised by NICE (National Institute for Health and Care Excellence).

We will continue to assess our role in both appraisals and in contributing to medical policy changes in 2025.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Goal 5: Creating a narrative to better reflect the reality people face

Communicating with people through our own communication, traditional or social media is essential in reaching those people that need us, those that fund us, and in increasing the wider understanding of the reality of living with leukaemia.

An average increase of 11 per cent in the reach of our own magazine and newsletter was achieved in 2024, with around 10 per cent more people opening our monthly online newsletter when compared to the previous year.

We increased our reach across all social media platforms, and saw our videos viewed more than 667,000 times (578,000 in 2023). This was helped by a successful SpotLeukaemia campaign backed by celebrity TV Doctor Amir Khan whose posts received more than 200,000 views.

We also secured more than 100 pieces of press coverage and were able to place the issues of a leukaemia diagnosis into millions of homes around the country thanks to a partnership with the ITV tv show Emmerdale which saw our Helpline lead Nurse work with the ITV scriptwriters on a leukaemia-related storyline which ran for many weeks in the Spring and Summer.

Our website saw a reduction in the number of sessions in 2024 – but the time spent by each person on our site increased by more than 20 per cent as we worked to improve the quality of our information and navigation.

In 2025, two pieces of work will begin with a view to increasing our reach – a consultation on the effectiveness of the Leukaemia Care brand and messaging, and a project to examine the better use of technology including our website's accessibility, its use for delivery of information across different platforms and devices, and planning for technological advances including AI.

Fundraising summary

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and, therefore, agrees that when fundraising we will do so in accordance with the Fundraising Promise and the Code of Fundraising Practice as it applies to our fundraising methods. We agree to promote the Fundraising Promise (<https://www.fundraisingregulator.org.uk/>) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2024, the charity received no suppression requests through the Fundraising Preference Service and no fundraising complaints.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

2024 was a year of over-achievement in terms of funds raised by the charity. A total income of £2,821,699 was secured – almost £750,000 ahead of the year's target budget and more than £700,000 higher than in the previous year.

Much of that increase was due to the generosity of some supporters in leaving legacy donations to the charity – totaling £911,946.

With 257 runners taking part in the London Marathon for Leukaemia Care, we were able to raise £776,000 from that event, and other challenge event participants added a further £250,000 (approx.) to our funds.

Once again we were incredibly grateful to the staff and customers at the Dalata Hotels Group. Their support saw that partnership raise more than £70,000 for our work, and in 2025 we aim to build an even closer relationship with the company through the addition of a dedicated account manager.

Fundraising support came in all shapes and sizes for the charity during the year, and donations from individuals, community groups, and those remembering close ones affected by leukaemia raised more than £300,000 – exceeding expectations as we worked to improve our messaging and outreach.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

That was helped by the airing of our BBC Lifeline appeal, hosted by Arlene Phillips early in 2024, giving the charity two, nine-minute slots on BBC Television and featuring a number of patient stories and the positive impact Leukaemia Care has had on their lives.

With no major event taking place in 2024, and a re-structure of the fundraising team, costs in this area were reduced by around 20 per cent during the year.

Pharmaceutical grants

Leukaemia Care collaborates with the pharmaceutical industry to ensure that the interests of patients are considered during the development of new drugs and treatments. Our patient advisory work plays an important role in making sure treatments are thoroughly appraised and person-centred before they are made available to the public. As a way of helping us remain secure and to continue to be effective in our work with patients, many pharmaceutical companies provide us with funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care's own Code of Practice (see our website).

To ensure that we remain financially independent, limits are placed on all types of grant income. We do not allow the level of funding received from the pharmaceutical industry to exceed 25% of our total annual income, nor do we allow the funding received from any individual company to exceed 10% of our total annual income.

In 2024 we were grateful for the following support from pharmaceutical companies which totaled £167,764. Please note, this is funding that was received in 2024 – any funding that was intended for 2024 but not received until 2025 will be acknowledged in the annual report and accounts for 2025.

- Abbvie - £20,000 towards patient information
- Amgen - £6,000 towards AML videos
- Amgen - £1,000
- Astellas - £5,000 towards Spot Leukaemia work
- AstraZeneca UK - £15,000 towards hospital hubs
- Beigene - £45,764 towards side effects helpline
- Bristol Myers Squibb – £10,000 towards core funding
- Gilead - £20,000
- Janssen - £5,000 towards core services such as helpline
- Elly Lily - £10,000 towards Blood Cancer Awareness Month
- Takeda Pharmaceuticals - £30,000 towards core funding

Grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders who kindly pledged their support in 2024. Please note, this is grant funding that was received in 2024 – any funding that was pledged for 2024 but not received until 2025 will be acknowledged in the annual report and accounts for 2025.

- Alice Ellen Cooper-Dean Charitable Foundation
- Barbour Foundation
- Chalk Cliff Trust
- Charles and Elsie Sykes Trust
- Childwick Trust
- Ceramex Ltd
- Edgar E Lawley Foundation
- Esme Mitchell Trust
- E H Smith Charitable Trust
- Florence Trust
- Frazer Trust
- Fullagar Charitable Trust
- G J W Turner Trust
- Hodge Foundation

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

- Ian Askew Charitable Trust
- Jesse Spencer Trust
- John James Bristol Foundation
- Johnson Charitable Trust
- James T Howatt Charitable Trust
- Kilpatrick Fraser Charitable Trust
- Leukaemia and Lymphoma Northern Ireland
- Leukaemia UK
- Manson Family Charitable Trust
- Mills and Reeve Charitable Trust
- Mediacash Foundation
- Marsh Charitable Trust
- National Lottery (2 separate grants)
- Paul Bassham Charitable Trust
- Pennycress Trust
- Rothley Trust
- Simon Gibson Charitable Trust
- Strangward Trust
- Sovereign Health Care Charitable Trust
- Santa Barbara Heights Charitable Trust
- Sir Robert Gooch Charitable Trust
- Sir John Eastwood Foundation
- Templeton Goodwill Trust
- Thistledown Trust
- The Access Foundation
- The 29 May 1961
- The Cumber Family Charitable Trust
- The George Family Foundation
- The Eveson Charitable Trust
- The Lawson Trust CIO
- The Burford Trust
- The Patrick Trust
- The Geoffrey Watling Charity
- William Allen Young Charitable Trust
- W E Dunn Trust

Grant making by Leukaemia Care

Leukaemia Care has three grant making streams: the Cost of Living with Leukaemia Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service. These contribute to addressing the recommendations made in our Living with Leukaemia reports which inform our strategic aims.

• Cost of Living with Leukaemia Fund

This fund provides grants of up to £175 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

- **The Leukaemia Counselling Fund**

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £420. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

- **CAR-T Away from Home Service**

CAR-T (Chimeric Antigen Receptor) cell therapy is a type of treatment for leukaemia that has revolutionised the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future. The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment.

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first-come first-served basis until the fund is depleted.

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care, and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel.

We will also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc.

Volunteers

Our volunteers play a crucial role in ensuring that we provide essential support to individuals affected by leukaemia, MDS, or an MPN. Some volunteers offer direct support to patients and carers, while others contribute by advising on our information resources or assisting with fundraising efforts. Each volunteer brings unique experience and value, whether they are a patient, clinician, carer, or supporter.

In 2024, we developed and refined our volunteering programs, enhancing training, support, and engagement opportunities to create a more effective and rewarding experience for our volunteers.

- **Buddies Scheme**

The Buddy Scheme remains one of our most significant volunteer-led programs, providing one-on-one support to patients and carers from trained volunteers who have first-hand experience with a leukaemia, MPN, or MDS diagnosis. In 2024, we implemented several key changes:

- The scheme was overhauled, transitioning to a 12-week support model with an optional 12-week extension. This change has increased capacity and improved the safety and effectiveness of the program for both volunteers and beneficiaries.
- A new, custom-made buddy volunteer training program was introduced via our eLearning system (provided by the Charity Learning Consortium). This comprehensive training covers active listening, safeguarding, signposting, mental health awareness, and suicide awareness.
- A recruitment drive toward the end of 2024 resulted in 11 new buddies completing training, with several more set to finish in early 2025. Our goal for 2025 is to train an additional 40 buddies to meet growing demand.
- The management of the scheme was transitioned from spreadsheets to project management software Asana. By doing this we have improved efficiency and coordination. Asana allows for better task assignment, real-time progress tracking, and streamlined communication, making it easier to manage volunteers, track patient interactions, and ensure smooth program operations.
- In 2024, volunteers provided support to 90 new patients and carers—almost three times the number assisted in the previous year.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

• **Advisory Panel**

In 2024, our Patient Advisory Panel was restructured to become a more inclusive "Advisory Panel," welcoming not only patients but also family members, carers, and those who have lost loved ones to leukaemia. Additional improvements included:

- Implementing a focus group system, where groups of up to 12 volunteers met throughout the year to provide feedback on topics such as patient information, volunteering roles, campaigns, legacies, wills, and our website.
- Creating an Asana project to manage and coordinate the panel's activities efficiently.
- While membership remained stable, a few new members joined as some original members left. Active recruitment will resume in 2025 as the panel settles into its revised format.

• **Patient Information Reviewers**

Patient and carer volunteers played a key role in updating and improving our information resources in 2024. Notable contributions included:

- 34 volunteers participated, with at least 10 being new to volunteering with our charity.
- A total of 32 individual patient information resources were revised or newly published with the assistance of volunteer reviewers. These included booklets, website information, an animation, factsheets and leaflets.

•

• **Facebook Support Group Moderators**

Our Facebook support groups continued to be a valuable resource for patients and carers. However, the number of volunteers moderating these groups declined to five in 2024. Despite this, the remaining volunteers provided crucial support by answering questions and signposting individuals to Leukaemia Care services when needed. Looking ahead to 2025:

- The Patient Engagement Officer will begin overseeing the groups to enhance engagement.
- A recruitment and training initiative will be launched to attract new moderators and raise the profile of these groups.

• **Medical Advisory Panel**

The Medical Advisory Panel continued to play a vital role in 2024, ensuring that healthcare professionals remain actively involved in our work. Key activities included:

- Five panel meetings took place, with two sessions dedicated to nurses, two to haematology specialists, and one to GPs.
- Healthcare professionals also contributed as speakers and facilitators for our support groups.

Looking Ahead to 2025

As we move into 2025, our focus will be on expanding volunteer engagement, improving training and support systems, and ensuring that our programs continue to meet the needs of patients and carers. Key priorities include:

- Training 40 new buddies to enhance the capacity of the Buddy Scheme.
- Expanding the Advisory Panel's membership and optimizing its focus group system.
- Recruiting and training additional Facebook support group moderators.
- Continuing to integrate volunteers into the development of patient information resources.
- Reviewing and restructuring our Medical Advisory Panels using a similar approach to the one taken for our patient and carer panel.

We are incredibly grateful to all our volunteers for their dedication and commitment, and we look forward to building on these successes in the coming year.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Risk assessment and management

The Board of Trustees approved an updated Risk Register during the year as part of its on-going work to ensure compliance with the Charity Governance Code. That Risk Register is a standing item on Board meeting agendas, and is fully reviewed at each AGM alongside the Senior Management Team to ensure any risks the charity may face in the forthcoming year are addressed.

Key areas include:

- Ensuring the charity remains aligned to the blood cancer environment
- Quality training for all staff – especially those with patient-focused roles
- Sustainability of funds – and the allocation of restricted funds
- Financial controls
- Information security and data protection
- IT security
- Compliance with fundraising regulations

In addition, a full update, financial, and progress report including any identified or potential risks is provided to the Board by the CEO and COO quarterly, allowing Trustees to monitor progress against the charity's strategic objectives.

The Board of Trustees approves a detailed annual budget at its Autumn meeting (including cashflow and scenario planning), and the regular financial report provided to the Board identifies all changes in forecasts when compared to that budget.

In 2025, the Board is committed to the development of its Governance Sub-Committee with responsibility for analysis of the Risk Register. In addition, the charity has a schedule of regularly assessed and updated key policies and procedures (including Business Continuity Plan) covering all areas identified by the Risk Register.

The Trustees are confident that reasonable systems have been established to identify, mitigate, and manage new and existing risks, and that forward planning will enable the charity to be prepared for all future eventualities.

Trustee Indemnity insurance of £5,000,000 is in place.

Our Reserves Policy

Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care's policy to express reserves in terms of 'months of expenditure' for the purposes of external communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

- Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity.
- Provision to absorb setback - i.e. predominantly related to income-based risk.
- Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

In line with the considerations above, Leukaemia Care's policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure. Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the Board of Trustees at each AGM, with the reserves also reviewed in line with the policy at the Autumn Board meeting where the following year's budget is approved. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The Investment Policy is reviewed annually, and recommendations made to Trustees. Day-to-day investment management is delegated to authorised, professional investment advisors, regulated by the FCA.

Our Investment Policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term, but also to be available at short notice to support the on-going activities of Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

Structure, governance and management

Constitution

This is the fourth annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustees and their role

The Trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 Trustees in office at any one time are required by the constitution. At each AGM one-third of the Trustees, must retire from office but may stand for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to Trustee meetings. The Trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr Christopher R G Matthews-Maxwell (Chair)
 Mrs W J Davies (Treasurer)
 Dr Emmanouil Nikolousis (resigned 31 July 2024)
 Ms E Wilson (Vice Chair)
 Ms Kate Stallard (resigned 26 June 2024)
 Mr Robert Heppell
 Mr Dharmesh Mehta
 Professor Mhairi Copland (resigned 6 November 2024)
 Ms Carina Patterson
 Helen Knight (resigned 4 November 2024)
 Dr Sarah Searle

We are grateful for the support of the clinicians on our Trustee Board some of whom unfortunately due to the pressure of their workload as healthcare professionals resigned in the latter two quarters of 2024. Dr Nikolousis had been a Trustee for many years and supported Leukaemia Care to pilot its first hospital hub at Birmingham Heartlands Hospital in his clinic. Professor Copland joined as a Trustee in 2022 but supported the charity for years prior to that on our medical advisory panel, and as a conference and webinar speaker. Helen Knight also served as a Trustee since 2022 and continues to provide her insight and support with our Nottingham CLL support group, our Nurse Forum and Nottingham Hospital Hub.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

A special mention to Kate Stallard who as one of our patient representatives on the Board fronted many of our campaigns including our first Radio 4 appeal as well as our SpotLeukaemia campaign. After treatment, Kate retrained as a counsellor and now has a busy private practice.

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting, for example, healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, are interviewed by a number of the current Board. Successful applicants are co-opted as Trustees until their formal election at the next AGM.

On appointment, the new Trustees attend an induction at our offices in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The Essential Trustee". Trustees are also asked to complete the free online Trustee training provided by ICAEW which outlines their duties and responsibilities. Any trustee that takes on a specific role such as Safeguarding Trustee are provided with additional training relevant to their specialist role.

In 2025, the Board will carry out a further Skills Audit and Board Effectiveness Survey to identify key areas for improvement on the Board through recruitment.

Our trading subsidiary

Ahead of the launch of our art trail Unicornfest which took place in 2023, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest went through the subsidiary company. It has not been used for any other purpose since the trail ended in 2023.

Senior Management Team

The Trustees delegate day-to-day operations of the charity to the executive team.

Chief Executive Officer (joined 2 April 2024)	Colin Dyer
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Director of Engagement	Nicole Scully
Director of Patient Services	Jo Peplow

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

It is with great sadness that we announce that our President, Dr Richard Taylor died 26 June 2024. Richard was not only a president of Leukaemia Care for 15 years but also a friend to the charity and the people we help.

He was a staunch advocate for leukaemia patients and a man who embodied the six core NHS values of care, compassion, competence, communication, courage and commitment. We will miss our friend and are grateful he chose to support our community.

President	Dr Richard Taylor (died 26/06/2024)
-----------	-------------------------------------

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Vice Presidents Ms. Sue Merchant
 Professor Claire Harrison
 Dr Robert Marcus
 Professor Antonio Pagliuca
 Ms Sheila Hegarty
 Mr Jason Eliadis
 Mr Roland Maturi
 Mr Christopher Matthews-Maxwell
 Mr Peter Mondon
 Mr Anthony Gavin

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Prof. Ajay Vora
Dr. Tobias Menne
Dr. Claire Rowntree

Acute myeloid leukaemia panel

Prof. Mary Frances McMullin
Dr. Steve Knapper
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Dr. Mike Dennis
Dr. Ann-Louise Latif
Prof. Nigel Russell

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh
Prof. Chris Fegan
Prof. Guy Pratt
Assoc. Prof. Francesco Forconi
Prof. Adrian Bloor
Dr. Shankara Paneesha
Dr. Alison McCaig
Dr. Niamh Appleby
Dr. George Follows
Prof. Christopher Fox
Prof. John Gribben
Dr. Nicolas Martinez-Calle

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Dr Jonathan Kell
Dr. Nilima Parry-Jones
Dr. Piers Patten
Dr. Renata Walewska
Dr Sunil Lyengar

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)
Prof. Rachel Hough
Prof. Adam Mead

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Elaine Hampton
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Rachael Marchant
Dr. Pawan Randev
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith (Searle)
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Alicia Harris
Joanna Large
Catherine Langton
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis
Andrea Wooltorton
Aine Sheerin
O'Neil Jackson
Alice Ryan
Bryony Tyrell
Claire Ballantyne
Sheri Thompson
Tina Brooks
Alison York
Matthew Fowler
Christina Kirby
Eleanor Pearce
Catherine Chapple

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively. When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

The Board of Trustees are responsible for setting remuneration levels for the senior management team; CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in November. Salaries are reviewed annually in March following annual appraisals and take effect from April. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

- Mission and strategic aims of the charity and its general day-to-day needs.
- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy.
- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties.
- Current strategic business plan and how this might affect current and/or future needs.
- Leukaemia Care's financial ability to pay.
- Available information on charitable sector pay levels, alongside that of other sectors.
- Available information on regional pay levels
- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development.
- The charity's track record in recruiting and retaining high-performing staff.
- The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider public.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The report has been prepared having taken advantage of the small companies regime in the Companies Act 2006.

The Trustees' report was approved by the Board of Trustees.

Signed by:

6CF4719F0E4E433...

Mr Christopher R. G. Matthews Maxwell (Chair)

Trustee

Dated: 25 June 2025

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2024

The Trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'Charity') for the year ended 31 December 2024 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Trustees' report for the financial year for which the financial statements are prepared, which includes the directors' report prepared for the purposes of company law, is consistent with the financial statements; and
- the directors' report included within the Trustees' report has been prepared in accordance with applicable legal requirements.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations was as follows:

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained.
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made.
- an review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities.
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the company.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.


- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed.

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

058A9BD1D0D34B3...

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

25 June 2025

Chartered Accountants
Statutory Auditor

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Current financial year

	Notes	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Total 2023 £
<u>Income and endowments from:</u>					
Donations and legacies	3	1,286,476	299,383	1,585,859	840,277
Fundraising income	4	1,195,916	-	1,195,916	1,237,052
Investments	5	38,431	-	38,431	34,057
Other income	6	1,493	-	1,493	963
Total income		2,522,316	299,383	2,821,699	2,112,349
<u>Expenditure on:</u>					
Raising funds	7	861,052	-	861,052	1,092,989
Charitable activities	8	1,076,141	224,176	1,300,317	1,415,130
Material other expenditure	13	-	-	-	202,130
Total expenditure		1,937,193	224,176	2,161,369	2,710,249
Net gains on investments	14	46,609	-	46,609	30,632
Net income/(expenditure)		631,732	75,207	706,939	(567,268)
Other recognised gains and losses					
Revaluation of tangible fixed assets	16	(67,598)	-	(67,598)	12,640
Net movement in funds		564,134	75,207	639,341	(554,628)
Fund balances at 1 January 2024		2,424,435	148,342	2,572,777	3,127,405
Fund balances at 31 December 2024		2,988,569	223,549	3,212,118	2,572,777

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED) INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2024

Prior financial year

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
<u>Income and endowments from:</u>				
Donations and legacies	3	591,126	249,151	840,277
Fundraising income	4	1,237,052	-	1,237,052
Investments	5	34,057	-	34,057
Other income	6	963	-	963
Total income		1,863,198	249,151	2,112,349
<u>Expenditure on:</u>				
Raising funds	7	1,092,989	-	1,092,989
Charitable activities	8	1,158,403	256,727	1,415,130
Material other expenditure	13	202,130	-	202,130
Total expenditure		2,453,522	256,727	2,710,249
Net gains on investments	14	30,632	-	30,632
Net income/(expenditure)		(559,692)	(7,576)	(567,268)
<u>Other recognised gains and losses</u>				
Revaluation of tangible fixed assets	16	12,640	-	12,640
Net movement in funds		(547,052)	(7,576)	(554,628)
Fund balances on incorporation at 1 January 2023		2,971,487	155,918	3,127,405
Fund balances at 31 December 2023		2,424,435	148,342	2,572,777

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

LEUKAEMIA CARE

BALANCE SHEET

AS AT 31 DECEMBER 2024

	Notes	2024		2023	
		£	£	£	£
Fixed assets					
Tangible assets	16		806,869		887,448
Investments	17		698,764		646,230
			<u>1,505,633</u>		<u>1,533,678</u>
Current assets					
Stocks	19	-		8,435	
Debtors	20	332,322		301,802	
Investments	21	313,222		206,482	
Cash at bank and in hand		1,180,908		629,819	
			<u>1,826,452</u>	<u>1,146,538</u>	
Creditors: amounts falling due within one year	22	(119,967)		(107,439)	
Net current assets			<u>1,706,485</u>		<u>1,039,099</u>
Total net assets			<u>3,212,118</u>		<u>2,572,777</u>
Income funds					
Restricted funds	24		223,549		148,342
<u>Unrestricted funds</u>					
Designated funds	25	1,274,302		1,114,976	
General unrestricted funds		1,714,267		1,309,459	
			<u>2,988,569</u>		<u>2,424,435</u>
			<u>3,212,118</u>		<u>2,572,777</u>

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2024, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 25 June 2025


Signed by:



6CF4719F0E4E433...

Mr Christopher R. G. Matthews Maxwell (Chair)
Trustee

Signed by:



87B874DA56B142D...

Mrs W J Davies (Treasurer)
Trustee

Company Registration No. 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2024

	Notes	2024		2023	
		£	£	£	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	30		638,443		(525,632)
Investing activities					
Purchase of tangible fixed assets		(13,120)		(33,360)	
Purchase of other investments		(80,155)		(118,518)	
Proceeds on disposal of other investments		74,539		111,022	
Other investment movements		(309)		3,705	
Investment income received		38,431		34,057	
Net cash generated from/(used in) investing activities			19,386		(3,094)
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			657,829		(528,726)
Cash and cash equivalents at beginning of year			836,301		1,365,027
Cash and cash equivalents at end of year			1,494,130		836,301
Relating to:					
Cash at bank and in hand			1,180,908		629,819
Short term deposits included in current asset investments			313,222		206,482

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales (number: 11911752), a charity registered in England and Wales (number: 1183890) and Scotland (number: SC049802). The address of its registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Charities Act 2011, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)" and FRS102. The Charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Consolidated group financial statements have not been prepared in the current year as the sole subsidiary Leukaemia Care Trading Limited has been excluded from the group accounts. Its inclusion is not material for the purpose of giving a true and fair view due to it being virtually dormant. As the sole subsidiary has been excluded the requirement to prepare consolidated accounts does not apply and hence these are charity only financial statements.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future and that there are no material uncertainties about its ability to continue. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies

(Continued)

Event income is recognised as income on receipt, as this is when it becomes measurable.

Investment income is included in the SOFA in the year in which it is receivable.

Voluntary income is recognised as income when receivable, except insofar as when it is incapable of financial measurement.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies (Continued)

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

A subsidiary is an entity controlled by the Charity. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

1.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

1 Accounting policies (Continued)

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Freehold buildings held by the charity have been revalued during the year, by RICS qualified independent surveyors on a "Red Book" basis. Details of the valuation can be seen in note 16.

3 Income from donations and legacies

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Donations and gifts	297,130	197,619	494,749	271,297	179,151	450,448
Legacies	911,946	-	911,946	165,303	-	165,303
Grants	77,400	101,764	179,164	154,526	70,000	224,526
	<u>1,286,476</u>	<u>299,383</u>	<u>1,585,859</u>	<u>591,126</u>	<u>249,151</u>	<u>840,277</u>

4 Income from other trading activities

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Fundraising events	<u>1,195,916</u>	<u>1,237,052</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

5 Income from investments

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Rental income	-	6,475
Other income	11,434	9,452
Interest receivable	26,997	18,130
	<u>38,431</u>	<u>34,057</u>

6 Other income

	Unrestricted funds 2024 £	Unrestricted funds 2023 £
Solar panels	1,493	963
	<u>1,493</u>	<u>963</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

7 Raising funds

	Unrestricted funds	Unrestricted funds
	2024	2023
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	244,819	313,862
Advertising	16,954	48,883
Other fundraising costs	102,162	114,339
Staff costs	417,651	540,476
Depreciation and impairment	3,334	4,866
Investment management fees	5,514	5,661
Support costs (see note 10)	65,966	59,767
Governance costs (see note 10)	4,652	5,135
	<hr/>	<hr/>
Fundraising and publicity	861,052	1,092,989
	<hr/> <hr/>	<hr/> <hr/>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

8 Charitable activities

	2024	2023
	£	£
Staff costs	799,035	790,993
Depreciation and impairment	22,766	33,236
Patient Services costs	102,686	112,182
Conferences	1,679	2,126
Help Line costs	4,604	6,722
Leukaemia Matters/ Nursing Matters	26,100	34,315
Campaign costs	36,812	76,151
Other charitable activities	6,527	6,685
Nurse e-learning tool	309	3,056
GP's e-learning tool	-	7,099
Grants to individuals	119,200	155,500
Database costs	6,611	7,037
Patient Advocacy	1,075	1,481
Website costs	19,565	32,718
Press	5,629	9,159
	<u>1,152,598</u>	<u>1,278,460</u>
Share of support costs (see note 9)	138,012	124,689
Share of governance costs (see note 9)	9,707	11,981
	<u>1,300,317</u>	<u>1,415,130</u>
Analysis by fund		
Unrestricted funds	1,076,141	1,158,403
Restricted funds	224,176	256,727
	<u>1,300,317</u>	<u>1,415,130</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

9 Support costs

	Support costs	Governance costs	2024 Support costs		Governance costs	2023
	£	£	£	£	£	£
Staff costs	34,528	-	34,528	22,157	-	22,157
Other staff costs	23,585	-	23,585	43,500	-	43,500
Rent, rates and insurance	14,566	-	14,566	12,515	-	12,515
Heat and light	12,402	-	12,402	12,000	-	12,000
Repairs and renewals	19,256	-	19,256	13,415	-	13,415
Printing, postage and stationery	13,031	-	13,031	17,237	-	17,237
Telephone	13,346	-	13,346	11,486	-	11,486
Motor and other travel	756	-	756	858	-	858
Subscriptions	2,924	-	2,924	2,488	-	2,488
Other office costs	49,914	-	49,914	30,303	-	30,303
Bank charges	1,157	-	1,157	1,201	-	1,201
Sundry Expenses	18,513	-	18,513	17,296	-	17,296
Audit fees	-	5,400	5,400	-	6,600	6,600
Legal and professional	-	5,128	5,128	-	3,419	3,419
Trustee and meeting expenses	-	3,831	3,831	-	7,097	7,097
	<u>203,978</u>	<u>14,359</u>	<u>218,337</u>	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>
Analysed between						
Fundraising	65,966	4,652	70,618	59,767	5,135	64,902
Charitable activities	138,012	9,707	147,719	124,689	11,981	136,670
	<u>203,978</u>	<u>14,359</u>	<u>218,337</u>	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>

10 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

Fees payable	2024	2023
	£	£
Audit of the annual accounts	5,400	6,600
	<u>5,400</u>	<u>6,600</u>

11 Trustees

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2023 : 2) trustees for the current year were £3,831 (2023 : £5,748).

None of the Trustees (or any persons connected with them) received any remuneration during the year.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

11 Trustees (Continued)

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £3,045 (2023 : £3,069).

All trustees are covered by an indemnity insurance policy costing £906 (2023: £844)

12 Employees

The average monthly number of employees during the year was:

	2024 Number	2023 Number
Training and provision of care	24	27
Fundraising and publicity	17	22
Accounts and administration	5	5
	<hr/>	<hr/>
Total	46	54
	<hr/> <hr/>	<hr/> <hr/>

Employment costs	2024 £	2023 £
Wages and salaries	1,109,848	1,205,124
Social security costs	95,587	101,407
Other pension costs	45,779	47,095
	<hr/>	<hr/>
	1,251,214	1,353,626
	<hr/> <hr/>	<hr/> <hr/>

Redundancy and termination payments totalling £25,484 were made in the reporting period.

The remuneration of key management personnel through payroll and other fees is £191,758 (2023: £204,181).

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2024 Number	2023 Number
£60,001 to £70,000	2	1
	<hr/> <hr/>	<hr/> <hr/>

13 Other material expenditure

Other material expenditure in the prior year related to a provision for the intercompany debtor.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

14 Net gains on investments

	2024 £	2023 £
Revaluation of investments	46,609	24,702
Gains on sale of investments	-	5,930
	<u>46,609</u>	<u>30,632</u>

15 Taxation

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity.

16 Tangible fixed assets

	Freehold buildings £	Computers and other equipment £	Fixtures and fittings £	Total £
Cost or valuation				
At 1 January 2024	842,598	126,165	14,656	983,419
Additions	-	13,120	-	13,120
Disposals	-	(31,093)	-	(31,093)
Revaluation	(67,598)	-	-	(67,598)
At 31 December 2024	<u>775,000</u>	<u>108,192</u>	<u>14,656</u>	<u>897,848</u>
Depreciation and impairment				
At 1 January 2024	-	82,121	13,851	95,972
Depreciation charged in the year	-	25,611	489	26,100
Eliminated in respect of disposals	-	(31,093)	-	(31,093)
At 31 December 2024	<u>-</u>	<u>76,639</u>	<u>14,340</u>	<u>90,979</u>
Carrying amount				
At 31 December 2024	<u>775,000</u>	<u>31,553</u>	<u>316</u>	<u>806,869</u>
At 31 December 2023	<u>842,599</u>	<u>44,044</u>	<u>805</u>	<u>887,448</u>

Land and buildings with a carrying amount of ££775,000 were revalued at 2 July 2024 by Clarke & Jay Chartered Surveyors, independent valuers not connected with the Charity. The valuation conforms to RICS Valuation - Global Standards 2022 - "Red Book" and was based on current market valuation.

At 31 December 2024, had the revalued assets been carried at historic cost less accumulated depreciation and accumulated impairment losses, their carrying amount would have been approximately £842,599 (2023: £842,599).

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

17 Fixed asset investments

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2024	637,165	8,965	100	646,230
Additions	80,155	(80,155)	-	-
Valuation changes	46,609	-	-	46,609
Other cash movements	-	5,925	-	5,925
Disposals	(74,539)	74,539	-	-
At 31 December 2024	<u>689,390</u>	<u>9,274</u>	<u>100</u>	<u>698,764</u>
Carrying amount				
At 31 December 2024	<u>689,390</u>	<u>9,274</u>	<u>100</u>	<u>698,764</u>
At 31 December 2023	<u>637,165</u>	<u>8,965</u>	<u>100</u>	<u>646,230</u>

	Notes	2024 £	2023 £
Other investments comprise:			
Investments in subsidiaries	28	<u>100</u>	<u>100</u>

18 Financial instruments

	2024 £	2023 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	<u>689,390</u>	<u>637,165</u>

19 Stocks

	2024 £	2023 £
Finished goods and goods for resale	<u>-</u>	<u>8,435</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

20 Debtors		
	2024	2023
	£	£
Amounts falling due within one year:		
Trade debtors	51,994	51,266
Amounts owed by subsidiary undertakings	2,084	-
Other debtors	300	147
Prepayments and accrued income	277,944	250,389
	<u>332,322</u>	<u>301,802</u>
	<u><u>332,322</u></u>	<u><u>301,802</u></u>
21 Current asset investments		
	2024	2023
	£	£
Term deposits	313,222	206,482
	<u>313,222</u>	<u>206,482</u>
	<u><u>313,222</u></u>	<u><u>206,482</u></u>
22 Creditors: amounts falling due within one year		
	2024	2023
	£	£
Other taxation and social security	26,833	28,981
Trade creditors	23,486	22,137
Accruals	69,648	56,321
	<u>119,967</u>	<u>107,439</u>
	<u><u>119,967</u></u>	<u><u>107,439</u></u>
23 Retirement benefit schemes		
	2024	2023
	£	£
Defined contribution schemes		
Charge to profit or loss in respect of defined contribution schemes	45,779	47,095
	<u>45,779</u>	<u>47,095</u>
	<u><u>45,779</u></u>	<u><u>47,095</u></u>

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

LEUKAEMIA CARE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

24 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	Balance at 1 January 2023		Movement in funds		Balance at 1 January 2024		Movement in funds		Balance at 31 December 2024	
	£	£	Income	Expenditure	£	£	Income	Expenditure	£	£
The Lily Blaeu Hope Fund	9,384	-	-	(9,384)	-	-	-	-	-	-
Information Booklets	-	5,985	5,985	-	5,985	-	27,575	(33,120)	-	440
GP e-learning Tool	-	25,000	25,000	(25,000)	-	-	-	-	-	-
Nurse Advisor	-	-	-	-	-	-	45,764	(8,452)	-	37,312
Student/ Education	5,000	-	-	(5,000)	-	-	-	-	-	-
Glasgow Area	300	10,000	10,000	(7,471)	2,829	-	5,600	(6,396)	-	2,033
Support Group - Scotland	3,334	-	-	(756)	2,578	-	-	1,080	-	1,498
Counselling Fund	870	15,000	15,000	(15,870)	-	-	-	-	-	-
Support Group - Glasgow & Aberdeen	958	-	-	(958)	-	-	-	-	-	-
Support Group - Leicestershire	1,393	2,000	2,000	(278)	3,115	-	500	-	-	3,615
Birmingham Patient Conference	500	-	-	(500)	-	-	-	-	-	-
Belfast Hospital Support	11,999	-	-	-	11,999	-	3,000	(8,325)	-	6,674
Bristol Hospital Support	1,131	5,000	5,000	(5,725)	406	-	6,062	(6,468)	-	-
Financial Grants	-	60,000	60,000	(60,000)	-	-	30,000	(30,000)	-	-
Care Helpline Costs	-	5,000	5,000	(5,000)	-	-	-	-	-	-
Buddy Scheme	-	200	200	(200)	-	-	20,000	(12,330)	-	7,670
West Midlands Hospital Support	-	5,593	5,593	(5,593)	-	-	29,000	(12,497)	-	16,503
Spot Leukaemia	-	30,000	30,000	(30,000)	-	-	15,000	(15,000)	-	-
Newcastle Hospital Support	1,000	6,600	6,600	(3,294)	4,306	-	7,800	(7,994)	-	4,112
UCHL Hospital Support	1,015	-	-	(1,015)	-	-	-	-	-	-
Manchester Hospital Support	4,026	3,000	3,000	(4,196)	2,830	-	6,125	(6,418)	-	2,537
Nottingham Hospital Support	9,454	2,000	2,000	-	11,454	-	2,500	(4,210)	-	9,744
Patient Support Scotland	-	5,000	5,000	(3,294)	1,706	-	-	(750)	-	956

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

24 Restricted funds								(Continued)
William Davidson - Aberdeen Area	44,518	-	(10,990)	33,528	-	(300)	33,228	
CAR-T	10,000	-	(10,000)	-	-	-	-	
AML Information	15,000	-	(15,000)	-	-	-	-	
AML Education	23,135	-	(23,135)	-	-	-	-	
Yorkshire Patient Support	8,346	-	(4,610)	3,736	-	(353)	3,383	
Wales Hospital Support	3,965	-	(354)	3,611	31,680	(7,166)	28,125	
Support Group Wales	590	-	(590)	-	-	-	-	
Oxfordshire Hospital Support	-	2,000	-	2,000	1,000	-	3,000	
Support Group Leeds	-	1,580	(540)	1,040	-	(432)	608	
Good Hope Hospital Support	-	5,000	(5,000)	-	-	-	-	
Glasgow Hospital Support	-	7,000	-	7,000	-	-	7,000	
Northern Ireland Hospital Support	-	2,500	-	2,500	8,189	-	10,689	
NNUH Hospital Support	-	7,612	-	7,612	9,300	(5,895)	11,017	
Plymouth/Devon	-	9,441	(392)	9,049	-	(7,591)	1,458	
Cambridge	-	2,000	-	2,000	5,790	(7,789)	1	
Merseyside	-	6,000	-	6,000	-	-	6,000	
Swindon Hospital Supports	-	8,000	-	8,000	-	(4,224)	3,776	
Guy's & St Thomas Hospital Support	-	3,000	-	3,000	-	-	3,000	
Support Group Manchester	-	2,640	(1,728)	912	-	(756)	156	
Dorset (Bournemouth)	-	8,000	(854)	7,146	7,500	(9,981)	4,665	
Brighton	-	3,000	-	3,000	8,500	(5,398)	6,102	
Aberdeen	-	1,000	-	1,000	-	-	1,000	
Southampton Hospital Support	-	-	-	-	16,000	(9,553)	6,447	
Leeds Hospital Support	-	-	-	-	7,184	(7,184)	-	
Patient Support Reading	-	-	-	-	1,250	(450)	800	
Hospital Hubs	-	-	-	-	4,064	(4,064)	-	
	155,918	249,151	(256,727)	148,342	299,383	(224,176)	223,549	

LEUKAEMIA CARE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

24 Restricted funds **(Continued)**

The Lily Blae Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Glasgow Area - funds to support services in the Glasgow area.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas.

Support Group Leicestershire - to facilitate activities for support groups in these areas.

Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham.

Belfast Hospital Support - in support of the costs in providing ward support.

Bristol Hospital Support - in support of the costs in providing ward support.

Care Helpline costs: this represents income received specifically to meet the costs of the Care line.

Buddy Scheme - one to one support for patients.

West Midlands Hospital Support -to facilitate activities for local support groups.

Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

24 Restricted funds

(Continued)

Newcastle Hospital Support - in support of costs in providing ward support.

UCHL Hospital Support - in support of costs in providing ward support.

Manchester Hospital Support - in support of costs in providing ward support.

Nottingham Hospital Support - in support of costs in providing ward support.

Patient Support Scotland - to facilitate activities and support in this area.

William Davidson - Aberdeen Area - to facilitate activities and support in this area.

CAR-T - offer grants and information to patients being treated with CAR-T.

AML information - providing a new suite of AML information.

AML Education - Education of Healthcare Practitioners and patients on AML testing.

Yorkshire Support - to facilitate activities and support in this area.

Wales Hospital Support - in support of costs in providing ward support.

Support Group Wales - to facilitate activities for support groups in this area.

Oxfordshire Hospital Support - in support of costs in providing ward support

Support Group Leeds – to facilitate activities for support groups in this area

Good Hope Hospital Support - in support of costs in providing ward support

Glasgow Hospital Support - in support of costs in providing ward support

Northern Ireland Hospital Support - in support of costs in providing ward support

NNUH Hospital Support - in support of costs in providing ward support

LEUKAEMIA CARE
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024

24 Restricted funds (Continued)

Plymouth/Devon – to facilitate activities and support in this area

Cambridge - to facilitate activities and support in this area

Merseyside - to facilitate activities and support in this area

Swindon Hospital Support - in support of costs in providing ward support

Guy's & St Thomas' Hospital Support - in support of costs in providing ward support

Support Group Manchester - to facilitate activities for support groups in this area

Dorset - to facilitate activities and support in this area

Brighton - in support of costs in providing ward support

Aberdeen - to facilitate activities and support in this area

Southampton Hospital Support - in support of costs in providing ward support.

Leeds Hospital Support - in support of costs in providing ward support.

Patient Support Reading - to facilitate activities and support in this area.

Hospital Hubs - in support of costs for the running of our hospital ward support activity.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2024

25 Designated funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	Balance at 1 January 2023	Transfers	Balance at 1 January 2024	Transfers	Balance at 31 December 2024
	£	£	£	£	£
Fixed asset fund	879,551	7,897	887,448	(80,579)	806,869
Strategic implementation fund	468,272	(240,744)	227,528	239,905	467,433
	<u>1,347,823</u>	<u>(232,847)</u>	<u>1,114,976</u>	<u>159,326</u>	<u>1,274,302</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the delivery of strategy adopted by the Board of Trustees.

26 Analysis of net assets between funds

	Unrestricted funds 2024 £	Restricted funds 2024 £	Total 2024 £	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
Fund balances are represented by:						
Tangible assets	806,869	-	806,869	887,448	-	887,448
Investments	698,764	-	698,764	646,230	-	646,230
Current assets/(liabilities)	1,482,936	223,549	1,706,485	890,757	148,342	1,039,099
	<u>2,988,569</u>	<u>223,549</u>	<u>3,212,118</u>	<u>2,424,435</u>	<u>148,342</u>	<u>2,572,777</u>

27 Related party transactions

There were no disclosable related party transactions during the year (2023 - none) other than as disclosed in note 11.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2024

28 Subsidiaries

These financial statements are separate Charity financial statements for Leukaemia Care.

Details of the Charity's subsidiaries at 31 December 2024 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held	
				Direct	Indirect
Leukaemia Care Trading Limited	England	Unicorn walk	Ordinary	100.00	

The aggregate capital and reserves and the result for the year was as follows:

Name of undertaking	Profit/(Loss)	Capital and Reserves
	£	£
Leukaemia Care Trading Limited	(3,964)	(205,679)

29 Analysis of changes in net funds

The Charity had no material debt during the year.

30 Cash generated from operations	2024 £	2023 £
Surplus/(deficit) for the year	706,939	(567,268)
Adjustments for:		
Investment income recognised in statement of financial activities	(38,431)	(34,057)
Gain on disposal of investments	-	(5,930)
Fair value gains and losses on investments	(46,609)	(24,702)
Depreciation and impairment of tangible fixed assets	26,101	38,103
Movements in working capital:		
Decrease/(increase) in stocks	8,435	(2,210)
(Increase)/decrease in debtors	(30,520)	95,048
Increase/(decrease) in creditors	12,528	(24,616)
Cash generated from/(absorbed by) operations	638,443	(525,632)

LEUKAEMIA CARE

England & Wales - Charity number 1183890

Accounts

Charity Registration No. 1183890 (England and Wales)

Charity Registration No. SC049802 (Scotland)

Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE
ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

Leukaemia Care
YOUR Blood Cancer Charity

www.leukaemicare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons	Lady Penny Mountbatten Beverley Warboys	
Trustees	Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chair) Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland Ms Carina Patterson Helen Knight Dr Sarah Searle	
President	Dr Richard Taylor	
Vice Presidents	Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin	
Senior Management Team		
Chief Executive Officer	Colin Dyer	(appointed 02/04/2024)
Chief Executive Officer	Zack Pemberton-Whiteley	(resigned 30/11/2023)
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz	
Communications and Fundraising Director	Nicole Scully	
Medical Advisory Panels	As described in the Trustees' Report	
Secretary	Monica Izmajlowicz	
Charity number (England and Wales)	1183890	
Charity number (Scotland)	SC049802	
Company number	11911752	
Website	www.leukaemiacare.org.uk	
Registered office	One Birch Court Blackpole East Worcester WR3 8SG	

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Auditor	Kendall Wadley LLP Granta Lodge 71 Graham Road Malvern Worcestershire WR14 2JS
Bankers	Barclays Bank Plc 54 High Street Worcester WR1 2QQ
Solicitors	Harrison Clark Rickerbys 5 Deansway Worcester WR1 2JG
Investment advisors	Titan Private Wealth Limited 2 Greengate Cardale Park Harrogate HG3 1GY CCLA Senator house 85 Queen Victoria Street London EC4V 4ET Brewin Dolphin 12 Smithfield Street London EC1A 9BD

LEUKAEMIA CARE

CONTENTS

	Page
Trustees' report	1 - 20
Statement of trustees' responsibilities	21
Independent auditor's report	22 - 24
Statement of consolidated financial activities	25
Statement of financial activities - charity	26
Consolidated Balance sheet	27 - 28
Charity Balance sheet	29 - 30
Statement of cash flows	31
Notes to the financial statements	32 - 55

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable group's memorandum & articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

About us

Leukaemia Care is the UK's leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.

We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Purpose

The charity's objects are set out in its Articles of Association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders.
2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long-term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

But most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Why our work is important

To paint a picture of the scale of the issue across the UK:

- Leukaemia is the 12th most common form of cancer and 12th biggest cancer killer.
- Every year, 10,000 people are diagnosed with leukaemia in the UK.
- Every year, 5,000 people die from leukaemia in the UK.
- Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
- Over 50,000 people are living with leukaemia in the UK.
- There are 34,000 people living with MDS or MPN in the UK.

Our Strategic Goals

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner:

1. Improving diagnosis – through awareness and early detection.
2. Ensuring everyone receives high quality information, advice and support.
3. Tackling issues that impact people's lives.
4. Advancing treatment and care.
5. Creating a narrative to better reflect the reality people experience. But we need your help. If you believe in the future we are trying to create and want to help us get there faster, please get involved.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Leukaemia Care provides public benefit as a charity through all the charitable information, advice and support service areas detailed above. The Trustees have complied with their duty in accordance with the Charities Act 2011 to have due regard to the Charity Commission's guidance when reviewing the charity's aims and objectives, approving funding for projects and services, and in planning and undertaking current and future activities. Taking the Charity Commission's guidance into consideration, the Trustees are satisfied that our public benefit requirements have been met.

As examples, our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our HashtagSpot Leukaemia campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance

Executive summary

2023 was officially the Year of the Unicorn. Two years in the planning, Unicornfest – Leukaemia Care's public art trail in Bristol was a challenging new endeavour to raise funds for and raise awareness of leukaemia and Leukaemia Care.

In terms of awareness, people of all ages were engaged in the city of Bristol – throughout the trail and with the Farewell Festival – with overwhelmingly positive feedback received. Some of the specific numbers include: 339,083 scans of unicorns by visitors, 25,900 downloads of the app, 489,657 website views, 9,000 farewell festival attendees and repeated press coverage including BBC, ITV and many other publications. As a result, 67% of trail goers said they were more aware of Leukaemia Care because of the trail, and 52% said they were likely to support Leukaemia Care in the future.

It was a strong year for service delivery with investment from reserves allowing us to address rising demand for our patient services as shown in the Charitable Programmes Summary below. Recognising the importance of high- quality information to patients, families and the healthcare professionals looking after them, and our expanding portfolio of booklets, we formed a dedicated information team and appointed an experienced Information Manager to help us refine our strategy.

We continue to work closely with Leukaemia UK on raising awareness of the signs and symptoms of leukaemia with our Spot Leukaemia campaign and are an active member of the influential Blood Cancer Alliance.

Our engagement with supporters has improved, with over 400 respondents in our annual survey. We are grateful that so many people took the time to complete it and give us their feedback – we will be using it to inform our strategy in 2024 and beyond.

Fundraising continues to be challenging, with the art trail and other areas not reaching anticipated levels and developing income streams needing longer to come to fruition. This meant a greater investment from reserves than anticipated for 2023 and will be reflected in plans for 2024 and 2025. The Trustee Board remain committed to investing in services and growing income to meet increasing demand. However, when it became apparent that we were not going to reach those anticipated fundraising levels, savings in expenditure began to be planned across the charity which may also impact work in 2024.

After nine years of service in various roles, our CEO, Zack Pemberton-Whiteley left for new opportunities in December. Our COO and Director of Comms and Fundraising stepped in as joint Interim CEOs, and a new CEO was appointed in April 2024.

Charitable Programmes Summary

A breakdown of achievements against our five organisational goals is available in our Strategic Update section below. All funds assigned to Leukaemia Care's charitable services during the year were consistent with those goals set out in our *The Future We Will Create Together* strategy (published in 2022 and available at www.leukaemiacare.org.uk). Examples of the allocation of those funds and the continuing increase in demand for our patient services include:

- The provision of essential information with 34,259 information booklets (28,800 in 2022) either ordered as printed copies or downloaded directly from the Leukaemia Care website, and 2,905 welcome packs (1,005 in 2022) sent to people newly engaged with the charity.
- The charity's information helpline supported 1,192 people (compared to 906 in 2022).
- The work of our Welfare Officer who helped 301 people (217 in 2022), and our Advocacy Officer who supported 204 people (266 in 2022). 819 hardship grants (465 in 2022) were made and a further 30 families were given financial or accommodation support for CAR-T treatment, thanks in no small part to our partnership with Dalata Hotels.
- Our Hospital Support Workers helped 583 people (199 in 2022), a further 2,397 people (1,911 in 2022) attended 39 support groups, and 4,900 people were connected through our online forums (4,333 in 2022).
- The Leukaemia Care Buddy scheme matched 148 people (131 in 2022), while counselling was provided for 63 patients (56 in 2022).

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

- In terms of reach, our Why Spot Leukaemia video was viewed 1.85m times, and we reached 1.7billion people through 147 national and 323 regional pieces of media coverage along with our extensive online activity.

Financial summary

- 67 per cent of the charity's income was allocated to our charitable services and projects in 2023 compared to 56 per cent in the previous year.
- The total income raised during the year was £2,263,249 (£2,139,494 in 2022) against expenditure of £2,860,835 (£1,979,542 in 2022).
- Investment of £566,954 was made from the strategic implementation fund against a planned deficit of £468,272 – which was £98,682 higher due to lower than anticipated performance in some areas of fundraising.
- Total reserves stand at £2,573,092 of which £148,342 are restricted and £2,424,750 are unrestricted. Within the unrestricted funds is a designated fund called the 'Strategic Implementation Fund' which, at year end, stands at £227,528. This fund was designated to support the two-year strategy agreed by the Board of Trustees in January 2024.

Strategic update for 2023 including our plans for 2024

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner. For more information on our five goals, please visit our website www.leukaemiacare.org.uk

This report sets out Leukaemia Care's achievements in each of these priority areas during 2023, along with the charity's goals for the year ahead.

Goal 1: Improving diagnosis – through awareness and early detection

We achieve this through our annual SpotLeukaemia campaign, targeting awareness days like World Leukemia Day and through our education work with GPs and other healthcare professionals.

In 2023 we continued our collaboration with Leukaemia UK on the Spot Leukaemia campaign, focusing on raising awareness of the symptoms of leukaemia. We soft-launched at the end of August with our new creative video (Why Spot Leukaemia) which encourages people to access their inner child and ask "why" when they notice symptoms such as fatigue, repeated infections, bruising and bleeding, to then see their GP and ask for a blood test. The video was viewed 1.85 million times.

In 2024, we will review the Spot Leukaemia collaboration with Leukaemia UK, now in its fourth year, to determine its long-term direction and impact.

Throughout the year, we ran mini campaigns on awareness days such as World Leukemia Day, MDS Day, Know AML Day and World Cancer Day. We took part in 11 blood cancer awareness days sharing 50 patient stories across different leukaemias, MDS and MPN. World Leukemia Day (4 September) which was launched by Leukaemia Care in 2020 in partnership with worldwide patient advocate groups reached 28.3 million people in 2023 (30.1 million in 2022) on social media.

Uptake of our GP online learning modules via the Royal College of General Practitioners (RCGP) and Gateway C increased in 2023 (233 in 2022 vs. 340 in 2023). A further 87 GPs attended our two webinars, which were both rated as very good by attendees. We continued to attend and exhibit at conferences aimed at GPs such as the Best Practice, Guidelines and the RCGP annual conference with all contacts receiving follow-up information from us.

In 2024, we will do a complete review of our GP education to produce recommendations on what we could do better to raise awareness of leukaemia signs and symptoms with GPs.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 2: Ensuring everyone receives high quality information, advice and support

Leukaemia and blood cancer is highly complex. We know that at diagnosis people are significantly less likely to understand what is wrong with them than for other forms of cancer. Many are left worried and confused.

We know that high quality information, advice and support is key. Whilst most people receive information about their blood cancer, few receive information about emotional, practical and financial support.

This area of work covers our core frontline services for patients and their families. Our written information (hard copy and online), videos, podcasts, webinars and conferences. Our advice service incorporates the helpline, WhatsApp, email, advocacy casework and welfare advice, and hospital hubs. Our support services; support groups, online forums, one to one buddy support, financial grants, counselling and free wills.

As the range and volume of patient information produced by Leukaemia Care increases, we appointed an Information Manager to ensure we continue to provide good quality information.

In 2023, we focused on updating our patient information as and when it came up for review. We updated our MDS booklet in collaboration with MDS UK and released a factsheet alongside it.

We continue to offer our existing booklets alongside the new formats and in 2023, distributed 15,706 (13,862 in 2022) hard copies and 18,553 (15,118 in 2022) free copies were downloaded from our shop. We also maintained our accreditation with the PIF Tick scheme for patient information, ensuring our information continues to be produced and reviewed in a robust way.

We recognize that people like to access information in different formats, not just booklets, and that many would like an introduction to our services. We sent out 2,905 (1,005 in 2022) Welcome Packs introducing people to our services and signposting them to our booklets, blogs, monthly podcast, videos and webinars.

We ran 15 (20 in 2022) webinars on a variety of topics which were all recorded so they can be accessed time and time again for people looking for information and debate on key topics such as women's health, CLL and living well on watch and wait, our "understanding" series (hairy cell leukaemia, MPN, ALL, CML), vaccinations when living with leukaemia, MPN and MDS. Our webinars were viewed 11,429 (16,352 in 2022) times on social media.

Alongside our information, we offer the opportunity to seek advice and support from our clinical nurse specialists, trained advocates and welfare advisors. We provided 1,192 people (906 in 2022) with timely advice and support via our helpline, WhatsApp and email with an average feedback score of 4.75 out of 5.

Our Advocacy Caseworker supported 204 people (266 in 2022) with issues such as employment rights, early retirement, travel insurance, COVID-19 related-queries and non-COVID vaccines. They work closely with our Welfare Officer as many people have varied and complex needs that also affect finances.

The number of advocacy queries has been lower overall this year in comparison to 2022 because of a fall in the number of COVID-19 queries that we receive, as some patients become more confident in managing their risk without our guidance. Despite a lower number of cases, there has been an increase in more complex queries that have required more in-depth casework, working directly with patients to support them with issues such as employment and housing.

Our Welfare Officer supported 301 (217 in 2022) people with most queries being classed as major i.e. complex, helping people to apply for benefits, support with housing, challenge benefits decisions, apply for grants of money and goods and processing applicants for our Financial Hardship Fund, Exceptional Hardship Fund and CAR-T Away from Home Fund.

"This PIP approval is a game-changer, opening doors to assistance from my local council and occupational therapists. I cannot express enough gratitude for your unwavering support. Without your and Leukaemia Care's guidance, this wouldn't have been achievable. Your encouragement and advice have been an absolute lifeline."
Patient

Towards the end of 2023, we set up four new hubs in Gwent, Plymouth, Bournemouth, and Norfolk. We also ran a pilot hub with the Queen Elizabeth Hospital in Birmingham for a year which sadly was not extended.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our other locations are Solihull Hospital (West Midlands), Heartlands Hospital (Birmingham), St James Hospital (Leeds), Southampton General, University of Bristol Hospital, The Christie (Manchester), University College London Hospital, and Freeman Hospital, Newcastle.

Our hospital support workers provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2023, we supported 583 people (199 in 2022), in person and by phone as needed by the hospitals.

We ran 39 support groups (in person, hybrid and online only) supporting 2,397 people in 2023 (1,911 in 2022). Our specialist online support groups are well received especially by those with rarer leukaemias.

We also ran an online forum via HealthUnlocked and closed Facebook groups that collectively supported 4,900 (4,333 in 2022) people.

Our buddy service matches patients and families with people who have a similar diagnosis for emotional support. In 2023, we matched 148 (131 in 2022) patients for long-term or short-term buddying with some volunteer buddies supporting multiple patients.

"I had a really good chat with [my buddy] last night and gave me a good insight into what we are both going through. I'm really glad that I took up your service of support." **Patient**

We recognise that a leukaemia diagnosis can have a negative impact on people's finances especially during a cost-of-living crisis. In 2023, we awarded 819 (465 in 2022) hardship grants of between £100 to £200 and 12 exceptional hardship grants of up to £1,000. Our Cost-of-Living grants are run in partnership with Leukaemia UK.

Our CART-T Away from Home service provides patients undergoing CAR-T treatment and their families with access to paid hotel rooms and a £500 grant towards increased costs. This is a partnership with our corporate partner, the Dalata Hotels Group. In 2023, we supported 30 families with a combination of hotel stays (8 with an average stay of 24 days) and financial grants.

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2023, we supported 63 people (56 in 2022) seeking support with issues such as bereavement, coping with a diagnosis either as a patient, parent or child, coping with chronic leukaemia, and managing anxiety following a relapse.

We believe everyone diagnosed with a potentially life limiting illness such as leukaemia should have the chance to make a will. In 2023, 61 (53 in 2022) people made a will using our free wills service with 30 choosing to leave a gift in their will to Leukaemia Care although there is no obligation to do so.

In 2024, we will continue to expand our network of hospital hubs to ensure we support more people at diagnosis and throughout their blood cancer pathway. We will grow our Information Team and explore how we can make our information more accessible. We will review our support groups to ensure we reach as many people as possible and for those who cannot attend support groups, offer them a buddy. At a time when many organisations struggle to provide financial grants, we will continue to provide them while recognising that this is often only a brief respite from ongoing hardship because of a leukaemia diagnosis.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 3: Tackling issues that impact people's lives

This area of our work covers our advisory panels (medical and patient), our patient experience research, our policy and public affairs, campaigns and external advocacy projects.

Our medical and patient advisory panels provide feedback on not only our strategic plans but also our day-to-day work. We have 82 healthcare professionals including specialists in the four main leukaemias as well as MDS, MPN and rare leukaemias. These include consultant haematologists, clinical nurse specialists, GPs, psychologists and district general hospital doctors. Our patient advisory panel of 64 includes acute and chronic leukaemia patients, those with rare leukaemias, MDS and MPN.

In 2024, we will investigate new ways of engaging with our panels to ensure that we gather views in a timely manner. This will not be limited to online meetings but also incorporate quick polls and lengthier surveys. We will strive to ensure our patient panels reflect the diverse blood cancer community we serve and offer other opportunities to volunteer should members feel they no longer wish to serve on the panels.

When faced with a diagnosis, many will often think about the impact on a person's physical or mental health. Whether it's time off work for treatment causing a loss of wages, increased heating bills to warm through the home to cope with the effects of treatment or inflated food costs to help maintain a well-balanced diet, the financial implications are far and wide.

These are just some of the hidden costs that come with a leukaemia diagnosis but are often forgotten about. That's the Leukaemia Levy – the hidden tax, the cost of leukaemia, even when you are being treated and cared for by the NHS.

In March 2023, we launched our Hashtag Leukaemia Levy campaign to raise awareness and secure financial support for those affected by a diagnosis. Our three asks were: a Government Hospital Travel Fund, an extension to the support provided by the energy price guarantee and the energy bills scheme and increased financial assistance from energy companies.

We asked people to show their support by signing a petition standing behind these asks. We sent a letter to the Chancellor and Prime Minister, hand-delivering the letters to their respective doors on Downing Street. Mark Tami MP presented our petition to the house of Commons asking members to join us in urging the Government to provide more support for leukaemia patients.

In 2024, we will work with other charities and organisations collectively to continue to address the financial challenges faced by cancer patients.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Goal 4: Advancing treatment and care

This area covers our engagement with healthcare professionals – providing training and raising awareness of our services as well as our work on improving access to treatments.

Our Regional Coordinators raise awareness of our services within hospitals across the UK and in 2023, conducted 630 meetings both in person and online to engage with a diverse range of healthcare professionals working with blood cancer patients. Our coordinators successfully engaged with 252 health care professionals new to our services.

We awarded five bursaries to nurses seeking to improve their skill and knowledge of patient care through courses at the Royal Marsden Hospital and Coventry University.

We offer eight free online courses for nurses ranging from 1 to 4 hours. Four were removed from circulation pending updates. Topics covered are CAR-T, emergencies in leukaemia, end of life and acute leukaemia, GVHD, supportive care, MPNs, understanding blood and its components, diagnosis of leukaemia, and epidemiology, aetiology and risk factors. The average feedback score from users remains consistently high at 4.9/5 (4.25/5 in 2022) with 265 new subscribers (217 subscribers in 2022). In 2024, we will publish a new course on genetics in acute myeloid leukaemia. Due to resource limitations, as our courses reach their review date, they will be removed from circulation until they can be updated.

In 2023, we launched two new forums for MPN and acute leukaemia nurses alongside our existing chronic lymphocytic leukaemia forum. In 2023, 126 healthcare professionals (52 in 2022) attended to share updates from scientific and clinical meetings and best practice in patient care.

Leukaemia Care have committed to be actively involved in all relevant Health Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. In 2023, we were involved at every stage of the health technology appraisal process in 98% of appraisals and were involved in a stage of the process in 100% of appraisals. We secured patient experts for 67% of appraisals with 89% of appraisals also having input from patients via surveys.

Goal 5: Creating a narrative to better reflect the reality people face

Patient stories, press and social media all play a critical role in ensuring that patients and their families as well as the public understand the reality of living with leukaemia.

Seventy-two people shared their story with us to support others and raise awareness of the challenges they face with half of these having benefited from our services. Forty-four people keen to give back and raise awareness of the support available from Leukaemia Care provided testimonies to be used to encourage people to reach out for help.

In 2023, we received 147 (56 in 2022) pieces of national and 323 (651 in 2022) pieces of regional press coverage with an estimated reach of over 1.7 billion (1.4 billion in 2022).

Our symptoms of leukaemia information and blogs continue to be our most visited pages on our website especially on swollen lymph nodes and bruising. An accessibility toolbar has now been deployed on the website which offers translation in over 160 languages as well as accessibility features such as increasing the size of text and an audio function.

In 2024, we will continue to review our webpages focusing on our information for patients through the creation of hubs for different leukaemia types.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Fundraising summary

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (<https://www.fundraisingregulator.org.uk/>) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2023, the charity received no suppression requests through the Fundraising Preference Service and no fundraising complaints.

Our complaints procedure can be found on our website <https://www.leukaemicare.org.uk/about-us/>

After concluding 2022 on a positive note, having raised over £2 million for the first time, 2023 posed fundraising challenges and while fundraising income increased, the costs of raising those funds also saw a significant rise. The positive impact of that further investment in fundraising is expected to be seen in the coming years.

Reliable income streams such as legacies and pharmaceutical grants were lower than anticipated, and while we benefited from £165,303 (£411,669 in 2022) from gifts in wills – this was a significant decrease when compared to previous years.

The Unicornfest art trail was an excellent public event raising awareness of leukaemia and Leukaemia Care, however the return on time invested was lower than expected despite the fact that the auction raised a respectable £146K – the single highest amount raised for the charity in a single day.

We had some success with new initiatives such as our first ever matched donation campaign run during Blood Cancer Awareness Month in September made possible by a long-standing supporter and major donor which raised £22,524. Our corporate partnership with Dalata Hotels Groups allowed us to expand our CAR-T Away From Home service as hotel employees worked hard to raise funds. And we exceeded targets in some of our running and challenge events including the London Marathon in which we had 117 runners. Grants and trusts exceeded its target and includes support from Leukaemia UK towards our cost of living with leukaemia grants. We successfully launched our first joint fundraising and support initiative, linking our Bereavement service to In Memory fundraising. This integration resulted in a historical high for In Memory income, exceeding predictions by £25,000. Further growth is anticipated as we strengthen our work in this area. We also started work on our BBC Lifeline appeal which will air in early 2024 and launched our Christmas giving campaign "Snow Much Love" which will run into 2024.

Please see below for more details on the grants received from the pharmaceutical industry and grants and trusts foundations.

In 2024, we will focus on consolidating work done to date focusing on building our legacy, corporate and major donor income.

Pharmaceutical grants

Leukaemia Care collaborates with the pharmaceutical industry to ensure that the interests of patients are considered during the development of new drugs and treatments. Our patient advisory work plays an important role in making sure treatments are thoroughly appraised and person-centred before they are made available to the public. As a way of helping us remain secure and to continue to be effective in our work with patients, many pharmaceutical companies provide us with funding throughout the year. This funding is always received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care's own Code of Practice (see our website).

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

To ensure that we remain financially independent, limits are placed on all types of grant income. We do not allow the level of funding received from the pharmaceutical industry to exceed 25% of our total annual income, nor do we allow the funding received from any individual company to exceed 10% of our total annual income.

In 2023 we were grateful for the following support from pharmaceutical companies which totaled £214,472. We also received a further £9,479.11 in honorariums. Please note, this is funding that was received in 2023 – any funding that was intended for 2023 but not received until 2024 will be acknowledged in the annual report and accounts for 2024.

Abbvie - £15,800 towards improving the accessibility of our Information Programme
 Amgen - £5,000 in core funding
 AstraZeneca UK - £15,000 towards our work in early diagnosis
 Autolus - £10,000 in core funding
 Bristol Myers Squibb - £15,000 in core funding
 GlaxoSmithKline - £15,000 towards our Counselling Service
 Incyte - £15,000 towards our work in early diagnosis
 Jazz Pharmaceuticals - £20,000 towards our work in early diagnosis
 Kura Oncology - £10,000 in core funding
 Kyowa Kirin - £5,000 in core funding
 Novartis - £25,000 towards our work in early diagnosis
 Pleco Therapeutics - £8,672.27 in core funding
 Servier - £5,000 in core funding
 Takeda Pharmaceuticals - £50,000 in core funding

Grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders who kindly pledged their support in 2023. Please note, this is grant funding that was received in 2023 – any funding that was pledged for 2023 but not received until 2024 will be acknowledged in the annual report and accounts for 2024.

Acute Leukaemia Advocates Network
 The Alice Ellen Cooper-Dean Charitable Foundation
 AMW Charitable Trust
 The Barbour Foundation
 The Big Life Group
 Birmingham Hospital Saturday Fund
 Brighton District Nursing Association Trust
 The Burford Trust
 The C L Lloyd Charitable Trust
 The de Brye Charitable Trust
 Doris Field Charitable Trust
 The Earl Fitzwilliam Charitable Trust
 The Edward and Dorothy Cadbury Trust
 The Frank Litchfield Charitable Trust
 Fullagar Charitable Trust
 The Helen Jean Cope Charity
 The J Reginald Corah Foundation Fund
 The James Tudor Foundation
 John James Bristol Foundation
 The Livewell Foundation
 The Medicash Foundation
 The Meikle Foundation
 The Michael and Anna Wix Charitable Trust
 The National Lottery Community Fund
 The Nisbet Trust
 Norwich Charitable Trusts
 The Pennycress Trust
 Pilkington Charities Fund

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The R C Snelling Charitable Trust
 The Roger & Douglas Turner Trust
 The Rothley Trust
 The Rowlands Trust
 The Roy Proctor Foundation
 Santa Barbara Heights Trust
 Schroder Charitable Trust
 The Shanly Foundation
 Sir John Eastwood Foundation
 The Sovereign Healthcare Charitable Trust
 The Squire Patton Boggs Trust
 Sutton Coldfield Charitable Trust
 The Tyne & Wear Community Foundation
 W A Cargill Fund
 The W E Dunn Trust
 The Walter Guinness Charitable Trust
 The Wilmcote Chariturst

Grant making by Leukaemia Care

Leukaemia Care has five grant making streams: the Cost of Living with Leukaemia Fund (formerly the Financial Hardship Fund), the Exceptional Hardship Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service (launched in 2022) and nurse bursaries (relaunched in 2023). These contribute towards addressing the recommendations made in our Living with Leukaemia reports which inform our strategic aims.

Cost of Living with Leukaemia Fund

This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

Exceptional Hardship Fund

Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are considered for an additional grant of up to £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse to public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependant (adult and/or child) etc.

The Leukaemia Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

CAR-T Away from Home Service

CAR-T (Chimeric Antigen Receptor) cell therapy is a type of treatment for leukaemia that has revolutionized the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future. The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment.

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first-come first-served basis until the fund is depleted.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care, and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel.

We will also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc.

Nurse Bursaries (reintroduced in 2023)

This fund provides nurses caring for blood cancer patients up to £1,000 towards training, education or professional development that enhances the care of patients with leukaemia, MDS or MPN. This could be support with, attending a haematology conference or payment of a module that's part of a Masters degree in a relevant subject.

Volunteers

Our volunteers play a key role in ensuring that we can offer vital support to those affected by leukaemia, MDS or MPN. For some of our volunteers that involves working directly with those affected to provide support and guidance, for other volunteers it might be in supporting our fundraising goals or advising us on the information we produce. Each of our volunteers has their own unique experience and contributions, whether they are a patient, a clinician, a carer, or a supporter.

2023 has seen a continuation of the work we started in 2022, building our volunteering program to create a cohesive and highly valuable experience for all volunteers. This has involved continuing to build on the processes, training and support around each role, alongside including volunteers in new and exciting ways.

Our biggest volunteering involvement is our Buddy scheme, offering patients and carers one-to-one support with trained buddies who have themselves experienced leukaemia, MPN or MDS. The volunteers are DBS checked, trained and provided with ongoing support by both our volunteer coordinator and our Buddy coordinator, who is also a paid employee.

The newest role we have implemented for 2023 has been our Facebook Support Group Moderators. This is a group of volunteers who were given in depth training in moderation of online groups to allow them to support us in the running of three of our Facebook groups. The training included guidance on signposting, handling difficult conversations and safeguarding.

Patient and clinician volunteers have had a bigger involvement than ever with the reviewing of our patient information, both online and in print. They have been involved in the renewal of our CML and MDS information suites, as well as our new AML genetics booklet. We have increased the points which we get these volunteers involved, allowing them to influence decisions at a much earlier stage and continuing to feedback throughout the review process. In addition, we plan to review the format of our Patient Advisory Panel in 2024.

Our healthcare professional volunteers are a vital resource across the charity, they attend our medical advisory panels, review our patient information, and attend events with us. We are extremely grateful to all of these professionals, and the time they give. Included in this group are the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional, and administrative support to the group.

Our community fundraising volunteers place collection tins, hold supermarket collections, run events, and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. Our London Marathon cheer squads were particularly successful, we were able to get a large group of dental students involved in 2 different cheer squads, introducing Leukaemia Care to future clinical professionals, and giving them an insight into the work we are doing.

Our Unicornfest sculpture trail required a large input from volunteers in 2023, we recruited over 50 volunteers, most of whom had no existing connection to Leukaemia Care, to assist us in the event across the summer. Volunteers gave their time once or twice per week in our Unicornfest shop, assisting staff with selling official merchandise and unicorn themed goods. Over 30 volunteers got involved on a weekly basis in taking care of the unicorns whilst they were out in public, this involved them looking out for, reporting damage, and keeping their unicorn clean. This role allowed for family volunteering, with volunteers getting their children involved with helping them. We also made a connection with a team from Lloyds Bank who participated in a volunteering day of cleaning unicorns across the city and litter picking. The grand finale of Unicornfest saw us involve 43 volunteers in the Farewell Festival weekend.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Some feedback from our volunteers:

"It gives your cancer a sense of purpose a way to help others, fighting loneliness and misinformation... I've found LC very inclusive of physical and mental needs. Even more than I've expected. I'm physically disabled and neurodivergent and have always felt welcome at LC events and meetings." (Patient Advisory Panel Volunteer)

"It is very satisfying being able to help people and give something back after receiving so much from support charities and the NHS. There are not many positives to having leukaemia but being able to use one's personal experience to help others is definitely one." (Patient Advisor Panel and Buddy)

"To get me out and improve my mental health and wellbeing, the kids loved taking responsibility for the unicorn so was great they could be involved... Talking to others about our unicorn, I had so many friends asking different questions about the trail, shop or skating so I was able to bring a lot more people to the trail...do this with my kids. I normally miss out on a lot due to being a single mum with no childcare help" – (Unicornfest Mane-tainer Volunteer).

Risk assessment and management

A Serious Incident Report was submitted to the Charity Commission in January 2023 following a data breach which was also reported to the Information Commissioners Office (ICO). No further action was taken by either the ICO or the Charity Commission who were satisfied with Leukaemia Care's management of the issue.

We carry out an annual detailed review of the charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

- a comprehensive annual review to identify, where possible, the risks which the charity may face during the forthcoming year
- the establishment, where possible, of contingency plans to meet anticipated risk(s)
- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the charity should any such risk(s) materialise
- the prioritisation of the charity's activities both actual and planned
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan is dependent upon the charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

But we have also put in place several other protections beyond this, including:

- Building organisational resilience – ensuring coverage of key skill sets, and developing existing staff within and beyond their roles
- Diversifying income – we have sought to create a wide range of income streams, to ensure we are less reliant on the London Marathon
- Phased investment – at present we have created plans for 2023 and 2024 which include a significant deficit as we seek to grow income.
- Regular review - by SMT at least monthly and quarterly at Trustee meetings

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our Reserves Policy

Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care's policy to express reserves in terms of 'months of expenditure' for the purposes of external communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

- i. Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity.
- ii. Provision to absorb setback - i.e. predominantly related to income-based risk.
- iii. Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

In line with the considerations above, Leukaemia Care's policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure. Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget setting time and in time for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day-to-day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on-going activities of Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, governance and management

Constitution

This is the fourth annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustees in office at any one time are required by the constitution. At each AGM one-third of the trustees, must retire from office but may stand for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr Christopher R G Matthews-Maxwell (Chair)

Mrs W J Davies (Treasurer)

Dr Emmanouil Nikolousis

Ms E Wilson (Vice Chair)

Ms Kate Stallard

Mr Robert Heppell

Mr Dharmesh Mehta

Professor Mhairi Copland

Ms Carina Patterson

Helen Knight

Dr Sarah Searle

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee".

All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Our trading subsidiary

Ahead of the launch of our art trail Unicornfest, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest will go through the subsidiary company.

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team. In 2023, Zack resigned to take up a new role in the corporate sector, and Monica and Nicole stepped in as joint interim CEOs until Colin started in April 2024.

Chief Executive Officer (joined 2 April 2024)	Colin Dyer
Chief Executive Officer (left 30 November 2023)	Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Communications and Fundraising Director	Nicole Scully

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising.

President	Dr Richard Taylor
Vice Presidents	Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr Roland Maturi Mr Christopher Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Prof. Ajay Vora
Dr. Tobias Menne
Dr. Claire Rowntree

Acute myeloid leukaemia panel

Prof. Mary Frances McMullin
Dr. Steve Knapper
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Dr. Mike Dennis
Dr. Ann-Louise Latif
Prof. Nigel Russell

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh
Prof. Chris Fegan
Prof. Guy Pratt
Assoc. Prof. Francesco Forconi
Prof. Adrian Bloor
Dr. Shankara Paneesha
Dr. Alison McCaig
Dr. Niamh Appleby
Dr. George Follows
Prof. Christopher Fox
Prof. John Gribben
Dr. Nicolas Martinez-Calle

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Dr Jonathan Kell
Dr. Nilima Parry-Jones
Dr. Piers Patten
Dr. Renata Walewska
Dr Sunil Lyengar

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)
Prof. Rachel Hough
Prof. Adam Mead

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Elaine Hampton
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Rachael Marchant
Dr. Pawan Randev
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith (Searle)
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Alicia Harris
Joanna Large
Catherine Langton
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis
Andrea Woollorton
Aine Sheerin
O'Neil Jackson
Alice Ryan
Bryony Tyrell
Claire Ballantyne
Sheri Thompson
Tina Brooks
Alison York
Matthew Fowler
Christina Kirby
Eleanor Pearce
Catherine Chapple

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively. When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

The Board of Trustees are responsible for setting remuneration levels for the senior management team; CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in November. Salaries are reviewed annually in March following annual appraisals and take effect from April. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

- Mission and strategic aims of the charity and its general day-to-day needs.
- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy.
- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties.
- Current strategic business plan and how this might affect current and/or future needs.
- Leukaemia Care's financial ability to pay.
- Available information on charitable sector pay levels, alongside that of other sectors.
- Available information on regional pay levels
- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development.
- The charity's track record in recruiting and retaining high-performing staff.
- The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider public.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report was approved by the Board of Trustees.

DocuSigned by:

6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)

Trustee

7/4/2024

Date:

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charitable group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'charitable group') for the year ended 31 December 2023 which comprise the statements of financial activities, the balance sheets and the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable group's affairs as at 31 December 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charitable group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charitable group for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made
- a review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the charitable group

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.


A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

Chartered Accountants
Statutory Auditor

DocuSigned by:

058A9BD1D0D34B3...

.....
04/07/2024

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the charitable group by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
<u>Income and endowments from:</u>							
Donations and legacies	3	591,126	249,151	840,277	836,570	341,404	1,177,974
Trading income	4	150,900	-	150,900	193,750	-	193,750
Fundraising income	5	1,237,052	-	1,237,052	723,517	-	723,517
Investments	6	34,057	-	34,057	43,352	-	43,352
Other income	7	963	-	963	901	-	901
Total income		2,014,098	249,151	2,263,249	1,798,090	341,404	2,139,494
<u>Expenditure on:</u>							
Raising funds	8	1,445,705	-	1,445,705	784,794	-	784,794
Charitable activities	9	1,158,403	256,727	1,415,130	937,681	257,067	1,194,748
Total expenditure		2,604,108	256,727	2,860,835	1,722,475	257,067	1,979,542
Net gains/(losses) on investments	15	30,632	-	30,632	(77,221)	-	(77,221)
Net (outgoing)/incoming resources		(559,378)	(7,576)	(566,954)	(1,606)	84,337	82,731
Other recognised gains and losses							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		(546,738)	(7,576)	(554,314)	11,034	84,337	95,371
Fund balances at 1 January 2023		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035
Fund balances at 31 December 2023		2,424,750	148,342	2,573,092	2,971,488	155,918	3,127,406

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES - CHARITY INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
<u>Income and endowments from:</u>							
Donations and legacies	3	591,126	249,151	840,277	836,570	341,404	1,177,974
Fundraising income	5	1,237,052	-	1,237,052	794,529	-	794,529
Investments	6	34,057	-	34,057	43,352	-	43,352
Other income	7	963	-	963	901	-	901
Total income		1,863,198	249,151	2,112,349	1,675,352	341,404	2,016,756
<u>Expenditure on:</u>							
Raising funds	8	1,092,990	-	1,092,990	662,056	-	662,056
Charitable activities	9	1,158,403	256,727	1,415,130	937,681	257,067	1,194,748
Material other expenditure	14	202,130	-	202,130	-	-	-
Total expenditure		2,453,523	256,727	2,710,250	1,599,737	257,067	1,856,804
Net gains/(losses) on investments	15	30,632	-	30,632	(77,221)	-	(77,221)
Net (outgoing)/incoming resources		(559,693)	(7,576)	(567,269)	(1,606)	84,337	82,731
Other recognised gains and losses							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		(547,053)	(7,576)	(554,629)	11,034	84,337	95,371
Fund balances at 1 January 2023		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035
Fund balances at 31 December 2023		2,424,435	148,342	2,572,777	2,971,488	155,918	3,127,406

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Fixed assets					
Tangible assets	17		887,448		879,550
Investments	18		646,130		611,708
			<u>1,533,578</u>		<u>1,491,258</u>
Current assets					
Stocks	20	8,435		35,404	
Debtors	21	306,117		407,042	
Investments	22	206,482		403,520	
Cash at bank and in hand		629,819		961,507	
		<u>1,150,853</u>		<u>1,807,473</u>	
Creditors: amounts falling due within one year	23	<u>(111,339)</u>		<u>(171,325)</u>	
Net current assets			<u>1,039,514</u>		<u>1,636,148</u>
Total assets less current liabilities			<u>2,573,092</u>		<u>3,127,406</u>
Income funds					
Restricted funds	25		148,342		155,918
<u>Unrestricted funds</u>					
Designated funds	26	1,114,976		1,347,823	
General unrestricted funds		1,309,774		1,623,665	
			<u>2,424,750</u>		<u>2,971,488</u>
			<u>2,573,092</u>		<u>3,127,406</u>

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2023


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.


The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 26 June 2024.

DocuSigned by:

6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:

8FAD9028C739453...

.....
Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

CHARITY BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023		2022	
		£	£	£	£
Fixed assets					
Tangible assets	17		887,448		879,550
Investments	18		646,230		611,808
			<u>1,533,678</u>		<u>1,491,358</u>
Current assets					
Stocks	20	8,435		6,225	
Debtors	21	301,802		396,851	
Investments	22	206,482		403,520	
Cash at bank and in hand		629,819		961,507	
			<u>1,146,538</u>	<u>1,768,103</u>	
Creditors: amounts falling due within one year	23	(107,439)		(132,055)	
Net current assets			<u>1,039,099</u>		<u>1,636,048</u>
Total assets less current liabilities			<u>2,572,777</u>		<u>3,127,406</u>
Income funds					
Restricted funds	25		148,342		155,918
<u>Unrestricted funds</u>					
Designated funds	26	1,114,976		1,347,823	
General unrestricted funds		1,309,459		1,623,665	
			<u>2,424,435</u>		<u>2,971,488</u>
			<u>2,572,777</u>		<u>3,127,406</u>

LEUKAEMIA CARE

CHARITY BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2023


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.


The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 26 June 2024.

DocuSigned by:

6CF4719F0E4E433...

.....
Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:

8FAD9028C739453...

.....
Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	30		(525,632)		223,094
Investing activities					
Purchase of tangible fixed assets		(33,360)		(32,034)	
Purchase of investments		(118,518)		(69,247)	
Proceeds from disposal of investments		111,022		57,573	
Other investment movements		3,705		8,298	
Investment income received		34,057		40,580	
Net cash (used in)/generated from investing activities			(3,094)		5,170
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(528,726)		228,264
Cash and cash equivalents at beginning of year			1,365,027		1,136,763
Cash and cash equivalents at end of year			836,301		1,365,027
Relating to:					
Cash at bank and in hand			629,819		961,507
Short term deposits included in current asset investments			206,482		403,520

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable group's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable group is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charitable group. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination.

1.3 Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Leukaemia Care together with all entities controlled by the parent company (its subsidiaries).

All financial statements are made up to 31 December 2023. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group's financial statements from the date that control commences until the date that control ceases.

1.4 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable group has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charitable group.

1.6 Income

Income is recognised when the charitable group is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable group has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charitable group has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.7 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.8 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	Over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.9 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.10 Impairment of fixed assets

At each reporting end date, the charitable group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.11 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.12 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.13 Financial instruments

The charitable group has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable group's balance sheet when the charitable group becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost. Financial assets classified as receivable within one year are not amortised.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligated to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charitable group's contractual obligations expire or are discharged or cancelled.

1.14 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charitable group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charitable group's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by the review process.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

3 Donations and legacies Group and charity	Unrestricted funds		Restricted funds		Total		Unrestricted funds		Restricted funds		Total	
	2023	2023	2023	2023	2023	2023	2022	2022	2022	2022	2022	2022
	£	£	£	£	£	£	£	£	£	£	£	£
Donations and gifts	271,297	179,151	450,448	122,951	229,046	351,997	229,046	122,951	351,997	122,951	351,997	351,997
Legacies receivable	165,303	-	165,303	45,318	366,506	411,824	366,506	45,318	411,824	45,318	411,824	411,824
Corporate grants and donations	154,526	70,000	224,526	173,135	241,018	414,153	241,018	173,135	414,153	173,135	414,153	414,153
	591,126	249,151	840,277	341,404	836,570	1,177,974	836,570	341,404	1,177,974	341,404	1,177,974	1,177,974

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Trading income Group

Trading subsidiary 2023 £	Trading subsidiary 2022 £
150,900	193,750

Sales

5 Fundraising income

Group

Unrestricted funds 2023 £	Unrestricted funds 2022 £
1,237,052	723,517

Fundraising events

Charity

Unrestricted funds 2023 £	Unrestricted funds 2022 £
1,237,052	794,529

Fundraising events

6 Investments Group and charity

Unrestricted funds 2023 £	Unrestricted funds 2022 £
6,475	25,900
9,452	7,380
18,130	10,072
34,057	43,352

Rental income

Investment income

Interest receivable

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Other income Group and charity

Unrestricted funds	Unrestricted funds
2023	2022
£	£
Solar panels	901
	901

8 Raising funds Group

Unrestricted funds	Unrestricted funds
2023	2022
£	£
<u>Fundraising and publicity</u>	
Staging fundraising events	198,534
Advertising	43,972
Other fundraising costs	73,022
Staff costs	284,286
Depreciation and impairment	4,564
Support costs	50,504
	654,882
<u>Fundraising and publicity</u>	
	1,082,194
<u>Trading costs</u>	
Other trading activities	79,330
Staff costs	43,408
Support costs	3,170
	125,908
<u>Trading costs</u>	
	357,850
<u>Investment management</u>	
	4,004
	784,794
	1,445,705

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

8 Raising funds (Continued)

Charity

	Unrestricted funds	Unrestricted funds
	2023	2022
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	313,862	198,534
Advertising	48,883	43,972
Other fundraising costs	114,340	73,022
Staff costs	540,476	284,286
Depreciation and impairment	4,866	4,564
Support costs	59,767	50,504
	<hr/>	<hr/>
Fundraising and publicity	1,082,194	654,882
	<hr/>	<hr/>
<u>Trading costs</u>		
Support costs	5,135	3,170
	<hr/>	<hr/>
Trading costs	5,135	3,170
	<hr/>	<hr/>
<u>Investment management</u>	5,661	4,004
	<hr/>	<hr/>
	1,092,990	662,056
	<hr/> <hr/>	<hr/> <hr/>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

9 Charitable activities

	2023 £	2022 £
Staff costs	790,994	700,036
Depreciation and impairment	33,236	31,177
Patient Services costs	112,181	63,588
Conferences	2,126	2,256
Help Line costs	6,722	7,109
Leukaemia Matters/Nursing Matters	34,315	28,378
Campaign costs	76,151	42,683
Other charitable activities	6,685	18,913
Nurse e-learning tool	3,056	(1,081)
GP's e-learning tool	7,099	5,384
Other grants	155,500	168,054
Database costs	7,037	5,482
Patient Advocacy	1,481	(16,724)
Website costs	32,718	22,578
Other costs	9,159	2,842
	<u>1,278,460</u>	<u>1,080,675</u>
Share of support costs (see note 10)	124,689	106,677
Share of governance costs (see note 10)	11,981	7,396
	<u>1,415,130</u>	<u>1,194,748</u>
Analysis by fund		
Unrestricted funds	1,158,403	937,681
Restricted funds	256,727	257,067
	<u>1,415,130</u>	<u>1,194,748</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

10 Support costs Group and charity

	Support costs	Governance costs	2023	Support costs	Governance costs	2022
	£	£	£	£	£	£
Staff costs	22,157	-	22,157	16,753	-	16,753
Office costs	162,299	-	162,299	140,428	-	140,428
Audit fees	-	6,600	6,600	-	4,200	4,200
Legal and professional	-	3,419	3,419	-	3,298	3,298
Trustee and meeting expenses	-	7,097	7,097	-	3,068	3,068
	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>
Analysed between						
Fundraising	59,767	-	59,767	50,504	-	50,504
Trading	-	5,135	5,135	-	3,170	3,170
Charitable activities	124,689	11,981	136,670	106,677	7,396	114,073
	<u>184,456</u>	<u>17,116</u>	<u>201,572</u>	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>

Governance costs includes payments to the auditors of £6,600 (2022- £4,200) for audit fees, In addition included in the costs of other trading activities is £3,500 (2022 - £3,500) in respect of the audit of the financial statements of the subsidiary undertaking.

11 Auditor's remuneration

Fees payable to the charitable group's auditor and associates:	2023	2022
	£	£
Audit of the charitable group's annual accounts	6,600	4,200

In addition £3,500 is payable in respect of the audit of the subsidiary undertaking.

12 Trustees

The charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2022: 2) trustees for the current year were £5,748 (2022 : £2,521).

None of the trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arm's length basis and the amount paid during the year amounted to £3,069 (2022 : £2,186).

All trustees are covered by an indemnity insurance policy costing £844 (2022 : £819)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

13 Employees

The average monthly number of employees during the year was:

	2023 Number	2022 Number
Training and provision of care	27	20
Fundraising and publicity	22	16
Accounts and administration	5	4
	<hr/>	<hr/>
Total	54	40
	<hr/> <hr/>	<hr/> <hr/>

Employment costs

	2023 £	2022 £
Wages and salaries	1,296,086	930,750
Social security costs	101,407	78,226
Other pension costs	47,095	35,507
	<hr/>	<hr/>
	1,444,588	1,044,483
	<hr/> <hr/>	<hr/> <hr/>

The remuneration of key management personnel through payroll and other fees is £204,181 (2022 : £190,032).

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2023 Number	2022 Number
£60,001 - £70,000	1	1
	<hr/> <hr/>	<hr/> <hr/>

14 Material other expenditure

Material other expenditure is the write off of the loan with Leukaemia Care Trading Limited as this debt is no longer recoverable.

15 Net (losses)/gains on investments Group and charity

	Unrestricted funds	Unrestricted funds
	2023 £	2022 £
Revaluation of investments	24,702	(70,142)
Gain/(loss) on sale of investments	5,930	(7,079)
	<hr/>	<hr/>
	30,632	(77,221)
	<hr/> <hr/>	<hr/> <hr/>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

15 Net (losses)/gains on investments (Continued)

16 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

The subsidiary undertaking is required to Gift Aid profits arising to the parent charity such that no tax charge arises.

17 Tangible fixed assets Group and charity

	Freehold buildings	Computers and other equipment	Fixtures and fittings	Total
	£	£	£	£
Cost				
At 1 January 2023	842,599	276,673	14,656	1,133,928
Additions	-	33,360	-	33,360
Disposals	-	(183,869)	-	(183,869)
At 31 December 2023	842,599	126,164	14,656	983,419
Depreciation and impairment				
At 1 January 2023	-	241,993	12,385	254,378
Depreciation charged in the year	12,640	23,996	1,466	38,102
Eliminated in respect of disposals	-	(183,869)	-	(183,869)
Revaluation	(12,640)	-	-	(12,640)
At 31 December 2023	-	82,120	13,851	95,971
Carrying amount				
At 31 December 2023	842,599	44,044	805	887,448
At 31 December 2022	842,599	34,680	2,271	879,550

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

18 Fixed asset investments

Group

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2023	599,249	12,459	-	611,708
Additions	118,518	(118,518)	-	-
Valuation changes	24,702	-	-	24,702
Other cash movements	(212)	4,002	-	3,790
Loss on disposal	5,930	-	-	5,930
Disposals	(111,022)	111,022	-	-
	<u>637,165</u>	<u>8,965</u>	<u>-</u>	<u>646,130</u>
Carrying amount				
At 31 December 2023	<u>637,165</u>	<u>8,965</u>	<u>-</u>	<u>646,130</u>
At 31 December 2022	<u>599,249</u>	<u>12,459</u>	<u>-</u>	<u>611,708</u>

Charity

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2023	599,249	12,459	100	611,808
Additions	118,518	(118,518)	-	-
Valuation changes	24,702	-	-	24,702
Other cash movements	(212)	4,002	-	3,790
Loss on disposal	5,930	-	-	5,930
Disposals	(111,022)	111,022	-	-
	<u>637,165</u>	<u>8,965</u>	<u>100</u>	<u>646,230</u>
Carrying amount				
At 31 December 2023	<u>637,165</u>	<u>8,965</u>	<u>100</u>	<u>646,230</u>
At 31 December 2022	<u>599,249</u>	<u>12,459</u>	<u>100</u>	<u>611,808</u>

Other investments represents the interest in the subsidiary undertaking, see note 28.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

19 Financial instruments

Group and charity

	2023 £	2022 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	637,165	599,249

20 Stocks

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Finished goods and goods for resale	8,435	35,404	8,435	6,225

21 Debtors

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Amounts falling due within one year:				
Trade debtors	53,646	183,372	51,266	42,572
Amounts owed by subsidiary undertakings	-	-	-	137,317
Other debtors	2,082	8,467	147	1,759
Prepayments and accrued income	250,389	215,203	250,389	215,203
	<u>306,117</u>	<u>407,042</u>	<u>301,802</u>	<u>396,851</u>

22 Current asset investments

Group and charity

	2023 £	2022 £
Unlisted investments	206,482	403,520

23 Creditors: amounts falling due within one year

	Group 2023 £	Group 2022 £	Charity 2023 £	Charity 2022 £
Other taxation and social security	28,981	24,912	28,981	24,912
Trade creditors	22,137	66,584	22,137	31,064
Accruals and deferred income	60,221	79,829	56,321	76,079
	<u>111,339</u>	<u>171,325</u>	<u>107,439</u>	<u>132,055</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2023*

24 Retirement benefit schemes

Defined contribution schemes

The charitable group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charitable group in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £47,095 (2022 - £35,507).

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds Group and charity

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Balance at 1 January 2022		Movement in funds		Balance at January 2023		Movement in funds		Balance at 31 December 2023	
	£	£	Incoming resources	Resources expended ¹	£	£	Incoming resources	Resources expended	£	£
The Lily Blaeu Hope Fund	22,467	-	-	(13,083)	9,384	-	-	(9,384)	-	-
Information Booklets	23,587	-	-	(23,587)	-	5,985	-	-	5,985	5,985
GP e-learning tool	7,556	8,423	8,423	(15,979)	-	25,000	(25,000)	-	-	-
Nurse Advisor	-	30,346	30,346	(30,346)	-	-	-	-	-	-
Student/Education	5,000	-	-	-	5,000	-	-	(5,000)	-	-
Glasgow Area	-	1,900	1,900	(1,600)	300	10,000	(7,471)	-	2,829	2,829
Support Group - Scotland	4,510	-	-	(1,176)	3,334	-	(756)	-	2,578	2,578
Counselling Fund	-	10,005	10,005	(9,135)	870	15,000	(15,870)	-	-	-
Travel Grant	-	47,000	47,000	(47,000)	-	-	-	-	-	-
Support Group - Glasgow and Aberdeen	1,546	-	-	(588)	958	-	(958)	-	-	-
Support Group - South Shields	38	-	-	(38)	-	-	-	-	-	-
Support Group - Leicestershire	1,393	-	-	-	1,393	2,000	(278)	-	3,115	3,115
Birmingham Patient Conference	500	-	-	-	500	-	(500)	-	-	-
Welfare & Advocacy support	-	11,594	11,594	(11,594)	-	-	-	-	-	-
Belfast Hospital Support	2,000	9,999	9,999	-	11,999	-	-	-	11,999	11,999
Bristol Hospital Support	2,000	-	-	(869)	1,131	5,000	(5,725)	-	406	406
Financial Grants	-	-	-	-	-	60,000	(60,000)	-	-	-
Patient Conferences/Webinars	-	25,092	25,092	(25,092)	-	-	-	-	-	-
Care Helpline Costs	984	1,375	1,375	(2,359)	-	5,000	(5,000)	-	-	-
Nurse e-learning	-	3,175	3,175	(3,175)	-	-	-	-	-	-
Buddy Scheme	-	19,243	19,243	(19,243)	-	200	(200)	-	-	-
West Midlands Hospital Support	-	9,500	9,500	(9,500)	-	5,593	(5,593)	-	-	-
Spot Leukaemia	-	14,654	14,654	(14,654)	-	30,000	(30,000)	-	-	-

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds	(Continued)					
Support Groups	5,851	(5,851)	-	-	-	-
Newcastle Hospital Support	1,000	-	1,000	6,600	(3,294)	4,306
UCHL Hospital Support	2,000	(985)	1,015	-	(1,015)	-
Manchester Hospital Support	7,000	(2,974)	4,026	3,000	(4,196)	2,830
Nottingham Hospital Support	9,454	-	9,454	2,000	-	11,454
Patient Support Scotland	5,000	(5,000)	-	5,000	(3,294)	1,706
William Davidson - Aberdeen Area	45,318	(800)	44,518	-	(10,990)	33,528
CAR-T	20,000	(10,000)	10,000	-	(10,000)	-
AML Information	15,000	-	15,000	-	(15,000)	-
AML Education	23,135	-	23,135	-	(23,135)	-
Yorkshire Patient Support	10,000	(1,654)	8,346	-	(4,610)	3,736
Wales Hospital Support	3,965	-	3,965	-	(354)	3,611
Support Group Wales	1,375	(785)	590	-	(590)	-
Oxfordshire Hospital Support	-	-	-	2,000	-	2,000
Support Group Leeds	-	-	-	1,580	(540)	1,040
Good Hope Hospital Support	-	-	-	5,000	(5,000)	-
Glasgow Hospital Support	-	-	-	7,000	-	7,000
Northern Ireland Hospital Support	-	-	-	2,500	-	2,500
NNUH Hospital Support	-	-	-	7,612	-	7,612
Plymouth/Devon	-	-	-	9,441	(392)	9,049
Cambridge	-	-	-	2,000	-	2,000
Merseyside	-	-	-	6,000	-	6,000
Swindon Hospital Supports	-	-	-	8,000	-	8,000
Guy's & St Thomas Hospital Support	-	-	-	3,000	-	3,000
Support Group Manchester	-	-	-	2,640	(1,728)	912
Dorset (Bournemouth)	-	-	-	8,000	(854)	7,146
Brighton	-	-	-	3,000	-	3,000
Aberdeen	-	-	-	1,000	-	1,000
	71,581	(257,067)	155,918	249,151	(256,727)	148,342

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

The Lily Blaes Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services

Support Group West Midlands - to facilitate activities for support groups in the area

Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas

Support Group Leicestershire - to facilitate activities for support groups in these areas

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

Patient Support Worcestershire - to facilitate activities for support groups in this area

Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham

Welfare & Advocacy Support - in support of advocacy and welfare advise

Belfast Hospital Support - in support of the costs in providing ward support

Bristol Hospital Support - in support of the costs in providing ward support

Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers

Patient conferences/webinars - grants in support of conferences held in the year.

Care Helpline costs: this represents income received specifically to meet the costs of the Care line.

Support Groups - to facilitate activities for local support groups

Nurse e-learning - funds to support the advancement of knowledge in the nursing profession.

Buddy Scheme - one to one support for patients

West Midlands Hospital Support -to facilitate activities for local support groups

Digital support - to support digital and information projects

Support Group Cambridge - to facilitate activities for local support groups

Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia

CAR-T - offer grants and information to patients being treated with CAR-T.

AML information - Providing a new suite of AML information.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

AML Education - Education of Healthcare Practitioners and patients on AML testing.

Yorkshire Support - to facilitate activities and support in this area.

Wales Hospital Support - in support of costs in providing ward support.

Support Group Wales - to facilitate activities for support groups in this area.

Oxfordshire Hospital Support - in support of costs in providing ward support

Support Group Leeds – to facilitate activities for support groups in this area

Good Hope Hospital Support - in support of costs in providing ward support

Glasgow Hospital Support - in support of costs in providing ward support

Northern Ireland Hospital Support - in support of costs in providing ward support

NNUH Hospital Support - in support of costs in providing ward support

Plymouth/Devon – to facilitate activities and support in this area

Cambridge - to facilitate activities and support in this area

Merseyside - to facilitate activities and support in this area

Swindon Hospital Support – in support of costs in providing ward support

Guy's & St Thomas' Hospital Support - in support of costs in providing ward support

Support Group Manchester - to facilitate activities for support groups in this area

Dorset - to facilitate activities and support in this area

Brighton - in support of costs in providing ward support

_____ Aberdeen - to facilitate activities and support in this area

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

25 Restricted funds

(Continued)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

26 Designated funds Group and charity

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 January 2022	Transfers	Balance at 1 January 2023	Transfers	Balance at 31 December 2023
	£	£	£	£	£
Fixed asset fund	870,617	8,934	879,551	7,897	887,448
Strategic implemetation fund	216,510	251,762	468,272	(240,744)	227,528
	<u>1,087,127</u>	<u>260,696</u>	<u>1,347,823</u>	<u>(232,847)</u>	<u>1,114,976</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the two-year strategy adopted by the Trustees on 31 January 2024.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

27 Analysis of net assets between funds

Group

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2023 are represented by:						
Tangible assets	887,448	-	887,448	879,550	-	879,550
Investments	646,130	-	646,130	611,708	-	611,708
Current assets/(liabilities)	891,172	148,342	1,039,514	1,480,230	155,918	1,636,148
	<u>2,424,750</u>	<u>148,342</u>	<u>2,573,092</u>	<u>2,971,488</u>	<u>155,918</u>	<u>3,127,406</u>

Charity

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fund balances at 31 December 2023 are represented by:						
Tangible assets	887,448	-	887,448	879,550	-	879,550
Investments	646,130	-	646,130	611,708	-	611,708
Current assets/(liabilities)	890,857	148,342	1,039,199	1,480,230	155,918	1,636,148
	<u>2,424,435</u>	<u>148,342</u>	<u>2,572,777</u>	<u>2,971,488</u>	<u>155,918</u>	<u>3,127,406</u>

28 Related party transactions

The charity received £nil (2022 - £71,012) from the subsidiary undertaking under a Gift Aid arrangement. There were no other disclosable related party transactions during the year (2022 - none).

29 Subsidiaries

Details of the charitable group's subsidiaries at 31 December 2023 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held		% Held	
			Direct	Indirect	Direct	Indirect
Leukaemia Care Trading Limited	England & Wales	Fundraising	Ordinary		100.00	

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

30	Cash generated from operations	2023 £	2022 £
	(Deficit)/surplus for the year	(769,084)	82,731
	Adjustments for:		
	Investment income recognised in statement of financial activities	(34,057)	(43,352)
	(Gain)/loss on disposal of investments	(5,930)	7,079
	Fair value gains and losses on investments	(24,702)	70,142
	Depreciation and impairment of tangible fixed assets	38,103	35,741
	Movements in working capital:		
	Decrease/(increase) in stocks	26,969	(35,404)
	Decrease in debtors	303,055	12,466
	(Decrease)/increase in creditors	(59,986)	93,691
	Cash (absorbed by)/generated from operations	(525,632)	223,094
31	Analysis of changes in net funds		
	The charitable group had no debt during the year.		

LEUKAEMIA CARE

England & Wales - Charity number 1183890

Accounts

Charity Registration No. 1183890 (England and Wales)

Charity Registration No. SC049802 (Scotland)

Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE
ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2022

www.leukaemicare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons	Lady Penny Mountbatten Beverley Warboys
Trustees	Mr Christopher R G Matthews-Maxwell (Chair) Mrs W J Davies (Treasurer) Dr Emmanouil Nikolousis Ms E Wilson (Vice Chair) Ms Kate Stallard Mr Robert Heppell Mr Dharmesh Mehta Professor Mhairi Copland (Appointed 2 February 2022) Ms Carina Patterson Helen Knight (Appointed 4 May 2022) Dr Sarah Smith (Appointed 2 February 2022)
President	Dr Richard Taylor
Vice Presidents	Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Andrew Pettitt Dr Noel E M Harker Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Mr Albert Podesta
Senior Management Team	
Chief Executive Officer	Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Communications and Fundraising Director	Nicole Scully
Medical Advisory Panels	As described in the Trustees' Report
Secretary	Monica Izmajlowicz
Charity number (England and Wales)	1183890
Charity number (Scotland)	SC049802
Company number	11911752
Website	www.leukaemiacare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Registered office

One Birch Court
Blackpole East
Worcester
WR3 8SG

Auditor

Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Bankers

Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ

Solicitors

Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG

Investment advisors

Cardale Asset Management
2 Greengate
Cardale Park
Harrogate
HG3 1GY

CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET

Brewin Dolphin
12 Smithfield Street
London
EC1A 9BD

LEUKAEMIA CARE

CONTENTS

	Page
A word from our Chairman and CEO	1
Trustees' report	2 - 28
Statement of trustees' responsibilities	29
Independent auditor's report	30 - 32
Statement of consolidated financial activities	33
Statement of financial activities - charity	34
Consolidated Balance sheet	35 - 36
Charity Balance sheet	37 - 38
Statement of cash flows	39
Notes to the financial statements	40 - 61

LEUKAEMIA CARE

A word from our Chairman and CEO

FOR THE YEAR ENDED 31 DECEMBER 2022

2022 was a year of change at Leukaemia Care – including a new long-term strategy, with a fresh look at our vision, mission, and long-term goals and the way we operate after the challenges of the pandemic. Our new strategy focuses on “The future we will create together” setting out our vision and goals to 2030. Alongside this we implemented an ambitious operational plan including significant investment from reserves to ensure we are on the path to delivering our long-term goals.

A key part of the plan is to diversify and grow our income to allow us to deliver new services and expand existing ones to reach more people. To do this, we expanded our fundraising team bringing in expertise in areas such as grants and trusts, while increasing resources in existing fundraising streams.

Planning started on Leukaemia Care's first public art trail “Unicornfest”, with a trail of 60 sponsored unicorn statues throughout Bristol throughout the Summer of 2023 raising both awareness and funds for Leukaemia Care. Each sculpture is painted by a local artist, which will then be auctioned to raise money for the charity.

Other exciting developments include the launch of World Gaming Day on the 22 October – a new initiative from Leukaemia Care encouraging supporters to gather with friends to play games and raise money for charity.

2022 will also go down on record as the year Leukaemia Care raised over £2 million for the first time! This represents our best year ever and a 59% growth on income from 2021. We ended the year with income up on budget, and contrary to expectations of a significant deficit we ended up with a surplus of approximately £95k. With this improvement in our financial position, we will work to invest further from reserves for the long-term benefit of the charity.

However, 2022 was not without its challenges. Recruitment delays across fundraising until late in the year put pressure on our staffing team to deliver on an ambitious plan which makes many of these achievements even more significant and mean we will start 2023 on the front foot.

Other significant achievements to take note of include growth in the number of new people accessing our services, successful partnerships with other charities including on the Spot Leukaemia campaign, providing additional financial support for the Cost of Living crisis through our financial grants and oversubscribed welfare service, widespread press coverage of Leukaemia Care and the people we support, and increasing our reach to ensure more people are aware of us and the ways we can provide support.

The quotes and testimonials within this report speak to the impact we are making to the lives of people affected by leukaemia, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It is difficult not to be moved and we invite anyone to get involved and become part of this vibrant community of people working to improve the lives of people with blood cancer – we are, after all, *Your Blood Cancer* charity.

With warm wishes

Chris Matthews-Maxwell (Chair) and Zack Pemberton-Whiteley (CEO)

Date: 21 June 2023

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees present their annual report and financial statements for the year ended 31 December 2022.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charitable group's memorandum & articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019).

Objectives and activities

About us

Leukaemia Care is the UK's leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.

We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

We believe in improving lives and being a force for change. To do this, we have to challenge the status quo and do things differently.

Purpose

The charity's objects are set out in its articles of association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from Leukaemia and allied blood disorders.
2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - What we are doing to make that vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising public awareness, improving services, and ensuring access to effective treatments.

But most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our values - What do we stand for?

Leukaemia Care's values are at the heart of everything we do. They describe our approach to our work. They drive our thinking, our behaviours and our actions.

Mission based

We have a clear mission. We exist to improve the lives of people affected by leukaemia, MDS and MPN. We believe in doing the right thing. If it is not in the best interests of people affected by our mission, we will not do it. It is that simple. No ifs, no buts, no exceptions.

Collaborative

We are passionate about all forms of collaboration, especially with other charities. Our mission is bigger than Leukaemia Care. We know that working on our own will delay the day when everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support. That is why it is so important that we work in partnership with individual charities, charity coalitions, healthcare professionals and a wide range of other stakeholders to improve the lives of people affected.

Caring

It is in our name, and it is in our nature. We care deeply about every single person affected by leukaemia, MDS and MPN. We are on your side and always will be. This helps us deliver high quality support, but also underpins all other parts of the charity. We care about the people who dedicate their time to our mission – whether that is our colleagues, volunteers, supporters or fundraisers. We are a community united by a common mission and we care about each other.

Evidence based

We listen to and understand the experiences of people affected by leukaemia, MDS and MPN. We use the evidence we gather to adapt, improve our services and to focus our campaigns for change. We also work with healthcare professionals – including haematologists, nurses and GPs – to make sure we are rooted in the latest science.

Aspirational

We have ambitious goals and we set ourselves high standards to achieve them. We believe that everyone affected by leukaemia, MDS and MPN should get the best possible diagnosis, information, advice, treatment and support. Every day 44 people are diagnosed with leukaemia, MDS or MPN, we can't afford to wait. To achieve this change we must be innovators, problem solvers, challengers to the status quo and each and every one of us must go above and beyond, every single day.

Our values are key to everything we do. But we all make mistakes. If you see us acting in a way that you feel is not consistent with our values – please let us know!

Why our work is important

To paint a picture of the scale of the issue across the UK:

- Leukaemia is the 12th most common form of cancer and 12th biggest cancer killer.
- Every year, 10,000 people are diagnosed with leukaemia in the UK.
- Every year, 5,000 people die from leukaemia in the UK.
- Every year 6,000 people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
- Over 50,000 people are living with leukaemia in the UK.
- There are 34,000 people living with MDS or MPN in the UK.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our Strategic Goals

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. Over the last 50 years, we have come a long way, but there is more to be done.

We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

That will not happen overnight. But we are closer than ever before, and we are working to create that future every single day.

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner:

1. Improving diagnosis – through awareness and early detection.
2. Ensuring everyone receives high quality information, advice and support.
3. Tackling issues that impact people's lives.
4. Advancing treatment and care.
5. Creating a narrative to better reflect the reality people experience. But we need your help. If you believe in the future we are trying to create and want to help us get there faster, please get involved.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our '#SpotLeukaemia' campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our GP training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

Grant making by Leukaemia Care

Leukaemia Care has four grant making streams: the Financial Hardship Fund (now the Cost of Living with Leukaemia Fund), the Exceptional Hardship Fund, the Leukaemia Counselling Fund, and the CAR-T Away from Home Service (launched in 2022). These contribute towards addressing the recommendations made in our Living with leukaemia reports which inform our strategic aims.

Financial Hardship Fund (now the Cost of Living with Leukaemia Fund)

This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPN). There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month. In 2022, we collaborated with Leukaemia UK, who provided a £20,000 grant to enable an additional 100 families to access this support.

The Financial Hardship Fund ran out in September, but we continued to register interest from people who would like to apply when further funding became available. Demand for the Fund was amplified with the UK's recent cost of living crisis. Compared with 2021, 2022 has seen a 4-fold increase in applications to the fund. Demand for the service increased throughout the year from 37 per month in Q2 to 64 per month in Q3.

In December, we launched a short-term "Cost of Living with Leukaemia Fund" in partnership with Leukaemia UK who provided a £27,000 grant to co-fund the project, to help families affected by leukaemia, MDS and MPN get through the winter. Due to high demand, this was a £100 grant to eligible applicants rather than the usual £200. Our intention is to rename the Financial Hardship Fund going forward as the "Cost of Living with Leukaemia Fund".

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Exceptional Hardship Fund

Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are considered for an additional grant of up to £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse to public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependant (adult and/or child) etc.

The Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

CAR-T Away from Home Service

CAR-T (Chimeric Antigen Receptor) t-cell therapy is a type of treatment for leukaemia that has revolutionized the way leukaemia is treated. It was first approved for B cell acute lymphoblastic leukaemia (ALL) but is expected to change the way other forms of leukaemia patients are treated in the future.

The way the therapy is delivered means that patients often have long periods of waiting and spending time near to hospital to receive the treatment.

There are a limited number of specialist hospitals currently able to deliver CAR-T therapy in England, Wales and Northern Ireland. As a result, patients may need to travel to a different part of the country to receive treatment and need accommodation nearby. This can cost a lot of money directly or stop the person from being able to earn an income in this time.

Leukaemia Care believes that financial circumstances should never prevent someone from accessing the treatment they need. We have set up this project with our partners, Dalata Hotels Group, to prevent this from happening to as many patients as possible.

People can apply for accommodation, grant funding or both with one grant per family. This grant is only open to those currently going through CAR-T therapy and people can apply as soon as they become aware that CAR-T is recommended as a treatment for them. The fund does not have a closing date and funds are allocated on a first come first served basis until the fund is depleted.

Thanks to our hotel partner Dalata, we can offer free accommodation in one double or twin room per family per stay for up to 30 days. This is booked and arranged by Leukaemia Care and we must know the dates in advance. This cannot be exchanged for money, vouchers, or another hotel.

We also pay up to £500 in a cash grant to help with other expenses related to having CAR-T therapy. This could include, but is not limited to travel expenses, increased food costs while away from home etc.

Achievements and performance

A new long-term strategy is launched

The pandemic accelerated our long-term planning, and we spent six months re-evaluating our vision, mission, and strategic goals. In November 2021, the Trustees formally approved a new long-term strategy alongside a three-year operational and organisational plan and budget for 2022 to 2024. This was mentioned in the "Our future plans section" of our annual report and accounts for 2021.

Long-Term Strategy

As the UK's leading leukaemia charity, we exist to improve the lives of people affected by leukaemia and related blood cancer types – myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

Our long-term strategy aims to set out afresh Leukaemia Care's vision, mission, values and five clear goals to guide us forward. It is a statement of intent. For the first time ever, we have made this a public document that can be accessed in the "About us" section of our website, allowing us to clearly and publicly state who we are and what we stand for, encouraging people to join us in our mission to create a future where everyone gets the best possible diagnosis, information, advice, treatment and support.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

This public statement helps clarify our positioning as the UK's leading leukaemia charity, covering everything related to leukaemia and related blood cancers (e.g. support, information, campaigning, researching patient experience, being a strong voice for the leukaemia community), except funding clinical research.

We will continue to develop collaborations with other charities depending upon their focus, organisational similarities or topic specific expertise. We recognise that other organisations are better placed to provide this support for other forms of blood cancer - such as lymphoma or myeloma, and we continue to signpost people to the best possible information, advice and support for their particular circumstances (e.g. Lymphoma Action, Myeloma UK).

Operational Plan

The new operational plan has been reorganised to align with our long-term strategy, as the first steps towards achieving our long-term goals. Whilst it contains many activities from previous years (as well as some new ones), it is now organised by our strategic goal (why we are doing it) rather than a delivery plan (who or how we will deliver it).

This recognises our need to work as a whole organisation, rather than individual teams, to achieve our collective goals. Whilst an individual or a department may lead on an activity, we work as one team and seek input and feedback from colleagues across the whole charity where appropriate.

Performance Measures

Our performance measures help us measure our progress towards our goals. For each activity at Leukaemia Care, we have set both targets (effective) and stretch targets (highly successful) for 2022. All targets are based on historical outcomes and expected outcomes in 2021 where a service is already in place, and for new services we have used informed assumptions. These will be used for reporting, with all targets for future years reviewed considering the performance and outcomes from the current financial year.

Organisational Plan

The organisational plan outlines our commitment to developing the charity through supporting employee wellbeing, effective recruitment and induction, targeted staff development and training, a performance management process that aligns with behaviours and our organisational values, and effective recruitment and management of volunteers towards delivering on our long-term strategy. It recognises that internal communication is vital, contributing to employee wellbeing as well as improving the delivery of our key objectives. We are committed to consulting with employees on key initiatives such as flexible working, wellbeing and internal communications, as well as other key topics that arise.

Development Process

The proposals within the operational plan are fully costed and seek to build upon measured outcomes from previous years and evidenced proposals from across Leukaemia Care with new opportunities and ideas.

At the centre of this plan is listening to and understanding the experience of people affected by leukaemia, MDS and MPN. This tells us why we do things. It starts with obtaining evidence through patient surveys (such as the Living with Leukaemia project and annual feedback survey) and external projects (such as Blood Cancer Alliance's work on unmet needs). But it also comes through seeking individual inputs more directly through our patient and medical advisory panels.

In 2021, we incorporated a much wider range of internal perspectives as part of the planning process. At the outset of the process, Trustees were invited to take part in a facilitated discussion with the CEO to seek their views, suggestions and long-term ambitions for the charity. There was a high level of alignment across the board. Feedback focused around perceptions of the charity, unmet needs for patients and healthcare professionals, organisational strengths and weaknesses, prioritisation of activities, external opportunities and challenges, differentiating Leukaemia Care from other blood cancer charities and investment of reserves into developing the organisation and its activities. Insights from these discussions have primarily informed the development of the long-term strategy and operational plan.

Employee input was sought through an anonymous survey, with responses analysed to consider both overall aligned perspectives and areas of differing views. Key themes that emerged from this exercise included inspiring people to support us by better demonstrating our impact, improving the way we do things internally to improve outcomes for patients and understanding what has the greatest impact on the wellbeing of employees. Following

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

the survey, employee focus groups were used to further explore or clarify these topics. These insights are at the core of developing the organisational plan, as well as providing a more nuanced view and insights as part of the operational plan.

Conclusion

As a result of this process, our new plan for 2022 to 2030 represents our best current thinking on the way to make our vision a reality, as soon as possible. But it is open to challenge, new ideas and change as things develop. We are more committed to achieving our vision than to any particular plan we happen to be following right now. We recognise this plan is ambitious and will be challenging to implement in its entirety. It is at the core of our values as an organisation to have ambitious goals and to set ourselves high standards to achieve them. We owe it to people affected by leukaemia, MDS and MPN to do our utmost to advance our vision, as quickly as possible. We owe it to people who donate their money to spend it in a way that makes this vision come true.

Our achievements

Improving diagnosis – through awareness and early detection

We achieve this through our annual Spot Leukaemia campaign, targeting awareness days like World Leukemia Day and through our education work with GPs and other healthcare professionals.

In 2022 we continued our collaboration with Leukaemia UK for our Spot Leukaemia campaign, focusing on raising awareness of the symptoms of leukaemia in the over 65's. We soft-launched at the end of August with our new creative video (featuring Henry the Parrot) and 36 patient stories along with national and regional PR. Within the first week we received 509 pieces of press both nationally and regionally as well as TV.

Overall the campaign reached over 15 million people on social media, with 161,285 views of our campaign video (Henry the Parrot) which raised awareness of the main symptoms of leukaemia; fatigue, bruising, bleeding and infection, urging people to go to their GP and ask for a blood test if they experienced these symptoms.

Throughout the year, we ran mini campaigns on awareness days such as World Leukemia Day, MDS Day, Know AML Day and World Cancer Day. World Leukemia Day (4 September) which was launched by Leukaemia Care in partnership with worldwide patient advocacy groups reached 30,185,694 people on social media exceeding the 8 million reached in 2021.

We continue to provide education for general practitioners (GPs) through our GP online learning modules via the Royal College of General Practitioners (RCGP) and Gateway C, including two new webinars for GPs. In person events with GPs prior to COVID had good uptake and feedback, but the RCGP has no plans yet to return to local in person training events. However, we continue to attend and staff information stands at conferences aimed at GPs such as the Best Practice conference. In 2023, we will review our approach and investigate ways of promoting our online learning modules.

Ensuring everyone receives high quality information, advice and support

Leukaemia and blood cancer is highly complex. We know that at diagnosis people are significantly less likely to understand what is wrong with them than for other forms of cancer. Many are left worried and confused.

We know that high quality information, advice and support is key. Whilst most people receive information about their blood cancer, few receive information about emotional, practical and financial support. Information is also more likely to be provided at diagnosis, with a drop off after treatment finishes. We are working to stop this.

This area of work covers our core frontline services for patients and their families. Our written information (hard copy and online), videos, podcasts, webinars and conferences. Our advice service incorporating the helpline, WhatsApp, email, advocacy casework and welfare advice, and hospital hubs. Our support services; support groups, online forums, one to one buddy support, financial grants, counselling and free wills.

In 2022, we adopted a new format for information suites of leukaemia information, with all the information tailored by leukaemia type and creating a pathway of different points where people can access information (e.g. diagnosis, starting treatment). This is a significant project and in 2022, we completed the new format for acute lymphoblastic leukaemia (ALL) resulting in 10 new booklets.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We continue to offer our existing booklets alongside the new formats and in 2022, distributed 13,862 hard copies and 15,118 digital copies were downloaded from our shop. We also gained accreditation with the Patient Information Forum "PIF Tick" scheme for patient information ensuring our information continues to be produced and reviewed in a robust way.

"I am a recently diagnosed Chronic Myeloid Leukaemia person and have felt quite scared by my recent diagnosis. However, having read this booklet, I felt much more positive. The practical advice and living beyond the diagnosis has made me feel less scared about the future." **Feedback from patient on our Living with Chronic Myeloid Leukaemia (CML) booklet**

We also provide information on the rarer leukaemias recognizing that these patients face additional challenges in both getting up to date accessible information on their cancer and meeting fellow patients who share their condition.

"It is very hard to find information about this rather rare condition but this leaflet is without doubt the best and most comprehensive summary I have found. A must for any recently diagnosed people." **Feedback from a patient on our Large Granular Lymphocytic Leukaemia (LGLL) booklet**

We recognize that people like to access information in different formats not just booklets and that many would like an introduction to our services. We sent out 1,005 Welcome Packs introducing people to our services and signposting them to our booklets, blogs, monthly podcast, videos and webinars.

We ran 20 webinars on a variety of topics which were all recorded so they can be accessed time and time again for people looking for information and debate on key topics. Our webinars were viewed 16,352 times on social media.

"I have been watching Leukaemia Care webinars since the start of lockdown and they have always been really interesting, informative and very supportive. I found this last one particularly pertinent, as I have been told by my consultant that I will need treatment soon. Thank you so much, I feel less scared now. I feel well informed and confident in the treatment I have been offered."

Patient feedback on CLL webinar

Alongside our information, we offer the opportunity to seek advice and support from our clinical nurse specialists, trained advocates and welfare advisors. We provided 906 people with timely advice and support via our helpline, WhatsApp and email with an average feedback score of 4.75 out of 5.

"This is the only place I can come to speak about my leukaemia, having a nurse who understands my condition available at the end of the phone is invaluable."

"It is amazing to have such a specialist service available for free."

Feedback from leukaemia patients

Our Advocacy caseworker supported 266 people with issues such as obtaining travel insurance and COVID booster vaccinations, making complaints about hospital care and getting support with additional needs such as enduring mental health problems alongside a blood cancer diagnosis. They work closely with our Welfare Officer as many people have varied and complex needs that also touch on finances.

"Your organization throughout me having to shield has been so helpful to me, supporting me with issues at work but also keeping blood cancer patients updated as to the latest regarding Covid. A big thank you,"

Our Welfare Officer supported 217 people with the majority of queries being classed as major i.e. complex, helping people to apply for benefits, challenge benefits decisions, apply for grants of money and goods and processing applicants for our Financial Hardship Fund, Exceptional Hardship Fund and CAR-T Away from Home Fund. The cost of living crisis has had a severe impact on people's finances already impacted by a leukaemia diagnosis.

"Dad had his letter today to say he is entitled to the lower rate of attendance allowance. Thank you so much for your help as he wouldn't have applied and he would have been missing out."

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

"I just wanted to let you know that my PIP application has been processed and I have been awarded the enhanced rate for both daily living and mobility! I am delighted as this now means I can apply for a blue badge! Thank you so much for all your support which without, I am sure, I would not have been able to get the enhanced rate. Thank you so much"

"...being able to plan some great summer holiday childcare while I'm in hospital having my stem cell transplant without worrying about how we were going to pay for it is such a blessing and a massive relief. It will give them something to look forward to and enjoy during such a difficult time. Your support has enabled my young children to be children. Thank you so much for all the hard work and support you have given to me."

We have ten hospital hubs based in Good Hope (Sutton Coldfield), Solihull Hospital, Heartlands Hospital, the Worcestershire Royal, St James Hospital in Leeds, Southampton General, University of Bristol Hospital, The Christie in Manchester, University College London Hospital and Freeman Hospital, Newcastle. Our hospital support workers provide emotional support, information and advice to patients and their families within haematology departments and on hospital wards, at diagnosis and throughout their treatment. In 2022, we supported 199 people, in person and by phone as needed by the hospitals.

"[HSW] is an asset to our team, supporting patients and us with information, a listening ear, and her time. So many of our patients have been lucky enough to have access to her in her role as Hospital Support Worker, and her support has been invaluable, helping them through very challenging and difficult times. Any questions we as Clinical Nurse Specialists have about the services and support available from Leukaemia Care have been answered quickly by the [HSW], which our team have found very beneficial and has improved our ability to provide the best support to our patients"

Feedback from Clinical Nurse Specialist at St James Hospital, Leeds

We run 38 support groups (in person, hybrid and online only) supporting 1,911 people in 2022 (1,600 in 2021). Many of our members are still uncomfortable about meeting in person due to COVID and clinical vulnerability, especially in Q2 of 2022 when patients were finding it difficult to access spring COVID boosters. Our specialist national support groups are well received especially by those with rarer leukaemias. New groups launched in 2022 include LGLL National, Northern Ireland National, Scotland National and Parents & Families of Children with Leukaemia National Support Group.

We also run an online forum via HealthUnlocked and closed Facebook groups that collectively supported 4,333 people.

"The support and solidarity of the groups and my telephone buddy helps me to remember that I'm not alone and encourages me as I navigate life after cancer. Thank you. Leukaemia Care!"

Feedback from Teesside support group member

"Thank you for the meeting, it was useful and good to speak to others in the same situation as myself. I hadn't thought of myself as a carer but my husband encouraged me to join the meeting! Your email is full of useful information, thank you. Everything still seems a little overwhelming at times but the support from yourselves has really helped us both. Thank you again"

Feedback from wife of ET patient

Our buddy services matches patients and families with people who have a similar diagnosis for emotional support. In 2022, we matched 131 patients for long-term or short-term buddying with some volunteer buddies supporting multiple patients.

"I just wanted to let you know that my buddy is a huge support, and she rings me fortnightly. [Buddy] as I am sure you know, has been through the same CLL treatment as I have had and helps me in so many ways. I was surprised when my telephone consultation re Venetoclax etc was reduced from four weekly to every 8 weeks, but [Buddy] reassured me this was completely normal. She is a very good listener, and such a help. My husband has been, still is very ill with lung & other problems, and [Buddy] always asks me how he is. We talk about all sorts of other things, like gardening which we both enjoy. Thank you so much for partnering the two of us."

Feedback from CLL patient

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

We also started a pilot CAR-T buddy scheme with Great Ormond Street Hospital with one parent ready to start supporting another family. In 2023, we will focus on growing this service which is still in its early stages.

We recognize that a leukaemia diagnosis can have a negative impact on people's finances especially during a cost of living crisis. In 2022, we awarded 465 hardship grants of £100 or £200 and 11 exceptional hardship grants of up to £1,000. Due to unprecedented demand, our Hardship grants ran out in September however, in partnership with Leukaemia UK, we launched a Cost of Living with Leukaemia Fund in December 2022 awarding £100 hardship grants.

We also launched our CAR-T Away from Home service providing patients undergoing CAR-T treatment and their families access to paid hotel rooms and a £500 grant towards increased costs. This is a partnership with our new corporate partner, the Dalata Hotels Group. Launched in September, we awarded three grants in the final three months of the year, helping these families with the financial costs of travelling to access this innovative form of treatment. In 2023, we will work on building relationships with hospitals to ensure they are aware of the service and know they can make an easy referral.

Our counselling fund provides much needed access to specialist support during a time when NHS counselling resources are stretched or non-existent. In 2022, we supported 56 people (35 in 2021) seeking counselling support with issues such as coming to terms with relapse or terminal illness, living with a chronic leukaemia and parents coping with a child's diagnosis.

"I can't express how grateful I am to Leukaemia Care for providing this fund – not just for the financial side of it (which is very generous), but also for how easy it was to get everything set up. I don't think I'd have been able to afford private therapy or had the patience to wait for an NHS appointment, so having such quick and simple access to free counselling made such a huge difference."

We believe everyone diagnosed with a potentially life limiting illness such as leukaemia should have the chance to make a will. In 2022, 53 (41 in 2021) people made a will using our free wills service with many choosing to leave a gift in their will to Leukaemia Care although there is no obligation to do so.

Tackling issues that impact people's lives

This area of our work covers our advisory panels (medical and patient), our patient experience research, our policy and public affairs, campaigns and external advocacy projects.

Our medical and patient advisory panels provide feedback on not only our strategic plans but also our day to day work, to ensure it meets the needs of people affected by leukaemia and other forms of blood cancer. We have 96 healthcare professionals including specialists in the four main leukaemias as well as MDS, MPN and rare leukaemias. These include consultant haematologists, clinical nurse specialists, GPs, psychologists and district general hospital doctors. Our patient advisory panel of 52 includes acute and chronic leukaemia patients, those with rare leukaemias, MDS and MPN.

We are always looking for new members to join our panels especially the patient panels both to ensure they reflect the diverse blood cancer community but also in acknowledgement that people's circumstances change. For instance, some people have been in remission for a while and choose to leave that part of their experience behind them - this is completely understandable.

With regards to our policy and public affairs work, generally, political changes continued to make it hard for us to keep stakeholder engagement up. We welcomed the new ministers with various responsibilities for Cancer, Primary Care and the Secretary of State for Health and Social Care but received no response. This is consistent with the experience of other charities when reaching out to the main stakeholders.

We collaborated with the Department of Health and NHS England on their winter vaccination campaign by creating co-branded assets to share on social media featuring two leukaemia patients. The aim was to encourage more people to come forward and get their booster vaccines, and the graphics were retweeted by the DHSC channel, increasing our reach online.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

The latest draft of the 10-year Scottish Cancer Strategy was released, and following calls from charities including Leukaemia Care the draft included specific consideration of blood cancers for the first time, as far as we are aware, in the Earlier and Faster Diagnosis section: "It is recognised that not all cancers can be conventionally staged so additional measurements, such as emergency presentations, will be required to track progress and improvements in other cancer types, including blood and brain". Although we want to see more emphasis on blood cancers in the final strategy, this is significant because previous strategies have failed to include blood cancers in early diagnosis. Later drafts have also acknowledged the need to frequently publish and share data. We will continue to respond to future drafts on behalf of people affected by leukaemia.

Each of the two campaigns we ran was different in what was most effective; Watch, Wait Worry showed the importance of patients telling their MPs about an issue too, whereas the Spot Leukaemia campaign showed the importance of a good external environment.

Watch, Wait, Worry campaign launched in April

Our 'Left to WatchWaitWorry' campaign aims to improve the lives of people with chronic lymphocytic leukaemia (CLL) on Watch and Wait, by calling for additional support and information. It is estimated that there are currently around 13,300 chronic lymphocytic leukaemia (CLL) patients living on Watch and Wait as their current treatment option. A time which patients often call 'Watch and Worry'.

As part of the campaign, we secured nine written parliamentary questions asked by MPs in Westminster and two parliamentary questions in Scotland on the WatchWaitWorry media campaign. This includes a response from the Cabinet Secretary for Health in Scotland. This gave us insights that we could use to inform our next steps on the campaign, such as including it in our response to the upcoming 10 year cancer plan and Scottish Cancer strategy. This included information about whether data is collected on CLL patients using mental health services and whether or not governments intend to include those on active monitoring in the upcoming plans.

On social media the WatchWaitWorry campaign saw some good engagement from parliamentarians, including tweets from Jeffery Donaldson MP, Robert Buckland MP, Emma Lewell Buck MP, Martyn Day MP, Alex Rowley MSP, Naomi Long MLA, among others.

We had a meeting with Sir George Howarth MP on this campaign and as a result, he posted about the campaign on his website, submitted written parliamentary questions and wrote a letter to the Secretary of State for Health and Social Care. In devolved nations, we met six politicians virtually. We targeted those politicians who had engaged with the emails from the constituents for meetings.

We presented the WatchWaitWorry media campaign report to the RM partners cancer alliance Haem-oncology pathway group meeting. There were haematologists across the West London region in attendance and we discussed the issues patients face and how to work together to improve them. We informed them that we were planning to develop guidelines for secondary care professionals on Watch and Wait which they would welcome. They also suggested we should do similar guidelines for primary care.

Additionally, we hope to pick up the work on best practice guidelines for supporting patients and submit a proposal to the British Society of Haematology guidelines committee by the end of the year.

Malignant Diagnosis, Surely campaign

Can you imagine being diagnosed with a condition and your healthcare team omitting to mention it is a type of cancer? Yet this has been the case for some people diagnosed with myelodysplastic syndromes (MDS).

MDS is a type of cancer and it is important that everyone calls MDS a cancer. By not mentioning the term 'cancer' immediately at diagnosis, and not explaining low-risk vs high-risk, there is a risk that patients find out by chance that MDS is a type of cancer, as soon as they look up any information after their initial appointment, such as using the NHS website. The shock of that discovery, when alone, and the lack of medical staff to check with can be traumatic for many. As a result of misunderstanding their diagnosis, patients might not receive the support that they are entitled to, such as employment rights and access to psychological and financial support.

That's why Leukaemia Care and MDS UK are working together as part of a Malignant Diagnosis, Surely? campaign. We launched a petition to insist that NHS England treat MDS as a cancer in everything they do.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

- Ensure patients get access to cancer care reviews from their GPs and the support of clinical nurse specialists for blood cancers
- Include MDS in NHS cancer data collection (e.g. including them in the Cancer Patient Experience Survey and the Cancer Quality of Life Metrics project).
- Issue communications to healthcare professionals regarding the importance of referring to MDS as a blood cancer, and explaining low vs high-risk types at the point of diagnosis.

We continue to play an active part in a variety of coalitions and alliances both national and international such as Cancer 52, the Blood Cancer Alliance, the Acute Leukaemia Advocates Network, the CML Advocates Network and the Chronic Lymphocytic Leukaemia Advocates Network. This is by no means an exhaustive list, and is just one part of our commitment to collaborate with other charities.

Advancing treatment and care

This area covers our engagement with healthcare professionals – providing training and raising awareness of our services as well as our work on improving access to treatments.

Our Regional Coordinators raise awareness of our services within hospitals across the UK and in 2022, contacted 212 hospitals with both in person visits and virtual meetings. They are also responsible for running our support groups and ensuring members receive the right information and support by signposting to our services.

"[RC] runs successful support groups for our group of patients and the feedback has been excellent, providing a safe and informative platform for people affected by leukaemia to meet and talk to others".

Feedback from a Clinical Nurse Specialist at St James's Hospital, Leeds

"RC is a breath of fresh air. She organises all our support groups and makes patients feel at ease. It has been a pleasure to work with her over the last few years in facilitating a support group for the people of Barnsley."

Feedback from a Clinical Nurse Specialist at Barnsley District General Hospital

Leukaemia Care also offers an online newsletter to healthcare professionals and in 2022, this had 1,904 subscribers. This provides information about our services as well as free training for nurses.

We offer 12 free online courses for nurses ranging from 1 to 4 hours on topics such as CAR-T, emergencies in leukaemia, end of life and acute leukaemia, extravasations, GVHD, supportive care, MPNs, understanding blood and its components, diagnosis of leukaemia, and epidemiology, aetiology and risk factors. The average feedback score from users was 4.25/5 with 217 subscribers in 2022.

Our Acute and Chronic Leukaemia Nurse Forums bring together haematology specialist nurses and allied healthcare professionals with an interest in acute/chronic leukaemia patient care to build capacity and provide opportunities for best practice sharing and networking. In 2022, 52 nurses attended these forums with topics discussed including research projects, vaccinations and leaflets for GPs about CLL.

Leukaemia Care have committed to be actively involved in all relevant Health Technology Appraisals for leukaemia, MDS and MPN to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. In 2022, we were involved at every stage of the health technology appraisal process in 97% of appraisals and were involved at some stage of the process in 100% of appraisals. In 85% of appraisals, patients were directly involved sharing their experience to effect change (e.g. by attending a NICE committee meeting). Outcomes (when the embargo on a decision is lifted by the appraising agency) are reported online via our website and social media as well as in our newsletters and patient magazine, Leukaemia Matters.

Creating a narrative to better reflect the reality people face

Patient stories, press and social media all play a critical role in ensuring that patients and their families as well as the public understand the reality of living with leukaemia.

Sixty-three people shared their story with us to support others and raise awareness of the challenges they face with half of these having benefited from our services. We also updated 51 stories shared in previous years with people and their relatives talking about returns to work and study after treatment, early retirement, ongoing challenges with late effects, and also facing bereavement and loss. Fifty people keen to give back and raise awareness of the support available from Leukaemia Care provided testimonies to be used to encourage people to reach out for help.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

In 2022, we received 56 pieces of national and 651 pieces of regional press coverage with an estimated reach of 1.4 billion. Our social media reach continues to grow especially as part of our Blood Cancer Awareness Month campaign in September (2.5 million in 2022). We invest in social media advertising and paid Google advertising to reach as many patients and potential fundraisers as possible, raising awareness of our free services and the opportunity to volunteer and raise money to support leukaemia, MDS and MPN patients and their families.

Visitors to our website have increased with 1.9 million visits and 2.6 page views in 2022 (1.5 million and 2 million respectively in 2021). Our symptoms of leukaemia information and blogs continue to be our most visited pages. The importance on thinking mobile first is even more prominent in 2022 as we saw a 29% increase in web traffic coming from a mobile device. We expect this to increase year on year and therefore we will have to make sure that any content and website integrations are fit for a mobile first platform.

The bounce rate for the LC website continues to remain high, however, plans to restructure one of the larger areas of the website are in progress and we would hope this changes once complete. It would help our high bounce rate as the user journey will become more streamlined to deliver relevant content to the user. Going forward in 2023, Google Analytics will be putting less emphasis on bounce rate as it will collectively rate web pages through 'engagement rate' which will take into consideration the bounce rate and time spent on a landing page.

Funding from legacies

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2022, we benefited from £411,669 from gifts in wills from the estates of William Davidson, Edward Manning, Violet Whitehead, Beatrice Youngman, Charles French, Jonathan Lovick, Judith Crompton, Lilian Taylor, Alexander McCubbin and Vera Philips. We wish to honour their memory for their support for leukaemia patients and their families.

We promoted our free wills scheme during Free Wills months in March and October. Under this scheme, people can make a simple will (online or by phone) and can leave a gift to the charity if they wish. We encourage anyone diagnosed with a life changing illness such as leukaemia to ensure they have an up to date will regardless of whether they choose to leave a gift to Leukaemia Care. In 2022, 53 people took up the offer of a free will from the charity with legacy pledges of approximately £348,729.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our plan to fund our activities – now and in the future

Our ambitious fundraising plan seeks to secure sustainable growth for the future, raising more money to ensure we can achieve our strategic goals. The charity's ability to deliver much needed activities (information, support, advice, campaigns) is reliant on our fundraising. We cannot improve the way we help people affected by leukaemia, MDS and MPN without expansion in this area.

As explained earlier, 2022 will go down on record as the year we raised over £2 million for the first time representing our best year ever and a 59% growth on income from 2021. This includes a strong legacy year but also better than expected performance from pharmaceuticals, Unicornfest, Ride London and In-Memory giving.

However, there were areas that did not perform as well as expected and some new initiatives that did not work first time round and need refining. Running events including the London Marathon suffered from poor sign-ups, drop-outs and deferrals of running places to following years which impacted 2022 income. Community fundraising also took a hit with our new community challenges failing to sign up enough participants.

Our fundraising team grew from six to sixteen members to allow the charity to develop new income streams and grow existing ones. We recruited expertise and resource in grants and trusts, digital, corporate, events and community fundraising.

New initiatives and partnerships in fundraising

Unicornfest

This is Leukaemia Care's first art trail and will be held in Bristol during summer 2023, raising both awareness and funds for the charity. The unicorns, painted by local artists will be placed throughout Bristol allowing locals and visitors to explore the city via a colourful and uplifting trail that ends with a ticketed farewell event and separate auction in autumn 2023. We ended 2022, with £227,000 raised in sponsorships from almost 40 sponsors. We do not expect further income until 2023 when the unicorns are auctioned. The art trail has been a huge undertaking for the charity with a steep learning curve but we are confident it will not only raise significant income but open the door to longer term corporate partnerships.

Dalata Hotels Group corporate partnership

We are delighted to be working with Dalata Hotel Group PLC from 2022 until 2025. They are the largest hotel operator in Ireland, with a growing presence in the United Kingdom and continental Europe and they will be supporting Leukaemia Care through its Maldron and Clayton hotel chains in England, Scotland and Wales.

The Dalata partnership will support leukaemia patients by providing long stay accommodation close to the hospital that can administer a new treatment called CAR-T. A limited number of specialist hospitals in Great Britain offer this treatment and the locations match conveniently with Dalata hotels, with this project ensuring it is possible for patients to get the treatment they need. Individual hotels will also be fundraising in aid of the charity.

World Gaming Day

Leukaemia Care launched World Gaming Day on the 22 October 2022. This is an opportunity to meet up with friends, play games and raise money for charity. Leukaemia Care sold World Gaming day packages to other charities making it easy for them to run their own World Gaming day fundraising event. Charity partners included Action for Children, Stroke Association, Epilepsy Society and more.

Unfortunately, uptake was limited for this new form of fundraising. We will not dismiss the concept as we believe it has merit, but we think this may take longer to develop and refine as an income stream.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2022*

Funding from legacies

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2022, we benefited from £411,669 from gifts in wills from the estates of William Davidson, Edward Manning, Violet Whitehead, Beatrice Youngman, Charles French, Jonathan Lovick, Judith Crompton, Lilian Taylor, Alexander McCubbin and Vera Philips. We wish to honour their memory for their support for leukaemia patients and their families.

We promoted our free wills scheme during Free Wills months in March and October. Under this scheme, people can make a simple will (online or by phone) and can leave a gift to the charity if they wish. We encourage anyone diagnosed with a life changing illness such as leukaemia to ensure they have an up to date will regardless of whether they choose to leave a gift to Leukaemia Care. In 2022, 53 people took up the offer of a free will from the charity with legacy pledges of approximately £348,729.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) *FOR THE YEAR ENDED 31 DECEMBER 2022*

Funding from grants and trusts

Leukaemia Care receives no statutory funding, but it does receive grants from independent trusts and other funders. These grants are an increasingly important part of our income and significantly improve our ability to deliver services to leukaemia patients and their families across the UK. We would like to thank the following funders for their kind support in 2022:

The 29th May 1961 Charity

The Blakemore Foundation

The Boots Charitable Trust

The Burford Trust

The Donibee Charitable Trust

The Edward and Dorothy Cadbury Trust

The Hospital Saturday Fund

The Hugh Fraser Foundation

The Joseph Strong Frazer Trust

Leukaemia UK

The Liz and Terry Bramall Foundation

Medicash

The National Lottery

The Patrick Trust

The Roger and Douglas Turner Charitable Trust

The Santa Barbara Heights Charitable Trust

The Templeton Goodwill Trust

Tyne and Wear Community Foundation

The Yardley Great Trust

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Funding from the pharmaceutical industry

The charity works with the pharmaceutical industry to ensure that the interests of patients are considered when developing new drugs and treatments for patients.

In addition to our patient advisory work, Leukaemia Care receives funding from a range of pharmaceutical companies. Any funds received from the pharmaceutical industry are received and dispersed strictly within the guidelines laid down by the Association of the British Pharmaceutical Industry (ABPI) and Leukaemia Care's own Code of Practice (see website).

To ensure that we remain financially independent, limits are placed on all types of funding. We do not allow the total level of funding received from the pharmaceutical industry to exceed 25% of our total annual income. Nor do we allow the funding received from an individual company to exceed 10% of our total annual income.

In 2022, Leukaemia Care had our most successful year ever with £402,576 secured in donations from the following pharmaceutical companies.

Abbvie	£15,000 for our AML Support Project
Amgen	£10,000 for core funding
Astellas	£25,000 for our Emotional Support Project
AstraZeneca	£25,000 for our Advice, Information and Support Project
Autolus	£5,000 for core funding
BeiGene	£20,000 for core funding
Bristol Myers Squibb	£15,000 for core funding and £15,000 on behalf of the Blood Cancer Alliance
Gilead	£40,000 core funding
Incyte	£30,000 for our Advice, Information and Support Project
Janssen	£5,000 for core funding
Jazz	£40,000 for our Advice, Information and Support project
Kura Oncology	£12,204 for core funding
Kyowa Kirin	£5,000 for core funding
Lilly	£5,000 for core funding
Mallinckrodt	£22,417 for our Advice, Information and Support Project
Otsuka	£10,000 for our Advice, Information and Support Project
Pfizer	£20,000 for core funding and £23,135 for the AML Testing Project
Pleco Therapeutics	£5,000 for core funding
Servier Labs	£5,000 for our Advice, Information and Support Project
Takeda	£30,000 for core funding and £20,000 for the CAR-T Project

We also received a grant of £15,000 from Gilead towards our Unicornfest art trail, not included in the figures above, with all other pharmaceutical work on this project to take place in 2023.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Financial review

The results for the year are set out in the financial statements commencing on page 32. The financial statements show incoming resources for the year of activities of £2,139,494 compared to incoming resources in 2021 of £1,346,169. Trustees would like to thank all staff and volunteers for the continuing hard work and commitment that have made this possible.

Total reserves stand at £3,127,406 (2021: £3,032,035) of which £155,918 (2021: £71,581) was restricted in application and £1,347,823 (2021: £1,087,127) were designated by the trustees to match the tangible fixed assets of the charity and fund certain projects identified as being required in the immediate future. Those designated funds connected to tangible fixed assets relate predominantly to the freehold property and are likely, given current market conditions, to remain whilst the relevant charitable entity continues to own title to the same. Funds remaining for general use were £1,623,665 (2021: £1,873,327).

The Trustees consider the results for the year to be satisfactory.

Risk assessment and management

We carry out an annual detailed review of the charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

- a comprehensive annual review to identify, where possible, the risks which the charity may face during the forthcoming year
- the establishment, where possible, of contingency plans to meet anticipated risk(s)
- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the charity should any such risk(s) materialise
- the prioritisation of the charity's activities both actual and planned
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan is dependent upon the charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

Our plans for 2023 and beyond

As we seek to grow our impact, we are currently limited by our income levels. Whilst we have high levels of reserves which would enable us to initiate most activities, our current income levels would not enable us to sustain those activities long-term. As such, our plan involves 'investing for growth' by focusing on investing from reserves into new fundraising activities to grow our income, before committing additional expenditure to service delivery from this new income.

Leukaemia Care remains in strong financial health, with total assets of c. £3.1m (including the office) and funds available for use of c. £1.6m.

Leukaemia Care's reserves policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure (2022: 7.1 months). We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily. As such, it is important we continue to invest our reserves to enhance the impact we can have.

We propose to undertake a significant investment from reserves in 2023. To facilitate better understanding of our expected financial position throughout the year, we have set the 2023 budget and targets in January using year-end figures for 2022 and forecasted quarterly for 2023 (income and expenditure). We intend to report against this at Trustee meetings. To accompany the 2023 - 2024 plan, we have produced a 5-year forecast to 2027, to show the longer-term impact of investing into new income streams, some of which (e.g. legacies) take time to bear fruit.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Mitigating Risks

At its centre, the plan includes a strong focus on managing risk, to control our approach to generating and spending new income. Whilst we expect to raise some new forms of income within our baseline plans, given the uncertainty quantifying new income streams this income is not already committed to new expenditure. Additional expenditure is subject to increasing our income or securing restricted funding for the activity, which is only triggered when we are comfortable that it is affordable.

But we have also put in place several other protections beyond this, including:

- Fixed-term contracts – new staff are recruited on a 3-year contract, with extension subject to funding and success of the roles
- Building organisational resilience – ensuring coverage of key skill sets, and developing existing staff within and beyond their roles
- Diversifying income – we have sought to create a wide range of income streams, to ensure we are less reliant on the London Marathon
- Phased investment – at present we have created plans for 2023 and 2024 which include a significant deficit as we seek to grow income. The result of this investment would be a return to breakeven by 2025 and significant surplus into 2026 and 2027, which could be reinvested as appropriate
- Regular review - to determine additional expenditure, reviewed by the senior management team at least monthly and quarterly at Trustee meetings

Performance Measures

Our performance measures help us measure our progress towards our goals. For each activity at Leukaemia Care, we have set both targets (effective) and stretch targets (highly successful).

All targets are based on historical outcomes from 2022 where a service is already in place, and for new dynamic activities we have used informed assumptions. For new dynamic activities, we have set targets per month or quarter, in recognition that these activities may be started at any point through the year.

These performance measures will be used for reporting, with all targets for future years reviewed considering the performance and outcomes from the current financial year.

Our Reserves Policy

Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care's policy to express reserves in terms of 'months of expenditure' for the purposes of external communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

- i. Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

ii. Provision to absorb setback - i.e. predominantly related to income-based risk.

iii. Funds designated for specific commitments – i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

In line with the considerations above, Leukaemia Care's policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure (£1,623,665 – 7.1 months as of 31/12/2022). Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget setting time and in time for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day to day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on-going activities of the Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Structure, governance and management

Constitution

This is the third annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustees in office at any one time are required by the constitution. At each AGM one-third of the trustees, must retire from office but may stand for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr Christopher R G Matthews-Maxwell (Chair)

Mrs W J Davies (Treasurer)

Dr Emmanouil Nikolousis

Ms E Wilson (Vice Chair)

Ms Kate Stallard

Mr Robert Heppell

Mr Dharmesh Mehta

Professor Mhairi Copland

(Appointed 2 February 2022)

Ms Carina Patterson

Helen Knight

(Appointed 4 May 2022)

Dr Sarah Smith

(Appointed 2 February 2022)

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester (Government restrictions permitting during the pandemic) with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee".

All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Our trading subsidiary

Ahead of the launch of our art trail Unicornfest, the Trustees of Leukaemia Care Limited decided to register a trading subsidiary – Leukaemia Care Trading Limited which was registered at Companies House on 21 April 2022 (Registered No: 14059389). Its Directors are Chris Matthews-Maxwell, Elizabeth Wilson and Wendy Davies who are also the Chair, Vice Chair and Treasurer of the parent charity, Leukaemia Care Limited. All trading activities relating to Unicornfest will go through the subsidiary company.

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (www.fundraisingregulator.org.uk/) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2022, the charity received no suppression requests through the Fundraising Preference Service and one fundraising complaint as detailed below.

Leukaemia Care received one fundraising complaint relating to the discontinued charity bags regarding fly-tipping of bags. This was reported to East London Textiles Limited who until September 2019 were contracted to deliver and collect charity textile recycling bags on our behalf. An apology was also made to the person making the complaint along with thanks for bringing the matter to our attention.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team

Chief Executive Officer	Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Communications and Fundraising Director	Nicole Scully

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising. we wish to honour the memory and service of Dr Noel Harker who sadly died 17 February 2022 after many years of steadfast support to the charity and blood cancer patients and their families.

President	Dr Richard Taylor
-----------	-------------------

Vice Presidents	Ms. Sue Merchant Professor Claire Harrison Dr Robert Marcus Professor Andrew Pettitt Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr Roland Maturi Mr Christopher Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Mr Albert Podesta
-----------------	---

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. David Marks
Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Dr. Deborah Yallop
Prof. Ajay Vora

Acute myeloid leukaemia panel

Dr. Manos Nikolousis
Prof. Mary Frances McMullin
Dr. Sahra Ali
Dr. Steve Knapper
Dr. Panagotis Kottaridis
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Prof. Antonio Pagluica

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh
Dr. Ben Kennedy
Prof. Chris Fegan
Prof. Guy Pratt
Assoc. Prof. Francesco Forconi
Prof. Adrian Bloor,
Dr. Shankara Paneesha,
Dr. Alison McCaig,

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Nick Cross
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Prof. Adam Mead
Dr Jonathan Kell
Prof. George Follows
Dr. Nilima Parry-Jones
Dr. Piers Patten
Dr. Chris Fox
Dr. Renata Walewska
Prof. Peter Hillmen
Prof. John Gribben
Dr Sunil Lyengar

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Sally Killick (MDS)
Dr. Robert Marcus (Lymphoma)
Simon Cheeseman (Pharmacist)
Prof. Judith Marsh (Aplastic anaemia, MDS)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Ruth Corbally
Dr. Elaine Hampton
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Rachael Marchant
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith (Searle)
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Roxanne Spencer
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Joanna Large
Catherine Langton
Catherine Kunatsa
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively.

When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

When drafting this policy, Leukaemia Care was influenced by the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration).

The Board of Trustees are responsible for setting remuneration levels for the senior management team. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

Salaries are reviewed annually in February following annual appraisals and take effect from April. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

The remuneration policy is reviewed annually by Trustees. Salaries are reviewed annually in March/April following annual appraisals and take effect from the 1st day of the following month. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health. All fixed salary increases are capped within the bandings, one off discretionary payments and cost of living payments are not capped within the bandings.

Influenced by the 2014 NCVO inquiry referred to above, the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements). Staff/pension costs: total organisational staff costs in 2022 were £1,044,486 (2021 £690,877). Overall, our staff costs as a proportion of overall expenditure was 52.76% for 2022 an increase from 51.61% in 2021.

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

Volunteers

Our volunteers are key in assuring anyone affected by a leukaemia, MDS or MPN diagnosis receives the information and support they need. A big thank you to all our volunteers who got involved in 2022, this included patients, carers, healthcare professionals and members of the public.

In 2022 we appointed a Volunteer Coordinator; this is an employee who can support and celebrate our existing volunteers, build our volunteering program and strategy, handle the day-to-day administration of volunteering, and ensure a cohesive experience for volunteers across all roles.

Our Volunteer Coordinator implemented several new elements to improve the experience of our volunteers, including a volunteer handbook and a volunteer Facebook group to provide our volunteers with a place to communicate with each other, and will begin working towards the Investing in Volunteers standard in 2023.

In August 2022 we held a volunteer awards ceremony as part of our annual conference to celebrate the impact of our volunteers with staff nominating volunteers from different areas of the charity's work.

Our aim is to continue to focus on creating a more cohesive experience for our volunteers. We plan to achieve the 'Investing in Volunteers' accreditation, to work closely with our volunteers to make sure that the experience is reflecting their needs, and to work to ensure that our volunteers reflect the diversity of the wider blood cancer community.

Our roles have grown in 2022, with the introduction of Area Ambassador volunteers. These are current patients who are happy to use their hospital visits to help us to ensure that our information is available in hospital waiting rooms and haematology clinics. The volunteers are onboarded and supported by our Volunteer Coordinator, who liaises with our Regional Coordinators on how each individual volunteer can make a difference in their hospital.

Our Buddy Support Service relies on patients and carers volunteering their time to support other patients and carers who may be struggling with their diagnosis or feeling isolated because of it. The volunteers are DBS checked, trained and provided with ongoing support by both our Volunteer Coordinator and our Buddy Coordinator, who is also a paid employee.

A huge amount of our information is distributed through our webinars, podcasts and online training events. These rely on patients and healthcare professionals to join us as speakers – providing attendees with relevant and up to date information not only on leukaemia, MDS and MPN but also tips on getting the most out of medical appointments, coping with fatigue, immunisations and the challenges of living with a compromised immune system among other topics.

Our healthcare professional volunteers are a vital resource across the charity, attending our medical advisory panels, reviewing our patient information, and attending policy events with us. We are extremely grateful to all these professionals, and the time they give. Included in this group are the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional, and administrative support to the group.

We also hold patient advisory panels made up of patients with a range of experiences of blood cancer and who are at a variety of stages of treatment, recovery or remission. These patients provide Leukaemia Care with vital feedback on our strategy and activities, ensuring our services remain relevant and timely. They also support with health technology appraisals, advice on advocacy requests from individual patients, content for articles, webinars and podcasts as well as reviewing patient information.

Our community fundraising volunteers place collection tins, hold supermarket collections, run events, and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. 2022 has continued to hold challenges for these roles, with a delayed return to normal following the COVID-19 pandemic. Throughout we have had a core of community volunteers who have continued to do everything they can to help us to raise vital funds.

We also have several areas where people volunteer their time less formally, including the signing of petitions, sharing of information and, most importantly, sharing their story. Each year people share and record their leukaemia stories as part of '#SpotLeukaemia' to raise awareness of the signs and symptoms. We recognise that people connect with stories and the people at the heart of them and each year they help us spread the '#SpotLeukaemia' message a little wider. Going forwards we aim to bring these smaller volunteering efforts together into a section of "micro-volunteering" tasks, allowing our supporters to pick tasks that will fit easily into their day, taking up 10, 30 or 60 minutes depending on the task that they choose.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

In 2023 and beyond we have several new volunteer roles that we are hoping to introduce, including Facebook support group moderators, clinic stand volunteers and volunteer speakers. We are also looking at the possibilities of including volunteering in our corporate partnerships. At the centre of this we will always aim to focus on how these volunteers will further the key aims and objectives of the charity.

Some feedback from our volunteers:

"From the first moment I offered help the team have been super friendly and supportive and have made getting involved very easy. I have always felt useful, needed and part of the team."

Feedback from Patient information reviewer and patient panellist

"I believe that patient input is crucial to achieving the most positive outcomes. I am a great advocate of support groups. I think that Leukaemia Care is a fantastic charity."

Feedback from Patient Panellist

"I feel very supported, the team always respond to my emails etc, nothing is too much trouble, they never fob me off with my new ideas saying no can't do, they always give them a try and thankfully my ideas up to now have paid off."

Feedback from community fundraiser

"The training is well organised, and the ongoing support is amazing."

Feedback from Buddy

"It's very rewarding personally and hopefully you're contributing to help someone get through difficult times and the R&D to improve treatments and outcomes... You have a vibrant, friendly, and efficient team - it's a pleasure to work with you"

Feedback from Buddy & Cheer Squad member

Related parties

In addition to the trading subsidiary undertaking, Leukaemia Care Trading Limited, the only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The trustees' report was approved by the Board of Trustees.

DocuSigned by:



6CF4719F0E4E433...

Mr Christopher R G Matthews-Maxwell (Chair)

Trustee

21 June 2023

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2022

The trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable group and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charitable group's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'charitable group') for the year ended 31 December 2022 which comprise the statements of financial activities, the balance sheets and the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable group's affairs as at 31 December 2022 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charitable group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees, who are also the directors of the charitable group for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charitable group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made
- a review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the charitable group

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE


- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

058A9BD1D0D34B3...

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

21 June 2023

Chartered Accountants
Statutory Auditor

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the charitable group by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
<u>Income and endowments from:</u>							
Donations and legacies	3	836,570	341,404	1,177,974	669,681	193,206	862,887
Trading income	4	193,750	-	193,750	-	-	-
Fundraising income	5	723,517	-	723,517	424,035	-	424,035
Investments	6	43,352	-	43,352	34,971	-	34,971
Other income	7	901	-	901	24,276	-	24,276
Total income		1,798,090	341,404	2,139,494	1,152,963	193,206	1,346,169
<u>Expenditure on:</u>							
Raising funds	8	784,794	-	784,794	569,908	-	569,908
Charitable activities	9	937,681	257,067	1,194,748	599,065	169,556	768,621
Total expenditure		1,722,475	257,067	1,979,542	1,168,973	169,556	1,338,529
Net gains/(losses) on investments	14	(77,221)	-	(77,221)	36,577	-	36,577
Net (outgoing)/incoming resources		(1,606)	84,337	82,731	20,567	23,650	44,217
Other recognised gains and losses							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		11,034	84,337	95,371	33,207	23,650	56,857
Fund balances at 1 January 2022		2,960,454	71,581	3,032,035	2,927,247	47,931	2,975,178
Fund balances at 31 December 2022		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES - CHARITY INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £
<u>Income and endowments from:</u>							
Donations and legacies	3	836,570	341,404	1,177,974	669,681	193,206	862,887
Fundraising income	5	794,529	-	794,529	424,035	-	424,035
Investments	6	43,352	-	43,352	34,971	-	34,971
Other income	7	901	-	901	24,276	-	24,276
Total income		1,675,352	341,404	2,016,756	1,152,963	193,206	1,346,169
<u>Expenditure on:</u>							
Raising funds	8	662,056	-	662,056	569,908	-	569,908
Charitable activities	9	937,681	257,067	1,194,748	599,065	169,556	768,621
Total expenditure		1,599,737	257,067	1,856,804	1,168,973	169,556	1,338,529
Net gains/(losses) on investments	14	(77,221)	-	(77,221)	36,577	-	36,577
Net (outgoing)/incoming resources		(1,606)	84,337	82,731	20,567	23,650	44,217
Other recognised gains and losses							
Revaluation of tangible fixed assets		12,640	-	12,640	12,640	-	12,640
Net movement in funds		11,034	84,337	95,371	33,207	23,650	56,857
Fund balances at 1 January 2022		2,960,454	71,581	3,032,035	2,927,247	47,931	2,975,178
Fund balances at 31 December 2022		2,971,488	155,918	3,127,406	2,960,454	71,581	3,032,035

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022		2021	
		£	£	£	£
Fixed assets					
Tangible assets	16		879,550		870,617
Investments	17		611,708		685,554
			<u>1,491,258</u>		<u>1,556,171</u>
Current assets					
Stocks	19	35,404		-	
Debtors falling due after one year	20	-		103,000	
Debtors falling due within one year	20	407,042		313,735	
Investments	21	403,520		402,060	
Cash at bank and in hand		961,507		734,703	
			<u>1,807,473</u>	<u>1,553,498</u>	
Creditors: amounts falling due within one year	22	(171,325)		(77,634)	
Net current assets			<u>1,636,148</u>		<u>1,475,864</u>
Total assets less current liabilities			<u><u>3,127,406</u></u>		<u><u>3,032,035</u></u>
Income funds					
Restricted funds	24		155,918		71,581
<u>Unrestricted funds</u>					
Designated funds	25	1,347,823		1,087,127	
General unrestricted funds		1,623,665		1,873,327	
			<u>2,971,488</u>		<u>2,960,454</u>
			<u><u>3,127,406</u></u>		<u><u>3,032,035</u></u>

LEUKAEMIA CARE

CONSOLIDATED BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2022


The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.


The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 21 June 2023

DocuSigned by:

6CF4719F0E4E433...

Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:

6883E98992D0489...

Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

CHARITY BALANCE SHEET

AS AT 31 DECEMBER 2022

	Notes	2022		2021	
		£	£	£	£
Fixed assets					
Tangible assets	16		879,550		870,617
Investments	17		611,808		685,554
			<u>1,491,358</u>		<u>1,556,171</u>
Current assets					
Stocks	19	6,225		-	
Debtors falling due after one year	20	-		103,000	
Debtors falling due within one year	20	396,851		313,735	
Investments	21	403,520		402,060	
Cash at bank and in hand		961,507		734,703	
			<u>1,768,103</u>	<u>1,553,498</u>	
Creditors: amounts falling due within one year	22	<u>(132,055)</u>		<u>(77,634)</u>	
Net current assets			<u>1,636,048</u>		<u>1,475,864</u>
Total assets less current liabilities			<u><u>3,127,406</u></u>		<u><u>3,032,035</u></u>
Income funds					
Restricted funds	24		155,918		71,581
<u>Unrestricted funds</u>					
Designated funds	25	1,347,823		1,087,127	
General unrestricted funds		1,623,665		1,873,327	
			<u>2,971,488</u>		<u>2,960,454</u>
			<u><u>3,127,406</u></u>		<u><u>3,032,035</u></u>

LEUKAEMIA CARE

CHARITY BALANCE SHEET (CONTINUED)

AS AT 31 DECEMBER 2022

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2022, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements under the requirements of the Companies Act 2006, for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 21 June 2023

DocuSigned by:

Chris Matthews-Maxwell

6CF4719F0E4E433...

Mr Christopher R G Matthews-Maxwell (Chair)
Trustee

DocuSigned by:

Wendy Davies

6883E98992D0489...

Mrs W J Davies (Treasurer)
Trustee

Company registration number 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2022

	Notes	2022 £	£	2021 £	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	29		223,094		(96,832)
Investing activities					
Purchase of tangible fixed assets		(32,034)		(12,364)	
Purchase of investments		(69,247)		(485,914)	
Proceeds from disposal of investments		57,573		101,638	
Other investment movements		8,298		(12,473)	
Investment income received		40,580		37,194	
Net cash generated from/(used in) investing activities			5,170		(371,919)
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			228,264		(468,751)
Cash and cash equivalents at beginning of year			1,136,763		1,605,514
Cash and cash equivalents at end of year			1,365,027		1,136,763
Relating to:					
Cash at bank and in hand			961,507		734,703
Short term deposits included in current asset investments			403,520		402,060

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charitable group's [governing document], the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charitable group is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charitable group. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Business combinations

In the parent company financial statements, the cost of a business combination is the fair value at the acquisition date of the assets given, equity instruments issued and liabilities incurred or assumed, plus costs directly attributable to the business combination.

1.3 Basis of consolidation

The consolidated group financial statements consist of the financial statements of the parent company Leukaemia Care together with all entities controlled by the parent company (its subsidiaries).

All financial statements are made up to 31 December 2022. Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with those used by other members of the group.

All intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated on consolidation. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred.

Subsidiaries are consolidated in the group's financial statements from the date that control commences until the date that control ceases.

1.4 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable group has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.5 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charitable group.

1.6 Income

Income is recognised when the charitable group is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charitable group has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charitable group has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

1.7 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.8 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	Over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.9 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.10 Impairment of fixed assets

At each reporting end date, the charitable group reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.11 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.12 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.13 Financial instruments

The charitable group has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charitable group's balance sheet when the charitable group becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost. Financial assets classified as receivable within one year are not amortised.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charitable group's contractual obligations expire or are discharged or cancelled.

1.14 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charitable group is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.15 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charitable group's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by the review process.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

3 Donations and legacies Group and charity

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2022	2022	2022	2021	2021	2021
	£	£	£	£	£	£
Donations and gifts	229,046	122,951	351,997	157,770	52,080	209,850
Legacies receivable	366,506	45,318	411,824	283,679	-	283,679
Corporate grants and donations	241,018	173,135	414,153	228,232	141,126	369,358
	<u>836,570</u>	<u>341,404</u>	<u>1,177,974</u>	<u>669,681</u>	<u>193,206</u>	<u>862,887</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

4 Trading income Group

	Trading subsidiary 2022 £	2021 £
Sales	193,750	-

5 Fundraising income Group

	Unrestricted funds 2022 £	Unrestricted funds 2021 £
Fundraising events	723,517	424,035

Charity

	Unrestricted funds 2022 £	Unrestricted funds 2021 £
Fundraising events	794,529	424,035

6 Investments Group and charity

	Unrestricted funds 2022 £	Unrestricted funds 2021 £
Rental income	25,900	25,900
Investment income	7,380	1,406
Interest receivable	10,072	7,665
	<u>43,352</u>	<u>34,971</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

7 Other income Group and charity

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
Government Grants	-	23,082
Solar panels	901	1,194
	<u>901</u>	<u>24,276</u>

The Government Grants were in relation to the Job Retention Scheme.

8 Raising funds Group

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	198,534	309,000
Advertising	43,972	18,597
Other fundraising costs	73,022	33,876
Staff costs	284,286	173,573
Depreciation and impairment	4,564	2,139
Support costs	50,504	25,802
	<u>654,882</u>	<u>562,987</u>
<u>Trading costs</u>		
Other trading activities	79,330	-
Staff costs	43,408	-
Support costs	3,170	2,265
	<u>125,908</u>	<u>2,265</u>
<u>Investment management</u>	4,004	4,656
	<u>784,794</u>	<u>569,908</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

8 Raising funds

(Continued)

Charity

	Unrestricted funds	Unrestricted funds
	2022	2021
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	198,534	309,000
Advertising	43,972	18,597
Other fundraising costs	73,022	33,876
Staff costs	284,286	173,573
Depreciation and impairment	4,564	2,139
Support costs	50,504	25,802
	<u>654,882</u>	<u>562,987</u>
<u>Trading costs</u>		
Support costs	3,170	2,265
	<u>3,170</u>	<u>2,265</u>
<u>Investment management</u>	4,004	4,656
	<u>662,056</u>	<u>569,908</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

9 Charitable activities

	2022 £	2021 £
Staff costs	700,036	504,029
Depreciation and impairment	31,177	27,250
Patient Services costs	63,588	35,692
Conferences	2,256	2,102
Help Line costs	7,109	4,109
Leukaemia Matters/Nursing Matters	28,378	11,172
Campaign costs	42,683	15,425
Other charitable activities	18,913	15,317
Nurse e-learning tool	(1,081)	512
GP's e-learning tool	5,384	2,400
Other grants	168,054	50,000
Database costs	5,482	4,469
Patient Advocacy	(16,724)	3,709
Website costs	22,578	13,669
Other costs	2,842	-
	<u>1,080,675</u>	<u>689,855</u>
Share of support costs (see note 10)	106,677	73,481
Share of governance costs (see note 10)	7,396	5,285
	<u>1,194,748</u>	<u>768,621</u>
Analysis by fund		
Unrestricted funds	937,681	599,065
Restricted funds	257,067	169,556
	<u>1,194,748</u>	<u>768,621</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

10 Support costs Group and charity

	Support costs £	Governance costs £	2022 £	Support costs £	Governance costs £	2021 £
Staff costs	16,753	-	16,753	13,275	-	13,275
Office costs	140,428	-	140,428	86,008	-	86,008
Audit fees	-	4,200	4,200	-	3,600	3,600
Legal and professional	-	3,298	3,298	-	2,370	2,370
Trustee and meeting expenses	-	3,068	3,068	-	1,580	1,580
	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>	<u>99,283</u>	<u>7,550</u>	<u>106,833</u>
Analysed between						
Fundraising	50,504	-	50,504	25,802	-	25,802
Trading	-	3,170	3,170	-	2,265	2,265
Charitable activities	106,677	7,396	114,073	73,481	5,285	78,766
	<u>157,181</u>	<u>10,566</u>	<u>167,747</u>	<u>99,283</u>	<u>7,550</u>	<u>106,833</u>

Governance costs includes payments to the auditors of £4,200 (2021- £3,600) for audit fees. In addition included in the costs of other trading activities is £3,500 (2021 - £nil) in respect of the audit of the financial statements of the subsidiary undertaking.

11 Auditor's remuneration

Fees payable to the charitable group's auditor and associates:	2022 £	2021 £
Audit of the charitable group's annual accounts	4,200	3,600

In addition £3,500 is payable in respect of the audit of the subsidiary undertaking.

12 Trustees

The charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2021: 2) trustees for the current year were £2,521 (2021 : £670).

None of the trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £2,186 (2021: £1,916).

All trustees are covered by an indemnity insurance policy costing £819 (2021 : £611)

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

13 Employees

The average monthly number of employees during the year was:

	2022	2021
	Number	Number
Training and provision of care	20	18
Fundraising and publicity	16	10
Accounts and administration	4	3
	<hr/>	<hr/>
Total	40	31
	<hr/> <hr/>	<hr/> <hr/>

Employment costs

	2022	2021
	£	£
Wages and salaries	930,750	615,806
Social security costs	78,226	47,835
Other pension costs	35,507	27,236
	<hr/>	<hr/>
	1,044,483	690,877
	<hr/> <hr/>	<hr/> <hr/>

The remuneration of key management personnel through payroll and other fees is £190,032 (2021:£158,284).

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2022	2021
	Number	Number
£60,001 - £70,000	1	1
	<hr/> <hr/>	<hr/> <hr/>

14 Net (losses)/gains on investments Group and charity

	Unrestricted	Unrestricted
	funds	funds
	2022	2021
	£	£
Revaluation of investments	(70,142)	15,328
Gain/(loss) on sale of investments	(7,079)	21,249
	<hr/>	<hr/>
	(77,221)	36,577
	<hr/> <hr/>	<hr/> <hr/>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

15 Taxation

The charity is exempt from tax on income and gains falling within section 505 of the Taxes Act 1988 or section 252 of the Taxation of Chargeable Gains Act 1992 to the extent that these are applied to its charitable objects.

The subsidiary undertaking is required to Gift Aid profits arising to the parent charity such that no tax charge arises.

16 Tangible fixed assets

Group and charity

	Freehold buildings	Computers and other equipment	Fixtures and fittings	Total
	£	£	£	£
Cost				
At 1 January 2022	842,599	244,639	14,656	1,101,894
Additions	-	32,034	-	32,034
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2022	842,599	276,673	14,656	1,133,928
	<hr/>	<hr/>	<hr/>	<hr/>
Depreciation and impairment				
At 1 January 2022	-	220,358	10,919	231,277
Depreciation charged in the year	12,640	21,635	1,466	35,741
Revaluation	(12,640)	-	-	(12,640)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2022	-	241,993	12,385	254,378
	<hr/>	<hr/>	<hr/>	<hr/>
Carrying amount				
At 31 December 2022	842,599	34,680	2,271	879,550
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 December 2021	842,599	24,281	3,737	870,617
	<hr/>	<hr/>	<hr/>	<hr/>

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

17 Fixed asset investments

Group

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2022	663,937	21,617	-	685,554
Additions	69,247	(69,247)	-	-
Valuation changes	(70,142)	-	-	(70,142)
Other cash movements	859	2,516	-	3,375
Loss on disposal	(7,079)	-	-	(7,079)
Disposals	(57,573)	57,573	-	-
	<u>599,249</u>	<u>12,459</u>	<u>-</u>	<u>611,708</u>
At 31 December 2022	599,249	12,459	-	611,708
Carrying amount				
At 31 December 2022	<u>599,249</u>	<u>12,459</u>	<u>-</u>	<u>611,708</u>
At 31 December 2021	<u>663,937</u>	<u>21,617</u>	<u>-</u>	<u>685,554</u>

Charity

	Listed investments £	Cash in portfolio	Other investments	Total £
Cost or valuation				
At 1 January 2022	663,937	21,617	-	685,554
Additions	69,247	(69,247)	100	100
Valuation changes	(70,142)	-	-	(70,142)
Other cash movements	859	2,516	-	3,375
Loss on disposal	(7,079)	-	-	(7,079)
Disposals	(57,573)	57,573	-	-
	<u>599,249</u>	<u>12,459</u>	<u>100</u>	<u>611,808</u>
At 31 December 2022	599,249	12,459	100	611,808
Carrying amount				
At 31 December 2022	<u>599,249</u>	<u>12,459</u>	<u>100</u>	<u>611,808</u>
At 31 December 2021	<u>663,937</u>	<u>21,617</u>	<u>-</u>	<u>685,554</u>

Other investments represents the interest in the subsidiary undertaking, see note 28.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

18 Financial instruments Group and charity

	2022 £	2021 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	599,249	663,937

19 Stocks

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Finished goods and goods for resale	35,404	-	6,225	-

20 Debtors

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Amounts falling due within one year:				
Trade debtors	183,372	48,208	42,572	48,208
Amounts owed by subsidiary undertakings	-	-	137,317	-
Other debtors	8,467	99,626	1,759	99,626
Prepayments and accrued income	215,203	165,901	215,203	165,901
	<u>407,042</u>	<u>313,735</u>	<u>396,851</u>	<u>313,735</u>

Amounts falling due after more than one year:

	2022 £	2021 £	2022 £	2021 £
Prepayments and accrued income	-	103,000	-	103,000

Total debtors	<u>407,042</u>	<u>416,735</u>	<u>396,851</u>	<u>416,735</u>
----------------------	----------------	----------------	----------------	----------------

21 Current asset investments Group and charity

	2022 £	2021 £
Unlisted investments	403,520	402,060

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

22 Creditors: amounts falling due within one year

	Group 2022 £	Group 2021 £	Charity 2022 £	Charity 2021 £
Other taxation and social security	24,912	13,668	24,912	13,668
Trade creditors	66,584	16,002	31,064	16,002
Accruals and deferred income	79,829	47,964	76,079	47,964
	<u>171,325</u>	<u>77,634</u>	<u>132,055</u>	<u>77,634</u>

23 Retirement benefit schemes

Defined contribution schemes

The charitable group operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charitable group in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £35,507 (2021 - £27,236).

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds Group and charity

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			Balance at 31 December 2022
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at January 2022	Incoming resources	Resources expended	
	£	£	£	£	£	£	£
The Lily Blaen Hope Fund	24,428	-	(1,961)	22,467	-	(13,083)	9,384
Information Booklets	-	84,125	(60,538)	23,587	-	(23,587)	-
GP e-learning tool	-	19,817	(12,261)	7,556	8,423	(15,979)	-
Nurse Advisor	-	-	-	-	30,346	(30,346)	-
Student/Education	5,000	-	-	5,000	-	-	5,000
Worcester Support Group	251	-	(251)	-	-	-	-
Glasgow Area	-	1,900	(1,900)	-	1,900	(1,600)	300
KAy Kendall	93	-	(93)	-	-	-	-
Support Group - Taunton	267	-	(267)	-	-	-	-
Support Group - Scotland	6,472	-	(1,962)	4,510	-	(1,176)	3,334
Counselling Fund	-	1,000	(1,000)	-	10,005	(9,135)	870
Travel Grant	-	-	(267)	-	47,000	(47,000)	-
Support Group - Glasgow and Aberdeen	2,000	-	(454)	1,546	-	588	958
Support Group - South Shields	1,000	1,000	(1,962)	38	-	(38)	-
Support Group - Leicestershire	1,393	-	-	1,393	-	-	1,393
Patient Support - Worcestershire	1,900	-	(1,900)	-	-	-	-
Birmingham Patient Conference	500	-	-	500	-	-	500
Welfare & Advocacy support	627	21,681	(22,308)	-	11,594	(11,594)	-
Belfast Hospital Support	2,000	-	-	2,000	9,999	-	11,999
Bristol Hospital Support	2,000	-	-	2,000	-	(869)	1,131
Patient Conferences/Webinars	-	7,000	(7,000)	-	25,092	(25,092)	-
Care Helpline Costs	-	5,000	(4,016)	984	1,375	(2,359)	-
Nurse e-learning	-	10,183	(10,183)	-	3,175	(3,175)	-

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

Buddy Scheme	-	1,500	(1,500)	-	19,243	(19,243)	-
West Midlands Hospital Support	-	5,000	(5,000)	-	9,500	(9,500)	-
Digital Support	-	33,000	(33,000)	-	-	-	-
Support Group - Cambridge	-	500	(500)	-	-	-	-
Spot Leukaemia	-	1,500	(1,500)	-	14,654	(14,654)	-
Support Groups	-	-	-	-	5,851	(5,851)	-
Newcastle Hospital Support	-	-	-	-	1,000	-	1,000
UCHL Hospital Support	-	-	-	-	2,000	(985)	1,015
Manchester Hospital Support	-	-	-	-	7,000	(2,974)	4,026
Nottingham Hospital Support	-	-	-	-	9,454	-	9,454
Patient Support Scotland	-	-	-	-	5,000	(5,000)	-
William Davidson - Aberdeen Area	-	-	-	-	45,318	(800)	44,518
CAR-T	-	-	-	-	20,000	(10,000)	10,000
AML Information	-	-	-	-	15,000	-	15,000
AML Education	-	-	-	-	23,135	-	23,135
Yorkshire Patient Support	-	-	-	-	10,000	(1,654)	8,346
Wales Hospital Support	-	-	-	-	3,965	-	3,965
Support Group Wales	-	-	-	-	1,375	(785)	590
	<u>47,931</u>	<u>193,206</u>	<u>(169,556)</u>	<u>71,581</u>	<u>341,404</u>	<u>(257,067)</u>	<u>155,918</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

The Lily Blaen Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services

Support Group West Midlands - to facilitate activities for support groups in the area

Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas

Support Group Leicestershire - to facilitate activities for support groups in these areas

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

Patient Support Worcestershire - to facilitate activities for support groups in this area

Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham

Welfare & Advocacy Support - in support of advocacy and welfare advise

Belfast Hospital Support - in support of the costs in providing ward support

Bristol Hospital Support - in support of the costs in providing ward support

Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers

Patient conferences/webinars - grants in support of conferences held in the year.

Care Helpline costs: this represents income received specifically to meet the costs of the Care line.

Support Groups - to facilitate activities for local support groups

Nurse e-learning - funds to support the advancement of knowledge in the nursing profession.

Buddy Scheme - one to one support for patients

West Midlands Hospital Support -to facilitate activities for local support groups

Digital support - to support digital and information projects

Support Group Cambridge - to facilitate activities for local support groups

Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia

CAR-T - offer grants and information to patients being treated with CAR-T.

AML information - Providing a new suite of AML information.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2022

24 Restricted funds

(Continued)

AML Education - Education of Healthcare Practitioners and patients on AML testing.

Yorkshire Support - to facilitate activities and support in this area.

Wales Hospital Support - in support of costs in providing ward support.

Support Group Wales - to facilitate activities for support groups in this area.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

25 Designated funds Group and charity

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds						
	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	Balance at 1 January 2022	Transfers	Balance at 31 December 2022
	£	£	£	£	£	£	£
Fixed asset fund	875,003	-	-	(4,386)	870,617	8,934	879,551
Strategic implemen- tation fund	459,100	252,116	(494,706)	-	216,510	251,762	468,272
	<u>1,334,103</u>	<u>252,116</u>	<u>(494,706)</u>	<u>(4,386)</u>	<u>1,087,127</u>	<u>260,696</u>	<u>1,347,823</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the three year strategy adopted by the Trustees on 1 February 2023.

26 Analysis of net assets between funds Group and charity

	Unrestricted funds	Restricted funds	Total Unrestricted funds		Restricted funds	Total
	2022	2022	2022	2021	2021	2021
	£	£	£	£	£	£
Fund balances at 31 December 2022 are represented by:						
Tangible assets	879,550	-	879,550	870,617	-	870,617
Investments	611,708	-	611,708	685,554	-	685,554
Current assets/(liabilities)	1,480,230	155,918	1,636,148	1,404,283	71,581	1,475,864
	<u>2,971,488</u>	<u>155,918</u>	<u>3,127,406</u>	<u>2,960,454</u>	<u>71,581</u>	<u>3,032,035</u>

27 Related party transactions

The charity received £71,012 (2021 - £nil) from the subsidiary undertaking under a Gift Aid arrangement. There were no other disclosable related party transactions during the year (2021 - none).

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2022

28 Subsidiaries

Details of the charitable group's subsidiaries at 31 December 2022 are as follows:

Name of undertaking	Registered office	Nature of business	Class of shares held	% Held	
				Direct	Indirect
Leukaemia Care Trading Limited	England & Wales	Fundraising	Ordinary	100.00	

29 Cash generated from operations	2022 £	2021 £
Surplus for the year	82,731	44,217
Adjustments for:		
Investment income recognised in statement of financial activities	(43,352)	(34,971)
Loss/(gain) on disposal of investments	7,079	(21,249)
Fair value gains and losses on investments	70,142	(15,328)
Depreciation and impairment of tangible fixed assets	35,741	29,389
Movements in working capital:		
(Increase) in stocks	(35,404)	-
Decrease/(increase) in debtors	12,466	(101,139)
Increase in creditors	93,691	2,249
Cash generated from/(absorbed by) operations	<u>223,094</u>	<u>(96,832)</u>

30 Analysis of changes in net funds

The charitable group had no debt during the year.

LEUKAEMIA CARE

England & Wales - Charity number 1183890

Accounts

ANNUAL REPORT AND FINANCIAL STATEMENTS



FOR THE YEAR ENDED 31 DECEMBER 2021

Margaret Miller, diagnosed
with chronic lymphocytic leukaemia (CLL)



Charity Registration No. 1183890 (England and Wales)
Charity Registration No. SC049802 (Scotland)
Company Registration No. 11911752 (England and Wales)

www.leukaemiacare.org.uk

Leukaemia Care
YOUR Blood Cancer Charity

Legal and administrative information

Patrons Lady Penny Mountbatten
Beverley Warboys

Trustees Mr C. R. G. Matthews Maxwell (Chair)
Mrs Wendy Davies (Treasurer)
Dr Emmanouil Nikolousis
Mrs Elizabeth Wilson (Vice Chair)
Ms Kate Stallard
Mr Robert Heppell
Mr Dharmesh Mehta
Professor Mhairi Copland (Appointed 2 February 2022)
Ms Carina Patterson (Appointed 3 November 2021)
Dr Sarah Smith (Appointed 2 February 2022)
Helen Knight (Appointed 4 May 2022)
Mr Matthew Fowler (Resigned 17 May 2021)
Dr Barbara Compitus (Resigned 15 June 2021)

President Dr Richard Taylor

Vice Presidents Ms Sue Merchant
Mr Roland Maturi
Professor Claire Harrison
Dr Robert Marcus
Professor Andrew Pettitt
Dr Noel E M Harker
Professor Antonio Pagliuca
Ms Sheila Hegarty
Mr Jason Eliadis
Mr C.R.G. Matthews-Maxwell
Mr Peter Mondon
Mr Anthony Gavin
Mr Albert Podesta

Senior Management Team

Chief Executive Officer Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO Monica Izmajlowicz
Communications and Fundraising Director Nicole Scully

Medical Advisory Panels As described in the Trustees' Report

Secretary Monica Izmajlowicz

Charity number (England and Wales) 1183890
Charity number (Scotland) SC049802
Company number 11911752

Website: www.leukaemiacare.org.uk

Registered office

One Birch Court
Blackpole East
Worcester
WR3 8SG

Auditor

Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Bankers

Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ

Solicitors

Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG

Investment advisors

Cardale Asset Management
2 Greengate
Cardale Park
Harrogate
HG3 1GY

CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET

Brewin Dolphin
12 Smithfield Street
London
EC1A 9BD

Contents

A word from our Chair and CEO

5

Trustees' report

6

Statement of Trustees' responsibilities

34

Independent auditor's report

35

Statement of financial activities

38

Balance sheet

40

Statement of cash flows

41

Notes to the financial statements

42

A word from our Chair and CEO

Despite an inauspicious start to 2021 with a third lockdown on 6 January, Leukaemia Care was prepared and continued to support patients and their families delivering support online and by phone.

The world and the way we live has been changed by the pandemic, challenging all of our assumptions about how to live and what is important. For leukaemia patients and their families, the easing of restrictions has been an especially anxious time, wondering if the vaccines will protect them or to what extent. It was important that we could give them accurate and timely information, and this is where our involvement in key coalitions and policy groups paid off.



Recognising this shift, Leukaemia Care is changing too. Next year, we will launch our long-term strategy for 2022-2030 which clearly sets out our goals under our five strategic areas. For the first time we are publishing our strategy on our website – please have a look and if you want to be part of the change we will create, do get in touch.

Reflecting over the past year, we keep coming back to the wonderful feedback from people accessing our services and wanted to highlight a few that we found especially moving.

“**"You've been like a family."**

“**"This service has been a lifeline."**

“**"I was so scared, but you have taken the time to explain my diagnosis."**

“**"During a time when I have felt so isolated and lonely, the webinars have felt like a caring hug from Leukaemia Care."**

This ethos of community and caring – one of our core values as an organisation, comes through so strongly and is embedded across the charity. Without the hard work and dedication of our employees, volunteers, donors and fundraisers many people would struggle with such a life changing diagnosis, and for many leukaemia patients who continue to shield, we remind them that they are not alone and have someone in their corner.

We wish to thank everyone who has worked so hard to support our blood cancer community during yet another challenging year. Our volunteers generously share their time and expertise alongside navigating their own leukaemia journey – raising funds, providing one to one support to fellow patients and their families, reviewing patient information, acting as critical friends among other activities. Those who are healthcare professionals juggle their jobs with speaking on our webinars empowering people with knowledge to make the best possible decisions for their care and wellbeing. Thank you to fellow Trustees and our employees who continue to work hard to make a difference to people's lives.

With warm wishes

Chris Matthews-Maxwell (Chair) and Zack Pemberton-Whiteley (CEO)



Christopher Riley, diagnosed with chronic lymphocytic leukaemia (CLL)

Trustee's report (including director's report)

The Trustees present their annual report and financial statements for the year ended 31 December 2021.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's memorandum and articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

About us

Leukaemia Care is the UK's leading leukaemia charity. For over 50 years, we have been dedicated to ensuring that everyone affected receives the best possible diagnosis, information, advice, treatment and support.

We are here for everyone affected by leukaemia and related blood cancer types – such as myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

We believe in improving lives and being a force for change. To do this, we have to challenge the status quo and do things differently.

Purpose

The charity's objects are set out in its articles of association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from leukaemia and allied blood disorders.
2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision - our long term ideal

A future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

Our mission - what we are doing to make our vision a reality

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN.

We provide information, advice and support for anyone affected, this includes patients and their friends and families too. We raise awareness of the issues impacting people affected by leukaemia, MDS and MPN, and campaign to fix them. We are driving early diagnosis, raising

public awareness, improving services, and ensuring access to effective treatments. But most importantly, we bring people together and unite them behind our common goal. Together, we will create the future we all believe in.

Our values - what do we stand for?

Leukaemia Care's values are at the heart of everything we do. They describe our approach to our work. They drive our thinking, our behaviours and our actions.

Mission based

We have a clear mission. We exist to improve the lives of people affected by leukaemia, MDS and MPN. We believe in doing the right thing. If it is not in the best interests of people affected by our mission, we will not do it. It is that simple. No ifs, no buts, no exceptions.

Collaborative

We are passionate about all forms of collaboration, especially with other charities. Our mission is bigger than Leukaemia Care. We know that working on our own will delay the day when everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support. That is why it is so important that we work in partnership with individual charities, charity coalitions, healthcare professionals and a wide range of other stakeholders to improve the lives of people affected.

Caring

It is in our name, and it is in our nature. We care deeply about every single person affected by leukaemia, MDS and MPN. We are on your side and always will be. This helps us deliver high quality support, but also underpins all other parts of the charity. We care about the people who dedicate their time to our mission - whether that is our colleagues, volunteers, supporters or fundraisers. We are a community united by a common mission and we care about each other.

Evidence based

We listen to and understand the experiences of people affected by leukaemia, MDS and MPN. We use the evidence we gather to adapt, improve our services and to focus our campaigns for change. We also work with healthcare professionals - including haematologists, nurses and GPs - to make sure we are rooted in the latest science.

Aspirational

We have ambitious goals and we set ourselves high standards to achieve them. We believe that everyone affected by leukaemia, MDS and MPN should get the best possible diagnosis, information, advice, treatment and support. Every day 44 people are diagnosed with leukaemia, MDS or MPN, we can't afford to wait. To achieve this change we must be innovators, problem solvers, challengers to the status quo and each and every one of us must go above and beyond, every single day.

Our values are key to everything we do. But we all make mistakes. If you see us acting in a way that you feel is not consistent with our values - please let us know!

Why our work is important

To paint a picture of the scale of the issue across the UK:

-  Leukaemia is the **12th** most common form of cancer and 12th biggest cancer killer.
-  Every year, **10,000** people are diagnosed with leukaemia in the UK.
-  Every year, **5,000** people die from leukaemia in the UK.
-  Every year **6,000** people in the UK will be diagnosed with conditions that may develop into leukaemia, including myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
-  Over **50,000** people are living with leukaemia in the UK.
-  There are **34,000** people living with MDS or MPN in the UK.

Our strategic goals

We exist to improve the lives of everyone affected by leukaemia, MDS and MPN. Over the last 50 years, we have come a long way, but there is more to be done.

We are committed to creating a future where everyone affected by leukaemia, MDS and MPN gets the best possible diagnosis, information, advice, treatment and support.

That will not happen overnight. But we are closer than ever before, and we are working to create that future every single day.

Our organisational strategy focuses on the future we believe we can create and sets five clear goals for the work we will be doing until 2030 to make this a reality sooner:

1. Improving diagnosis – through awareness and early detection.
2. Ensuring everyone receives high quality information, advice and support.
3. Tackling issues that impact people's lives.
4. Advancing treatment and care.
5. Creating a narrative to better reflect the reality people experience. But we need your help. If you believe in the future we are trying to create and want to help us get there faster, please get involved.

For more information on our five goals, please visit our website www.leukaemiacare.org.uk

Public benefit

Our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our '#SpotLeukaemia' campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed free training on aspects of caring for blood cancer patients thus enhancing their care.

Grant making

Leukaemia Care has three grant making streams: the Financial Hardship Fund (formerly the Hospital Travel Fund), the Exceptional Hardship Fund and the Ann Ashley Leukaemia Counselling Fund. These contribute towards addressing the recommendations made in our "Living with leukaemia" reports which inform our strategic aims.

Financial Hardship Fund (formerly the Hospital Travel Fund)

This fund provides grants of up to £200 for essential living costs to patients and their families affected by leukaemia, MDS or MPN. There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

Exceptional Hardship Fund

Applicants who have received the Financial Hardship Fund of £200 within the year and are assessed as experiencing exceptional hardship are considered for an additional grant of up to £1,000. They are likely to be facing multiple challenges alongside a leukaemia diagnosis such as no recourse to public funds, homelessness or poor housing, significant mental health issues, care for a disabled dependant (adult and/or child) etc.

The Ann Ashley Leukaemia Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

Achievements and performance

Our response to the COVID-19 pandemic in 2021

In October 2020, we reviewed our strategy alongside our emergency response plan drafted in the weeks prior to the first national lockdown on the 23 March 2020. With the ongoing pandemic and the clinically extremely vulnerable status of many of our beneficiaries, we decided to continue to deliver most of our services digitally. When appropriate, many would return in a hybrid format, making use of the increased demand for virtual support alongside our traditional in-person services. This proved to be wise as we entered the third national lockdown on the 6 January 2021.

We continued to:

- prioritise the safety of our employees and the people we support.
- ensure patients and their families continue to receive support albeit modified to online or by phone.
- safeguard income wherever possible recognising that 2021 was likely to be another challenging year for fundraising.
- promote early diagnosis recognising the impact of lockdowns on cancer referrals and the inevitable later diagnoses of cancer that result from them.
- recognise and address the extra challenges leukaemia patients face after lockdowns have finished and restrictions ease.
- re-start in person activities such as support groups in consultation with patients and their families, keeping in place social distancing and face coverings alongside the option of online support groups.

Our achievements

The Leukaemia Care Annual Survey launched in September aimed to measure awareness of our activities among our stakeholders, gain feedback on them and capture equality data so we could better understand the demographics of people on our database. We learned that the top five ways people heard about the charity were online search, our patient information booklets, signposting by a consultant or nurse, social media and our '#SpotLeukaemia' campaign. This aligns with our investment in raising awareness of our services online and in person through our network of Regional Coordinators and Hospital Support Workers nationwide in the lead up to 2020.

Recruitment and retention of employees continued to be a challenge throughout 2021 especially in fundraising and we expect this to continue through to 2022. Obviously, this is likely to have a significant impact on fundraising alongside the deteriorating wider economic climate resulting from the pandemic.

Patient Support: providing high quality information and emotional support

Our Advice Service comprising the helpline, email and WhatsApp handled 4,697 queries (5,692 queries in 2020). Our two nurses, both haematology clinical nurse specialists, provided much needed advice and emotional support throughout the pandemic and this complemented the information provided in our webinars and support groups. At the start of 2021 due to lockdown, most helpline calls were about COVID-19 vaccines and from family members who were unable to visit their loved ones in hospital. We also saw an increase in calls from newly diagnosed patients alongside calls about shielding. As restrictions eased, patients continued to be worried about the efficacy of vaccines and their vaccine antibody levels.

“I was so scared, but you have taken the time to explain my diagnosis. I feel a lot more in control and clearer about what to expect.”

“I'm so glad I called, I feel so much better now you have explained everything to me.”

“Thank you so much for all your help and support. You have made a difficult time much easier. Your support throughout 2021 has been amazing. Having you at the end of the phone this year has been a lifesaver.”

“This service has been a lifeline.”

“I only have you to talk to about this.”

Our Buddy Service provided one to one support to 98 patients (77 in 2020) on an ongoing basis by phone and email. All of our buddies are DBS checked and receive induction training.

“I decided to use the buddy service despite being in remission

from AML diagnosed in 2019. I then relapsed in the summer and found my buddy very supportive. She has been through a stem cell transplant and so has prepared me for what to expect."

69% reported an improvement when asked how anxious their diagnosis made them feel compared to when they joined the buddy scheme. 86% felt they better understood their diagnosis after talking to their buddy.

"The buddy scheme has been a great support for me personally - to be able to speak to someone who has had a similar experience and can offer advice and empathy whenever needed."

71% of patients reported a significant improvement when asked how isolated they now felt about their diagnosis.

"Excellent - this was the best help I could have possibly accessed."

Due to the pandemic, we postponed any in-person conferences until 2022. Instead, we continued to provide a series of webinars addressing patient's immediate concerns around COVID-19 and their specific leukaemia and expanded the range to cover end of life care, living with fatigue, making the best of your medical appointments, employment rights (with ACAS) and CAR-T therapy. We held 28 webinars in 2021 (23 in 2020) and these would not have been possible without the generosity of healthcare professionals and patients donating their time to support others with their expertise. Average attendance at each webinar was 111 people.

"I thought the content was comprehensive, informative, and pitched at exactly the right level. The speakers all spoke knowledgeably on their topics, reflecting their experience and empathy for patients, which I felt inspired confidence." (Patient feedback on "Understanding advocacy and what advocates can do for leukaemia patients" webinar.)

"Good to know that a trusted organization is tapping into the best of what is available on our behalf." (Patient feedback on "Making the best of your CLL medical appointments" webinar.)

"These webinars are invaluable to those of us shielding - so rarely mentioned in national news bulletins."

"During a time when I have felt so isolated and lonely, the webinars have felt like a caring hug from Leukaemia Care."

In 2021, we reviewed our support groups to assess the viability of each group long-term. With the introduction of 13 online national meetings, many support group members are now attending these groups as well as their regular pre-pandemic in person group (now online). We

actively invited patients and their families to attend any of our online support groups as often as they wished given geographic location was no longer a factor.

We trialed seven in person support groups in consultation with members. Four had high attendance and will be repeated in 2022 with the remaining three reverting to online due to low attendance. Full risk assessments were performed and given the vulnerability of patients and their family members, only venues with good ventilation and sufficient space for social distancing were used alongside face coverings and other measures to reduce the risk of COVID-19.

We supported 1,677 people (1,564 in 2020) across our 53 online support groups. Our national online meetings drew members from across our regional online groups enabling them to meet new people and share experiences more widely. National meetings included specific ones for family and friends, issues specific to women diagnosed with a blood cancer, issues specific to men diagnosed with blood cancer as well as meetings for specific leukaemias and myelodysplastic syndromes.

Support groups are key in supporting people through the isolation many face following a diagnosis and for some people, Leukaemia Care provides the sense of community and support that comes from being part of a family.

**““ These groups really help. My initial thought when I was diagnosed was I didn't think I'd make it to Christmas.”
- CML patient**

““ You're the best medicine I've had in 4 weeks.”

““ These were very helpful in breaking the isolation of spending 56 weeks shielding at home alone.” - CML patient and regular SG attendee

““ You've been like a family.” - CML patient

““ These groups are like a surrogate family.”

““ Talking to other people who have been through it is really useful. I've enjoyed being part of the family”. - CML patient

““ Without these support groups, I would feel very isolated.”

““ Leukaemia Care have been invaluable, if didn't have these meetings, I would've really struggled. You're part of the family!” - CML patient

““ You have these preconceptions about support groups that they're going to all be negative and doom and gloom, but it's

been really positive and I'm glad I joined." - APL patient

The Ann Ashley Leukaemia Counselling Fund aimed to provide 35 individuals with up to six sessions with a counsellor of their choice (subject to registration with relevant professional bodies). We awarded 42 grants to help adults and children come to terms with their diagnosis or that of a family member, including relapse following treatment and coping with bereavement.

“The counselling gave me the perfect outlet for my worries, and some of the anger I have been feeling in regards to my diagnosis or more in particular the side effects I am suffering from treatment. During my sessions I could talk about all the thoughts and worries I had without feeling the need to worry about anyone else's feelings. I feel less alone and a lot more understood than I ever have done since my diagnosis – I just wish I could afford to keep it going. But the help I have received in getting these sessions have been worth more to me than I can put words to.”

“The counselling has been the best emotional support I have received following my diagnosis. I felt very much like the NHS "fixed" me physically and left me to recover emotionally on my own.”

We recognise that for some people, six sessions may not be enough, but our aim is to provide rapid access to counselling support when waiting times on the NHS are very long. We always signpost people to our other support services such as our helpline, buddies and support groups which they can access alongside their counselling or following it.

In 2021, we expanded the remit of our Hospital Travel Fund to include other essential living costs that can contribute to the financial burden of a leukaemia, MDS or MPN diagnosis. It is now known as the Financial Hardship Fund. Alongside this we offered an Exceptional Hardship Fund for 10 people of up to £1,000 each. Both funds were awarded on a first come, first served basis, and were exhausted by September. We supported 200 people with financial hardship grants of £200 and 11 people with an exceptional hardship grant. We were able to support more people than expected with an exceptional hardship grant as not everyone needed the full £1,000 when they applied.

“Thank you so much for acting so quickly! We as a service really appreciate it. The grant has really helped the couple out during this difficult time. Thanks once again!”

“Having the leukaemia CML, I feel like I'm cheating as I am at work but do find I'm short on money often due to hospital visits and I seem to eat more. Not one for asking for help, I appreciated the money thank you.”

We work closely with nurses and support workers at hospitals who raise awareness of our hardship funds ensuring we can support more people struggling financially.

In 2021, we continued to expand our information with two new booklets and reviewed 41 bringing our total number of publications to 43. These were Gilteritinib for Acute Myeloid Leukaemia and Liposomal daunorubicin- cytarabine for acute myeloid leukaemia. We continue to signpost to our fellow blood cancer charities especially for lymphomas and myelomas. We distributed 13,304 (15,360 in 2020) hardcopy booklets mainly to hospitals. A further 25,538 booklets (8,000 in 2020) were downloaded from our website – reflecting the increased demand for online resources.

“The Caring for Carers booklet was a lifeline for me, I read it over and over and I still have it on my bedside even though my husband is over a year in remission and nearly a year out of treatment. For anyone with a loved one going through diagnosis or treatment, I would highly recommend reading it.”

“Have been using LC (Leukaemia Care) booklets for a good few years, give them to patients on a new diagnosis and patients find them extremely helpful as they have usually had info overload and this enables them to go home and re-cap. The feedback that we get is that they are easy to read and understand, informative and useful to family members who are now unable to attend the appointment.”

To complement our patient information booklets, we produced 130 videos (175 in 2020) covering patient stories and ways to get involved but also edited our webinars which can be viewed on demand on our YouTube channel <https://www.youtube.com/leukaemiacare>. We filmed testimonial videos with patients and family members to raise awareness of our support services. Our videos have been viewed 426,577 times across our social media outlets (576,668 in 2020). A huge thank you to everyone who shared their story and expertise.

We produced 13 episodes of our podcast "Leukaemia Chatters" – which had 3,670 downloads (2,672 downloads in 2020). We used the podcasts as an opportunity to talk to patients who have accessed our services and used the content across our social media and in Leukaemia Matters magazine to raise awareness of and encourage people to access our free services. The circulation of our quarterly magazine, Leukaemia Matters increased to 7,228 (6,456 in 2020) with slightly more subscribing to electronic than hardcopy editions. 98% of readers rated our magazine as excellent or good and we continue to ensure it remains informative and engaging.

Eight hospitals across the UK normally host Hospital Support Workers who work alongside healthcare professionals one day a week in haematology clinics and on wards providing information, practical and emotional support to patients and their families. These are at Heartlands Hospital (Birmingham), Good Hope Hospital (Sutton Coldfield), Solihull Hospital (Birmingham), St James (Leeds), Southampton, Worcestershire Royal Hospital and the Christie Hospital in Manchester.

For the majority of 2021, our Hospital Support Workers were on part-time furlough until October when they resumed their contractual hours. Our hospital hub in Leeds reopened in July but experienced closures due to COVID-19 and our hubs at Good Hope, Solihull, Worcester and Southampton reopened in October. Patients at our Heartlands hub were supported by phone and The Christie hub remained closed due to restrictions on honorary workers due to COVID-19.

Our hospital support workers continued to support patients by phone whenever possible as referred by the clinical nurse specialist contact in each hub.

“The service you have provided has been absolutely brilliant. I’m so happy to have met you as you have been so supportive and helpful to me and my family in the worst time. Every time I called you, you answered, or you rang me back. You listened and heard me. You helped with any questions or concerns I had, and you also became a friend. You were a fresh voice and face when I needed it the most and you tried your utmost best for me and my children. You gave us strength and hope... thank you.”

Our Regional Coordinators continued to raise awareness of our free support services with hospitals despite being unable in most cases to visit in person due to COVID-19 restrictions. The strong nationwide contacts they made pre-pandemic ensured healthcare professionals were willing to speak at our webinars and continued to support our now online, support groups.

Patient Advocacy: campaigning for access to treatment and services

Our Advocacy Officer helped 211 (194 in 2020) people with a variety of issues. Once again, COVID-19 related issues dominated (accessing vaccines and understanding shielding guidance). However, we have also seen an increase in general issues with care such as lack of access to appointments, changing medication or feeling unsupported by their healthcare team, where COVID-19 had an indirect link or influence on the severity of the situation.

There has also been an increase in the number of people struggling to come to terms with bereavement and who wish to complain about their care; again we believe this to have been influenced by less time and ability to communicate with care teams due to COVID-19.

“My query concerned the suitability of the two vaccines for my conditions, CLL. The response was very prompt and unambiguous and communicated with friendliness and professionalism. It gave me confidence in accepting the invitation for my first jab. I’m now waiting for a date for my second. I was grateful for your advice.”

Our Welfare Advice Service supported 183 people (140 in 2020) with accessing benefits but also helping with housing and homelessness, people facing discrimination at work on diagnosis, making grant applications for financial support, pension advice and challenging Personal Independence Allowance decisions.

“Thank you so much for helping me with the application for a cooker. I am absolutely thrilled with it. Having a cooker has made a huge difference to my life. I’m now making healthy meals.”

“Your help has been amazing. We are now receiving attendance allowance and have a blue badge to help when attending hospital appointments. Thank you.”

“Thank you so much for helping me with my claim for attendance allowance. I have just been awarded the high rate and can now afford to pay for meals on wheels.”

“Thank you for all your help and advice. I am now receiving pension credit. I really appreciate all of your help with this and telling me about my other entitlements.”

Leukaemia Care have committed to be actively involved in all relevant Health Technology Appraisals for leukaemia, to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. We also get involved in other blood cancer related appraisals where there is an unmet clinical need and a need for patient input in the appraisal. The Patient Advocacy team was involved in nine health technology appraisals at various stages and secured direct patient involvement in 100% of appraisals.

Early diagnosis within primary care: supporting GPs

With COVID-19 affecting the public’s confidence in seeking medical help, encouraging early diagnosis through our SpotLeukaemia campaign was more important than ever. World Leukemia Day on the 4 September reached over 8 million with the ‘#WorldLeukemiaDay’ over the course of the campaign. Our ‘#SpotLeukaemia’ reached over 11 million people alone. As part of our SpotLeukaemia campaign we collaborated with Leukaemia UK, The Eve Appeal, Bloody Good Period, Luke 1977, OPAAL, Honest, Dr Amir Khan and Ade Williams. Twenty-eight buildings nationwide were lit up red representing the 28 people diagnosed with leukaemia every day, and we benefitted from 14 national and 53 regional pieces of press.

905 GPs signed up to our online leukaemia awareness courses with 80 attending our webinars held in partnership with the Royal College of General Practitioners. We also launched a free leukaemia awareness online course for care home staff alongside "Symptom Spotlight" videos; six one-minute videos focusing on a different symptom of leukaemia.

Each year we reach out to people to share their experiences of being diagnosed with leukaemia to encourage others to become more aware of the signs and symptoms, and each year we are moved by the generosity of people willing to share often challenging experiences to help others. You can read all the stories on our website.

Campaigning to raise awareness of the financial impact of a leukaemia diagnosis: '#LifeVsLivelihood'

One of the factors that determine the extent to which someone is financially impacted by a leukaemia diagnosis, is whether they are in employment or not. Following diagnosis and treatment, leukaemia patients can face several barriers in returning to work. This has been further complicated by the COVID-19 pandemic and the lifting of restrictions such as social distancing, the wearing of masks and guidance on working from home from the 19 July. Therefore, in July 2021, we launched our '#LivevsLivelihood' campaign.

This campaign was targeted at:

- **Patients directly affected by the issue:** we published checklists covering people rights at work including talking to employers about a safe return to work alongside template letters requesting reasonable adjustments at work.
- **Employers of people with blood cancer:** we published checklists and signposting to information to help employers understand the needs of those who may still be vulnerable to severe COVID-19 illness. We worked with ACAS and Macmillan to raise awareness of the information, but also asked patients to tell us who their employer was so we could share details of the campaign anonymously.
- **Policy and decision makers:** we asked policy makers to improve the advice to both patients and their employers, acknowledging those who were still at risk and making employers aware of their obligations. We also asked for the furlough scheme to continue. We wrote to MPs, including the Health Secretary and Ministers across the devolved nations, but also asked supporters to email their MP.

Over 400 people sent an email on behalf of clinically extremely vulnerable people to their MP. Unfortunately, the campaign failed to achieve any of our asks of policy and decision makers. However, we raised awareness of the issue with the campaign hashtag reaching 87,000 people and the checklists acting as useful tools for patients negotiating a safe return to work.

Haematology nurse education: specific and affordable training for nurses caring for blood cancer patients

We had 2,152 sign ups to our online Nurse Academy including our Clinical Nurse Specialist course, CAR-T therapy, Treatment Free Remission and PCR testing, Minimal Residual disease, end of life and acute leukaemia, Myeloproliferative Neoplasms: Diagnosis, treatment and management of side effects, GVHD and extravasations.

“**Concise and precise course. Recommended for those who are familiar with the name of therapeutic technique and want to learn the science behind it." (Feedback on our CAR-T course)**

We also held three webinars for nurses on topics to support their patient care.

“**It was one of the best Nurses Forums I attended recently via a digital platform. I was fully engaged in the discussions and gained a lot of knowledge from it. I thoroughly benefitted from discussions around venetoclax management and troubleshooting. As the nurse led clinics for venetoclax are just**

about to begin at my workplace, this forum happened just at the right time for me. Many thanks Leukaemia Care, for arranging this meeting."

Raising funds to deliver patient services

Although restrictions continued throughout 2021, online donations and regular giving did exceptionally well following improved asks on our website and in our communications. UK challenges such as skydives, corporate fundraising, in memory, grants and trusts and pharmaceutical fundraising all exceeded their targets.

The London Marathon took place on the 3 October and Leukaemia Care had 101 runners in the physical event and 59 in the Virtual London Marathon, with 90 places rolling over to 2022. Some of these places were unfilled due to individuals failing to reach their fundraising targets or people feeling uncomfortable with doing an in-person event. Obviously, this had a significant impact on the amount raised which together with costs carried over from the 2020 London Marathon (mostly the costs of places purchased), meant we did not achieve our London Marathon fundraising target for 2021.

Virtual fundraising raised over £20,000 mainly from our new virtual challenge "Step out for Leukaemia Care" and our Visufund page allowing supporters to make a donation and pay tribute in memory of a loved one or a dedication to someone special in their life.

Our Christmas campaign #LonelyWithLeukaemia, launched to show the public how vital our services are to leukaemia patients and their quality of life, raised over £8,000 and with the hashtag reaching over half a million impressions.

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2021, we benefited from £283,679 from gifts in wills from Ethel Hackett, Margaret Clark, Edward Manning, William Turnbull, Teresa Davies, Sheila Ann Mahoney, Georgina Wells, Howard Tait, Martin Davy, Vera Phillips, Glenys Bridges, Peter Jones and Jean Godebout. We wish to honour their memory for their support for blood cancer patients and their families.

We promoted our free wills scheme during Free Wills months in March and October. Under this scheme, people can make a simple will and can leave a gift to the charity if they so wish. We encourage anyone diagnosed with a life changing illness such as leukaemia to ensure they have an up to date will regardless of whether they choose to leave a gift to Leukaemia Care. In 2021, 34 people took up the offer of a free will from the charity with legacy pledges of approximately £264,680.

The charity works with the pharmaceutical industry to ensure that the interests of patients are considered when developing new drugs and treatments for patients. Leukaemia Care had our most successful year ever with £368,368 secured in donations from the following pharmaceutical companies in accordance with our Code of Practice (see website).

To ensure that we remain financially independent, limits are placed on all types of funding. We do not allow the total level of funding received from the pharmaceutical industry to exceed 25% of our total annual income. Nor do we allow the funding received from an individual company

to exceed 10% of our total annual income.

Abbvie	£12,000 core funding and £450 honorarium
Adaptive	£10,000
Amgen	£5,000 support services
Autolus	£25,000 core funding
Astellas	£15,000 digital support and £725 honorarium
Astraze	£15,000 patient support
Celgene	£65,000 patient activities of which £15,000 is for the Blood Cancer Alliance
Gilead	£25,000 core funding and £420 honorarium
Glycostem	£7,500 core funding
Incyte	£30,000 core funding
INO Therapeutics	£11,125
Janssen	£10,000 support activities for patients and £180 honorarium
Jazz	£30,000 awareness and patient support
Kyowa Kirin	£10,000
Novartis	£25,000 core funding, £25,000 for videos, podcasts and webinars and £487 honorarium
Pfizer	£10,000 core funding
Servier Labs	£5,000 core funding
Takeda	£30,000 core funding and £855 honorarium

Financial review

The results for the year are set out in the financial statements commencing on page 28. The financial statements show incoming resources for the year of activities of £1,346,169 compared to incoming resources in 2020 of £1,185,076. Trustees would like to thank all staff and volunteers for the continuing hard work and commitment that have made this possible.

Total reserves stand at £3,032,035 (2020: £2,975,178) of which £71,581 (2020: £47,931) was restricted in application and £1,087,127 (2020: £1,334,103) were designated by the trustees to match the tangible fixed assets of the charity and fund certain projects identified as being required in the immediate future. Those designated funds connected to tangible fixed assets relate predominantly to the freehold property and are likely, given current market conditions, to remain whilst the relevant charitable entity continues to own title to the same. Funds remaining for general use were £1,873,327 (2020: £1,593,144).

In light of the issues created by the Covid-19 pandemic, the Trustees consider the results for the year to be satisfactory.

Risk assessment and management

We carry out an annual detailed review of the charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

- a comprehensive annual review to identify, where possible, the risks which the charity may face during the forthcoming year.
- the establishment, where possible, of contingency plans to meet anticipated risk(s).

- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the charity should any such risk(s) materialise.
- the prioritisation of the charity's activities both actual and planned.
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to anyone affected by blood cancer. Successful implementation of the plan is dependent upon the charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

Reserves Policy

Leukaemia Care's reserves policy has been developed in line with best practice guidance to maintain resilience within the finances of the Charity. By developing an intelligent reserves policy with a clear understanding of income and expenditure, we aim to consider and mitigate against financial risk more effectively.

We recognise that money is donated to advance our charitable purposes. As such, our policy is to only hold reserves for a particular objective or to mitigate a particular risk, to avoid tying up money unnecessarily.

Leukaemia Care has a separate Investment Policy which considers the best use of reserves for generating financial return, preserving capital value, and meeting unanticipated cash flow requirements. For the purposes of investment, Leukaemia Care has divided its reserves into two those expected to be held for a long-term time horizon and those that may be needed in the short term.

It is Leukaemia Care's policy to express reserves in terms of 'months of expenditure' for the purposes of external communications.

Our policy identifies three factors requiring the charity to hold reserves. These are considered in the context of both individual risks and by summation (the addition of multiple risks happening at once):

- Liabilities and contingencies - i.e. staffing costs to provide services, wind-down costs based on the costs of closing down the Charity.
- Provision to absorb setback - i.e. predominantly related to income-based risk.
- Funds designated for specific commitments - i.e. operational plan commitments, including forecast deficits or existing committed projects and activities.

In line with the considerations above, Leukaemia Care's policy is to hold sufficient funds to cover between six to nine months of budgeted ongoing expenditure (£1,125,512 - 6.6 months as of 31/12/2021). Ongoing expenditure excludes one-off projects and depreciation, which are met through designation.

Our policy is subject to annual review by the board of Trustees, with the reserves reviewed in line with the policy at budget setting time and in time for the new financial year. Notwithstanding this, the reserves amount is calculable at any point of the year if required, as the financial position of the charity changes or plans alter.

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

Our Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day to day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on going activities of the Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

Our future plans for 2022 to 2030

The pandemic accelerated our long-term planning and we spent six months re-evaluating our vision, mission, and strategic goals. In November 2021, the Trustees formally approved a new long-term strategy alongside a three-year operational and organisational plan and budget for 2022 to 2024.

Long-Term Strategy

Our long-term strategy aims to set out afresh Leukaemia Care's vision, mission, values and five clear goals to guide us forward. It is a statement of intent. For the first time ever, we have made this a public document that can be accessed in the "About us" section of our website, allowing us to clearly and publicly state who we are and what we stand for, encouraging people to join us in our mission to create a future where everyone gets the best possible diagnosis, information, advice, treatment and support.

This public statement helps clarify our positioning as the UK's leading leukaemia charity, covering everything related to leukaemia and related blood cancers (MDS and MPN) except clinical research (e.g. support, information, campaigning, researching patient experience, being a strong voice for the leukaemia community). We will continue to develop collaborations with other charities depending upon their focus, organisational similarities or topic specific expertise.

As the UK's leading leukaemia charity, we exist to improve the lives of people affected by leukaemia and related blood cancer types – MDS and MPN. We recognise that other organisations are better placed to provide this support for other forms of blood cancer - such as lymphoma or myeloma. We have a responsibility to signpost people to the best possible information, advice and support for their particular circumstances.

Sometimes this will be as well as our own support (e.g. Young Lives Vs Cancer, Teenage Cancer Trust) and sometimes this will be instead of our services (e.g. Lymphoma Action, Myeloma UK).

Operational Plan

The new operational plan has been reorganised to align with our long-term strategy, as the first steps towards achieving our long-term goals. Whilst it contains many activities from previous years (as well as some new ones), it is now organised by our strategic goal (why we are doing it) rather than a delivery plan (who or how we will deliver it).

This recognises our need to work as a whole organisation, rather than individual teams, to achieve our collective goals. Whilst an individual or a department may lead on an activity, we work as one team and seek input and feedback from colleagues across the whole charity where appropriate.

Performance Measures

Our performance measures help us measure our progress towards our goals. For each activity at Leukaemia Care, we have set both targets (effective) and stretch targets (highly successful) for 2022. All targets are based on historical outcomes and expected outcomes in 2021 where a service is already in place, and for new services we have used informed assumptions. These will be used for reporting, with all targets for future years reviewed considering the performance and outcomes from the current financial year.

Organisational Plan

The organisational plan outlines our commitment to developing the charity through supporting employee wellbeing, effective recruitment and induction, targeted staff development and training, a performance management process that aligns with behaviours and our organisational values, and effective recruitment and management of volunteers towards delivering on our long-term strategy. It recognises that internal communication is vital, contributing to employee wellbeing as well as improving the delivery of our key objectives. We are committed to consulting with employees on key initiatives such as flexible working, wellbeing and internal communications, as well as other key topics that arise.

Development Process

The proposals within the operational plan are fully costed and seek to build upon measured outcomes from previous years and evidenced proposals from across Leukaemia Care with new opportunities and ideas. At the centre of this plan is listening to and understanding the experience of people affected by leukaemia, MDS and MPN. This tells us why we do things. It starts with obtaining evidence through patient surveys (such as the Living with Leukaemia project and annual feedback survey) and external projects (such as Blood Cancer Alliance's work on unmet needs). But it also comes through seeking individual inputs more directly through our patient and medical advisory panels.

In 2021, we incorporated a much wider range of internal perspectives as part of the planning process. At the outset of the process, Trustees were invited to take part in a facilitated discussion with the CEO to seek their views, suggestions and long-term ambitions for the charity. There was a high level of alignment across the board. Feedback focused around perceptions of the charity, unmet needs for patients and healthcare professionals, organisational strengths and weaknesses, prioritisation of activities, external opportunities and challenges, differentiating Leukaemia Care from other blood cancer charities and investment of reserves into developing the organisation and its activities. Insights from

these discussions have primarily informed the development of the long-term strategy and operational plan.

Employee input was sought through an anonymous survey, with responses analysed to consider both overall aligned perspectives and areas of differing views. Key themes that emerged from this exercise included improving internal communications, inspiring people to support us by better demonstrating our impact, improving the way we do things internally to improve outcomes for patients and understanding what has the greatest impact on the wellbeing of employees. Following the survey, employee focus groups were used to further explore or clarify these topics. These insights are at the core of developing the organisational plan, as well as providing a more nuanced view and insights as part of the operational plan.

Conclusion

As a result of this process, our new plan for 2022 to 2030 represents our best current thinking on the way to make our vision a reality, as soon as possible. But it is open to challenge, new ideas and change as things develop. We are more committed to achieving our vision than to any particular plan we happen to be following right now. We recognise this plan is ambitious and will be challenging to implement in its entirety. It is at the core of our values as an organisation to have ambitious goals and to set ourselves high standards to achieve them. We owe it to people affected by leukaemia, MDS and MPN to do our utmost to advance our vision, as quickly as possible. We owe it to people who donate their money to spend it in a way that makes this vision come true.

Structure, governance and management

Constitution

This is the second annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of 12 trustees in office at any one time are required by the constitution. At each AGM one-third of the trustees, must retire from office but may stand for re-election. A Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet six times a year (currently online or hybrid meetings) and delegate day-to-day running of the charity to the senior management team. In 2021, the January, April and July meetings were held online only, with the November meeting held as a hybrid event following the purchase of conferencing equipment that made this viable.

Our Trustee Board together bring a balanced mix of skills in governance, finance, business, healthcare, law and administration to the Board with half of our Board being patients. Two Trustees resigned in 2021 - we thank Matt and Barbara for their service to the Board of Trustees and Leukaemia Care and wish them all the best. One new Trustee was appointed during the period of this report: Carina Patterson.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr Christopher R. G. Matthews Maxwell (Chair)	
Mrs Elizabeth Wilson (Vice Chair)	
Mrs Wendy Davies (Treasurer)	
Dr Emmanouil Nikolousis	
Mr Matthew Fowler	(Resigned 17 May 2021)
Dr Barbara Compitus	(Resigned 15 June 2021)
Ms Kate Stallard	
Mr Robert Heppell	
Mr Dharmesh Mehta	
Professor Mhairi Copland	(Appointed 2 February 2022)
Ms Carina Patterson	(Appointed 3 November 2021)
Dr Sarah Smith	(Appointed 2 February 2022)
Helen Knight	(Appointed 4 May 2022)

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer role specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester (Government restrictions permitting during the pandemic) with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee".

All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (www.fundraisingregulator.org.uk/) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this

service to anyone enquiring directly to the charity about concerns with our fundraising ask. In 2021, the charity received no suppression requests through the Fundraising Preference Service and total of seven fundraising complaints as detailed below.

Leukaemia Care received six fundraising complaints relating to the discontinued charity bags: five regarding fly-tipping of bags and one regarding fly-tipping of bags belonging to another blood cancer charity. All were reported to East London Textiles Limited who until September 2019 were contracted to deliver and collect charity textile recycling bags on our behalf. We also received one complaint from a fundraiser who felt that his London Marathon target was not made sufficiently clear on the website prior to signing up and wished to withdraw. Although this is stated explicitly multiple times throughout the application process and in the terms and conditions, his application was withdrawn. He was offered a place in the virtual London Marathon available which had a lower fundraising target.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team.

Chief Executive Officer	Zack Pemberton-Whiteley
Chief Operating Officer and Deputy CEO	Monica Izmajlowicz
Communications and Fundraising Director	Nicole Scully

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising. We wish to honour the memory and service of Dr Noel Harker who sadly died 17 February 2022 after many years of steadfast support to the charity and blood cancer patients and their families.

President Dr Richard Taylor

Vice Presidents

- Ms. Sue Merchant
- Professor Claire Harrison
- Dr Robert Marcus
- Professor Andrew Pettitt
- Dr Noel E M Harker (deceased 17 February 2022)
- Professor Antonio Pagliuca
- Ms Sheila Hegarty
- Mr Jason Eliadis
- Mr Roland Maturi
- Mr Christopher Matthews-Maxwell
- Mr Peter Mondon
- Mr Anthony Gavin

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. David Marks
Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Dr. Deborah Yallop
Prof. Ajay Vora

Acute myeloid leukaemia panel

Dr. Manos Nikolousis
Prof. Mary Frances McMullin
Dr. Sahra Ali
Dr. Steve Knapper
Dr. Panagotis Kottaridis
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Prof. Antonio Pagluica

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh	Dr. Chris Fox
Dr. Ben Kennedy	Dr. Renata Walewska
Prof. Chris Fegan	Prof. Peter Hillmen
Prof. Guy Pratt	Prof. John Gribben
Assoc. Prof Francesco Forconi	Dr Sunil Lyengar
Prof. Adrian Bloor	
Dr. Shankara Paneesha	
Dr. Alison McCaig	

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Nick Cross
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Prof. Adam Mead
Dr Jonathan Kell
Prof. George Follows

Dr. Nilima Parry-Jones
Dr. Piers Patten

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Sally Killick (MDS)
Dr. Robert Marcus (Lymphoma)
Simon Cheeseman (Pharmacist)
Prof. Judith Marsh (Aplastic anaemia, MDS)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Ruth Corbally
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Roxanne Spencer
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Joanna Large

Catherine Langton
Catherine Kunatsa
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively.

When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

When drafting this policy, Leukaemia Care was influenced by the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration).

The Board of Trustees are responsible for setting remuneration levels for the senior management team. This is currently identified as the CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

Salaries are reviewed annually in February following annual appraisals and take effect from April. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

- Mission and strategic aims of the charity and its general day to day needs.
- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy.
- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties.
- Current strategic business plan and how this might affect current and/or future needs. Leukaemia Care's financial ability to pay.
- Available information on charitable sector pay levels, alongside that of other sectors.
- Available information on regional pay levels.
- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development.
- The charity's track record in recruiting and retaining high-performing staff.
- The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider public.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

This includes a proposal to increase staff salaries each year in line with the cost of living (capped within the above bandings). Staff are also eligible for performance related reviews. All salary increases are capped within the bandings.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in January/early February.

Influenced by the 2014 NCVO inquiry referred to above, the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting
- Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements). Staff/ pension costs: total organisational staff costs in 2021 were £690,877 (2020 - £720,136). Overall, our staff costs as a proportion of overall expenditure were 51.6% for 2021 a decrease from 64.1% in 2020.

Volunteers

A huge thank you to our volunteers in 2021 – patients, carers and healthcare professionals who continued to support anyone affected by a leukaemia, MDS or MPN diagnosis online or by phone. They were key in ensuring anyone affected by a leukaemia diagnosis received timely information and support during the ongoing pandemic and once restrictions started to ease. By sharing their personal experience and knowledge while shielding themselves or working on the COVID-19 frontline in healthcare, they went above and beyond to support others.

Our Buddy Support Service relies entirely on patients and carers volunteering their time to support other patients and carers who may be struggling with their diagnosis or feeling isolated because of it. The volunteers are DBS checked, trained and provided with ongoing support by our Buddy Co-ordinator who is a paid employee.

Our webinars and online training events rely largely on the generosity of healthcare professionals and patients who volunteer their time as speakers – providing attendees with relevant and up to date information not only on leukaemia, MDS and MPN but also tips on getting the most out of medical appointments, coping with fatigue, immunisations and the challenges of living with a compromised immune system among other topics.

We are grateful to the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional and administrative support to the group.

Our medical and patient advisory panels provide Leukaemia Care with feedback on our strategy and activities ensuring our services remain relevant and timely. They also support with health technology appraisals, advice on advocacy requests from individual patients, content for articles, webinars and podcasts as well as reviewing patient information. Each year people share and record their leukaemia stories as part of '#SpotLeukaemia' to raise awareness of the signs and symptoms. We recognise that people connect with stories and the

people at the heart of them and each year they help us spread the '#SpotLeukaemia' message a little wider.

Our community fundraising volunteers place collection tins, hold supermarket collections, run events and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. We recognise that 2021 continued to be a very challenging year for them as many activities were put on hold.

Related parties

The only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

Kendall Wadley LLP were appointed first auditors to the charitable company. In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.



Mr Christopher R. G. Matthews Maxwell (Chair)

Trustee

Dated: 29 June 2022

**Peter Threader, diagnosed with
hypoplastic myelodysplasia (MDS)**



Statement of trustees' responsibilities

The Trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditor's report

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'Charity') for the year ended 31 December 2021 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations was as follows:

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made
- an review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the company

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.


- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

058A9BD1D0D34B3...

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

29 June 2022

Chartered Accountants
Statutory Auditor

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2021

Current financial year

	Notes	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Total 2020 £
<u>Income and endowments from:</u>					
Donations and legacies	3	669,681	193,206	862,887	764,690
Fundraising income	4	424,035	-	424,035	330,142
Investments	5	34,971	-	34,971	37,808
Other income	6	24,276	-	24,276	52,436
Total income		1,152,963	193,206	1,346,169	1,185,076
<u>Expenditure on:</u>					
Raising funds	7	569,908	-	569,908	277,077
Charitable activities	8	599,065	169,556	768,621	846,897
Total resources expended		1,168,973	169,556	1,338,529	1,123,974
Net gains on investments	14	36,577	-	36,577	13,691
Net incoming resources		20,567	23,650	44,217	74,793
<u>Other recognised gains and losses</u>					
Revaluation of tangible fixed assets	16	12,640	-	12,640	12,640
Net movement in funds		33,207	23,650	56,857	87,433
Fund balances at 1 January 2021		2,927,247	47,931	2,975,178	2,887,745
Fund balances at 31 December 2021		2,960,454	71,581	3,032,035	2,975,178

The statement of financial activities includes all gains and losses recognised in the period.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

Prior financial year

		Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
	Notes			
<u>Income and endowments from:</u>				
Donations and legacies	3	615,967	148,723	764,690
Fundraising income	4	330,142	-	330,142
Investments	5	37,808	-	37,808
Other income	6	52,436	-	52,436
		<hr/>	<hr/>	<hr/>
Total income		1,036,353	148,723	1,185,076
		<hr/>	<hr/>	<hr/>
<u>Expenditure on:</u>				
Raising funds	7	277,077	-	277,077
		<hr/>	<hr/>	<hr/>
Charitable activities	8	700,320	146,577	846,897
		<hr/>	<hr/>	<hr/>
Total resources expended		977,397	146,577	1,123,974
		<hr/>	<hr/>	<hr/>
Net gains on investments	14	13,691	-	13,691
		<hr/>	<hr/>	<hr/>
Net incoming resources		72,647	2,146	74,793
		<hr/>	<hr/>	<hr/>
<u>Other recognised gains and losses</u>				
Revaluation of tangible fixed assets	16	12,640	-	12,640
		<hr/>	<hr/>	<hr/>
Net movement in funds		85,287	2,146	87,433
		<hr/>	<hr/>	<hr/>
Fund balances on incorporation at 1 January 2020		2,841,960	45,785	2,887,745
		<hr/>	<hr/>	<hr/>
Fund balances at 31 December 2020		2,927,247	47,931	2,975,178
		<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

The statement of financial activities includes all gains and losses recognised in the period.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

BALANCE SHEET

AS AT 31 DECEMBER 2021

	Notes	2021		2020	
		£	£	£	£
Fixed assets					
Tangible assets	16		870,617		875,003
Investments	17		685,554		252,228
			<u>1,556,171</u>		<u>1,127,231</u>
Current assets					
Debtors falling due after one year	19	103,000		-	
Debtors falling due within one year	19	313,735		317,819	
Investments	20	402,060		400,000	
Cash at bank and in hand		734,703		1,205,514	
		<u>1,553,498</u>		<u>1,923,333</u>	
Creditors: amounts falling due within one year	21		<u>(77,634)</u>		<u>(75,386)</u>
Net current assets			1,475,864		1,847,947
Total assets less current liabilities			<u>3,032,035</u>		<u>2,975,178</u>
Income funds					
Restricted funds	23		71,581		47,931
<u>Unrestricted funds</u>					
Designated funds	24	1,087,127		1,334,103	
General unrestricted funds		1,873,327		1,593,144	
		<u>2,960,454</u>		<u>2,927,247</u>	
			<u>3,032,035</u>		<u>2,975,178</u>

The financial statements were approved by the Trustees on 29 June 2022

DocuSigned by:
Chris Matthews-Maxwell
6CF4719F0E4E433...

Mr Christopher R. G. Matthews Maxwell (Chair)
Trustee

DocuSigned by:
Wendy Davies
6883E98992D0489...

Mrs Wendy Davies (Treasurer)
Trustee

Company Registration No. 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2021

	Notes	2021 £	£	2020 £	£
Cash flows from operating activities					
Cash (absorbed by)/generated from operations	27		(96,832)		84,650
Investing activities					
Purchase of tangible fixed assets		(12,364)		(26,904)	
Purchase of investments		(485,914)		(121,618)	
Proceeds on disposal of investments		101,638		125,988	
Other investment movements		(12,473)		(4,251)	
Investment income received		37,194		37,808	
Net cash (used in)/generated from investing activities			(371,919)		11,023
Net cash used in financing activities			-		-
Net (decrease)/increase in cash and cash equivalents			(468,751)		95,673
Cash and cash equivalents at beginning of year			1,605,514		1,509,841
Cash and cash equivalents at end of year			1,136,763		1,605,514
Relating to:					
Cash at bank and in hand			734,703		1,205,514
Short term deposits included in current asset investments			402,060		400,000

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The Charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected.

Event income is recognised as an incoming resource on receipt, as this is when it becomes measurable.

Investment income is included in the SOFA in the year in which it is receivable.

Voluntary income is recognised as an incoming resource when receivable, except insofar as when it is incapable of financial measurement.

Time spent by volunteers is recorded and valued as income at an hourly rate payable in the market place for the services provided. An equivalent amount is included as expenditure.

Government grants in connection with Covid-19 support are taken to the Statement of Financial Activities when receivable. For funds received under the Job Retention Scheme, the income is allocated to the respective activity areas in direct proportion to the staff cost to which the claim relates.

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.7 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

1.8 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors are initially recognised at transaction price. Financial liabilities classified as payable within one year are not amortised.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by that review process.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2021	2021	2021	2020	2020	2020
	£	£	£	£	£	£
Donations and gifts	157,770	52,080	209,850	227,358	28,723	256,081
Legacies receivable	283,679	-	283,679	286,497	-	286,497
Corporate grants and donations	228,232	141,126	369,358	70,043	120,000	190,043
Donated goods and services	-	-	-	32,069	-	32,069
	<u>669,681</u>	<u>193,206</u>	<u>862,887</u>	<u>615,967</u>	<u>148,723</u>	<u>764,690</u>

4 Fundraising income

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Fundraising events - all unrestricted	<u>424,035</u>	<u>330,142</u>

5 Investments

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Rental income	25,900	25,900
Investment income	1,406	1,667
Interest receivable	7,665	10,241
	<hr/>	<hr/>
	34,971	37,808
	<hr/> <hr/>	<hr/> <hr/>

6 Other income

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
Government Grants	23,082	51,735
Solar panels	1,194	701
	<hr/>	<hr/>
	24,276	52,436
	<hr/> <hr/>	<hr/> <hr/>

The Government Grant is in relation to the Job Retention Scheme.

7 Raising funds

	Unrestricted funds	Unrestricted funds
	2021	2020
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	309,000	13,518
Advertising	18,597	4,107
Other fundraising costs	33,876	29,606
Staff costs	173,573	196,605
Depreciation and impairment	2,139	1,921
Investment management fees	4,656	1,785
Support costs (see note 10)	25,802	24,076
Governance costs (see note 10)	2,265	5,459
	<hr/>	<hr/>
Fundraising and publicity	569,908	277,077
	<hr/> <hr/>	<hr/> <hr/>

8 Charitable activities

	2021 £	2020 £
Staff costs	504,029	506,336
Depreciation and impairment	27,250	25,763
Patient Services costs	35,694	38,768
Conferences	2,102	5,692
Help Line costs	4,109	4,341
Leukaemia Matters/ Nursing Matters	11,172	11,091
Campaign costs	15,425	10,798
Other charitable activities	15,315	689
Nurse e-learning tool	512	22,342
Donated Help Line services	-	32,069
GP's e-learning tool	2,400	31,443
Other grants (see note 9)	50,000	50,000
Database costs	4,469	4,335
Patient Advocacy	3,709	1,257
Website costs	13,669	14,940
	<u>689,855</u>	<u>759,864</u>
Grant funding of activities (see note 9)	-	921
Share of support costs (see note 10)	73,481	73,374
Share of governance costs (see note 10)	5,285	12,738
	<u>768,621</u>	<u>846,897</u>
Analysis by fund		
Unrestricted funds	599,065	700,320
Restricted funds	169,556	146,577
	<u>768,621</u>	<u>846,897</u>

9 Grants payable

Grants of £Nil (2020- £921) were paid to individuals, being bursaries to nurses as provided for in designated funds. Further grants of £50,000 (2020- £50,000) were awarded to other individuals as part of the Hospital Travel programme.

10 Support costs

	Support costs £	Governance costs £	2021 £	Support costs £	Governance costs £	2020 £
Staff costs	13,275	-	13,275	17,195	-	17,195
Other staff costs	12,479	-	12,479	10,278	-	10,278
Rent, rates and insurance	8,721	-	8,721	7,424	-	7,424
Heat and light	6,245	-	6,245	6,601	-	6,601
Repairs and renewals	8,650	-	8,650	7,878	-	7,878
Printing, postage and stationery	10,170	-	10,170	7,261	-	7,261
Telephone	10,281	-	10,281	10,105	-	10,105
Motor and other travel	-	-	-	6,538	-	6,538
Subscriptions	1,509	-	1,509	2,149	-	2,149
Other office costs	17,641	-	17,641	14,146	-	14,146
Bank charges	999	-	999	2,085	-	2,085
Sundry Expenses	9,313	-	9,313	5,790	-	5,790
Audit fees	-	3,600	3,600	-	4,820	4,820
Legal and professional	-	2,370	2,370	-	10,674	10,674
Trustee and meeting expenses	-	1,580	1,580	-	2,703	2,703
	<u>99,283</u>	<u>7,550</u>	<u>106,833</u>	<u>97,450</u>	<u>18,197</u>	<u>115,647</u>
Analysed between						
Fundraising	25,802	2,265	28,067	24,076	5,459	29,535
Charitable activities	73,481	5,285	78,766	73,374	12,738	86,112
	<u>99,283</u>	<u>7,550</u>	<u>106,833</u>	<u>97,450</u>	<u>18,197</u>	<u>115,647</u>

11 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

Fees payable	2021 £	2020 £
Audit of the annual accounts	3,600	4,820
	<u>3,600</u>	<u>4,820</u>

12 Trustees

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 2 (2020 : 3) trustees for the current year were £670 (2020 : £2,619).

None of the Trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CKCA Limited to prepare the payroll, W Davies, trustee, is a director of this company. The services are provided on an arms length basis and the amount paid during the year amounted to £1,916 (2020 : £1,881).

All trustees are covered by an indemnity insurance policy costing £611 (2020: £750)

13 Employees

The average monthly number of employees during the year was:

	2021	2020
	Number	Number
Training and provision of care	18	19
Fundraising and publicity	10	9
Accounts and administration	3	4
	<hr/>	<hr/>
Total	31	32
	<hr/> <hr/>	<hr/> <hr/>

Employment costs

	2021	2020
	£	£
Wages and salaries	615,806	648,243
Social security costs	47,835	48,755
Other pension costs	27,236	23,138
	<hr/>	<hr/>
	690,877	720,136
	<hr/> <hr/>	<hr/> <hr/>

The remuneration of key management personnel through payroll and other fees is £158,284 (2020: £162,554).

The number of employees whose annual remuneration was more than £60,000 is as follows:

	2021	2020
	Number	Number
£60,001 to £70,000	1	-
	<hr/> <hr/>	<hr/> <hr/>

14 Net gains on investments

	2021 £	2020 £
Revaluation of investments	15,328	6,161
Gains on sale of investments	21,249	7,530
	<u>36,577</u>	<u>13,691</u>

15 Taxation

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity.

16 Tangible fixed assets

	Freehold buildings £	Computers and other equipment £	Fixtures and fittings £	Total £
Cost				
At 1 January 2021	842,599	232,275	14,656	1,089,530
Additions	-	12,364	-	12,364
	<u>842,599</u>	<u>244,639</u>	<u>14,656</u>	<u>1,101,894</u>
At 31 December 2021	842,599	244,639	14,656	1,101,894
Depreciation and impairment				
At 1 January 2021	-	205,074	9,453	214,527
Depreciation charged in the year	12,640	15,284	1,466	29,390
Revaluation	(12,640)	-	-	(12,640)
	<u>-</u>	<u>220,358</u>	<u>10,919</u>	<u>231,277</u>
At 31 December 2021	-	220,358	10,919	231,277
Carrying amount				
At 31 December 2021	<u>842,599</u>	<u>24,281</u>	<u>3,737</u>	<u>870,617</u>
At 31 December 2020	<u>842,599</u>	<u>27,201</u>	<u>5,203</u>	<u>875,003</u>

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

17 Fixed asset investments

	Listed investments £	Cash in portfolio	Total £
Cost or valuation			
At 1 January 2021	245,823	6,405	252,228
Additions	485,914	(485,914)	-
Valuation changes	15,328	-	15,328
Other cash movements	(2,739)	399,488	396,749
Profit on disposal	21,249	-	21,249
Disposals	(101,638)	101,638	-
	<u>663,937</u>	<u>21,617</u>	<u>685,554</u>
At 31 December 2021	663,937	21,617	685,554
Carrying amount			
At 31 December 2021	<u>663,937</u>	<u>21,617</u>	<u>685,554</u>
At 31 December 2020	<u>245,823</u>	<u>6,405</u>	<u>252,228</u>

18 Financial instruments

	2021 £	2020 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	<u>663,937</u>	<u>245,823</u>

19 Debtors

	2021 £	2020 £
Amounts falling due within one year:		
Trade debtors	48,208	9,839
Other debtors	99,626	-
Prepayments and accrued income	165,901	307,980
	<u>313,735</u>	<u>317,819</u>
Amounts falling due after more than one year:		
Prepayments and accrued income	<u>103,000</u>	<u>-</u>
Total debtors	<u>416,735</u>	<u>317,819</u>

20 Current asset investments

	2021	2020
	£	£
Term deposits	402,060	400,000
	<u> </u>	<u> </u>

21 Creditors: amounts falling due within one year

	2021	2020
	£	£
Other taxation and social security	13,668	13,057
Trade creditors	16,002	13,497
Accruals and deferred income	47,964	48,832
	<u> </u>	<u> </u>
	<u>77,634</u>	<u>75,386</u>

22 Retirement benefit schemes**Defined contribution schemes**

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £27,236 (2020 - £23,138).

23 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds		Movement in funds		Movement in funds		Movement in funds	
	Balance at 1 January 2020	Incoming resources	Resources expended	Balance at 1 January 2021	Incoming resources	Resources expended	Balance at 31 December 2021	
	£	£	£	£	£	£	£	
The Lily Blae Hope Fund	30,265	-	(5,837)	24,428	-	(1,961)	22,467	
Information Booklets	-	32,400	(32,400)	-	84,125	(60,538)	23,587	
GP e-learning Tool	-	5,935	(5,935)	-	19,817	(12,261)	7,556	
Nurse Advisor	-	29,125	(29,125)	-	-	-	-	
Student/ Education	5,000	-	-	5,000	-	-	5,000	
Worcester Support Group	251	-	-	251	-	(251)	-	
Glasgow Area	1,325	1,900	(3,225)	-	1,900	(1,900)	-	
Kay Kendall	1,856	-	(1,763)	93	-	(93)	-	
Support Group West Midlands	25	-	(25)	-	-	-	-	
Support Group - Durham	32	-	(32)	-	-	-	-	
Support Group - Taunton	283	-	(16)	267	-	(267)	-	
Support Group - Scotland	6,748	-	(276)	6,472	-	(1,962)	4,510	
Counselling Fund	-	5,440	(5,440)	-	1,000	(1,000)	-	
Travel Grant	-	47,600	(47,600)	-	-	-	-	
Support Group - Glasgow & Aberdeen	-	2,000	-	2,000	-	(454)	1,546	
Support Group - South Shields	-	1,000	-	1,000	1,000	(1,962)	38	
Support Group - Leicestershire	-	1,393	-	1,393	-	-	1,393	
Patient Support - Worcestershire	-	2,500	(600)	1,900	-	(1,900)	-	
Birmingham Patient Conference	-	500	-	500	-	-	500	
Welfare & Advocacy Support	-	5,000	(4,373)	627	21,681	(22,308)	-	
Belfast Hospital Support	-	2,000	-	2,000	-	-	2,000	
Bristol Hospital Support	-	2,000	-	2,000	-	-	2,000	
Staffing Costs	-	9,930	(9,930)	-	-	-	-	

23 Restricted funds

											(Continued)
Patient Conferences/Webinars	-	-	-	-	-	7,000	(7,000)	-	-	-	-
Care Helpline Costs	-	-	-	-	-	5,000	(4,016)	984	-	-	984
Nurse e-learning	-	-	-	-	-	10,183	(10,183)	-	-	-	-
Buddy Scheme	-	-	-	-	-	1,500	(1,500)	-	-	-	-
West Midlands Hospital Support	-	-	-	-	-	5,000	(5,000)	-	-	-	-
Digital Support	-	-	-	-	-	33,000	(33,000)	-	-	-	-
Support Group - Cambridge	-	-	-	-	-	500	(500)	-	-	-	-
Spot Leukaemia	-	-	-	-	-	1,500	(1,500)	-	-	-	-
	<u>45,785</u>	<u>148,723</u>	<u>(146,577)</u>	<u>47,931</u>	<u>193,206</u>	<u>(169,556)</u>	<u>71,581</u>				

23 Restricted funds

(Continued)

The Lily Blae Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services

Support Group West Midlands - to facilitate activities for support groups in the area

Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas

Support Group Leicestershire - to facilitate activities for support groups in these areas

23 Restricted funds

(Continued)

- Patient Support Worcestershire - to facilitate activities for support groups in this area
- Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham
- Welfare & Advocacy Support - in support of advocacy and welfare advise
- Belfast Hospital Support - in support of the costs in providing ward support
- Bristol Hospital Support - in support of the costs in providing ward support
- Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers
- Patient conferences/webinars - grants in support of conferences held in the year.
- Care Helpline costs: this represents income received specifically to meet the costs of the Care line.
- Support Groups - to facilitate activities for local support groups
- Nurse e-learning - funds to support the advancement of knowledge in the nursing profession.
- Buddy Scheme - one to one support for patients
- West Midlands Hospital Support -to facilitate activities for local support groups
- Digital support - to support digital and information projects
- Support Group Cambridge - to facilitate activities for local support groups
- Spot Leukaemia - to raise awareness of signs and symptoms of Leukaemia

24 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Balance at 1 April 2019		Movement in funds			Movement in funds			Balance at 31 December 2021		
	£	£	Incoming resources	Resources expended	Transfers	Balance at 1 January 2021	Incoming resources	Resources expended	Transfers	£	£
Fixed asset fund	863,138	11,862	-	-	3	875,003	-	-	(4,386)	870,617	
Strategic implementation fund	311,729	547,661	(400,290)	-	-	459,100	252,116	(494,706)	-	216,510	
	<u>1,174,867</u>	<u>559,523</u>	<u>(400,290)</u>	<u>(400,290)</u>	<u>3</u>	<u>1,334,103</u>	<u>252,116</u>	<u>(494,706)</u>	<u>(4,386)</u>	<u>1,087,127</u>	

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the three year strategy adopted by the Trustees on 28 November 2019.

25 Analysis of net assets between funds

	Unrestricted funds 2021 £	Restricted funds 2021 £	Total 2021 £	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £
Fund balances are represented by:						
Tangible assets	870,617	-	870,617	875,003	-	875,003
Investments	685,554	-	685,554	252,228	-	252,228
Current assets/ (liabilities)	1,404,283	71,581	1,475,864	1,800,016	47,931	1,847,947
	<u>2,960,454</u>	<u>71,581</u>	<u>3,032,035</u>	<u>2,927,247</u>	<u>47,931</u>	<u>2,975,178</u>

26 Operating lease commitments

At the reporting end date the Charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2021 £	2020 £
Within one year	1,325	1,325
Between two and five years	-	1,325
	<u>1,325</u>	<u>2,650</u>

26 Operating lease commitments**(Continued)****Lessor**

At the reporting end date the Charity had contracted with tenants for the following minimum lease payments:

	2021	2020
	£	£
Within one year	-	12,950

27 Cash generated from operations

	2021	2020
	£	£
Surplus for the year	44,217	74,793
Adjustments for:		
Investment income recognised in statement of financial activities	(34,971)	(37,808)
Gain on disposal of investments	(21,249)	(7,530)
Fair value gains and losses on investments	(15,328)	(6,161)
Depreciation and impairment of tangible fixed assets	29,390	27,683
Movements in working capital:		
(Increase)/decrease in debtors	(101,139)	77,969
Increase/(decrease) in creditors	2,248	(44,296)
Cash (absorbed by)/generated from operations	(96,832)	84,650

28 Analysis of changes in net funds

The Charity had no debt during the year.

Leukaemia Care is registered as a charity in England and Wales (no.1183890) and Scotland (no. SCO49802). Company number: 11911752. Registered office address: One Birch Court, Blackpole East, Worcester, WR3 8SG

LEUKAEMIA CARE

England & Wales - Charity number 1183890

Accounts

Charity Registration No. 1183890 (England and Wales)

Charity Registration No. SC049802 (Scotland)

Company Registration No. 11911752 (England and Wales)

LEUKAEMIA CARE
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2020

Leukaemia Care
YOUR Blood Cancer Charity

www.leukaemiacare.org.uk

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Patrons	Lady Penny Mountbatten Beverley Warboys	
Trustees	Mr C. R. G. Matthews Maxwell (Chair) Mrs Wendy Davies (Treasurer) Dr Emmanouil Nikolousis Mrs Elizabeth Wilson (Vice Chair) Ms K Stallard Mr R Heppell Mr D Mehta Mr Kristian Griffin Mr Matthew Fowler Dr Barbara Compitus	(Appointed 1 April 2020) (Appointed 16 December 2020) (Appointed 16 December 2020) (Resigned 29/07/20) (Resigned 17/05/21) (Resigned 15/06/21)
President	Dr Richard Taylor	
Vice Presidents	Ms Sue Merchant Mr Roland Maturi Professor Claire Harrison Dr Robert Marcus Professor Andrew Pettitt Dr Noel E M Harker Professor Antonio Pagliuca Ms Sheila Hegarty Mr Jason Eliadis Mr C.R.G. Matthews-Maxwell Mr Peter Mondon Mr Anthony Gavin Mr Albert Podesta	
Senior Management Team		
Chief Executive Officer	Mr Peter Mondon Zack Pemberton-Whiteley	(Retired 31 December 2020) (Appointed 1 October 2020)
Chief Operating Officer and Deputy CEO Communications and Fundraising Director	Monica Izmajlowicz Nicole Scully	
Medical Advisory Panels	As described in the Trustees' Report	
Secretary	Monica Izmajlowicz	
Charity number (England and Wales)	1183890	
Charity number (Scotland)	SC049802	
Company number	11911752	
Website	www.leukaemicare.org.uk	

LEUKAEMIA CARE

LEGAL AND ADMINISTRATIVE INFORMATION

Registered office

One Birch Court
Blackpole East
Worcester
WR3 8SG

Auditor

Kendall Wadley LLP
Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Bankers

Barclays Bank Plc
54 High Street
Worcester
WR1 2QQ

Solicitors

Harrison Clark Rickerbys
5 Deansway
Worcester
WR1 2JG

Investment advisors

Cardale Asset Management
2 Greengate
Cardale Park
Harrogate
HG3 1GY

CCLA
Senator house
85 Queen Victoria Street
London
EC4V 4ET

LEUKAEMIA CARE

CONTENTS

	Page
A word from our Chairman	1
Trustees' report	2 - 19
Statement of Trustees' responsibilities	20
Independent auditor's report	21 - 23
Statement of financial activities	24 - 25
Balance sheet	26
Statement of cash flows	27
Notes to the financial statements	28 - 46

LEUKAEMIA CARE

A word from our Chairman

FOR THE YEAR ENDED 31 DECEMBER 2020

A warm welcome to our readers of the first Annual Report of Leukaemia Care, the Limited Company. In 2020 we completed the process of updating our governance structure in that we moved from being an unincorporated Charity to that of a Company Limited by Guarantee. For all practical purposes, however, Leukaemia Care continues to be a Registered Charity, with our ethos and culture of care and support, remaining unchanged.

We live in very difficult times and there can be no doubt that 2020 has been a very testing time for us all. This Report details how we responded to the challenge and its impact on patients, families, carers and friends. After 2019, which was a year of celebration for Leukaemia Care, marking 50 years of supporting leukaemia and other blood cancer patients, we started 2020 with an ambitious strategy that included a bold expansion of our face-to-face support for patients and their families in hospitals nationwide. However, by March it was obvious, as a result of the pandemic, we needed to adapt our strategy and move services online wherever possible. The pandemic also identified the need for us to do more, to do it differently, and to respond more quickly to unmet demands. Requests for information and support increased, and lockdowns have caused fundraising activities to decline sharply.

People have enthusiastically embraced online support, which has also enabled us to reach many who may not have otherwise engaged with the Charity. In saying this, however, we are ever-mindful that some people cannot or prefer not to use digital services and, going forward, we will ensure we continue to be accessible to all by providing a mixture of digital and in-person services.

An inevitable consequence of Covid-19 has been the adverse impact that it has had on the NHS in terms of cancer referrals and the resultant later diagnoses of cancer. In view of this, our '#SpotLeukaemia' campaign remains a priority and, in 2020, we created the first ever World Leukemia Day, which reached over 20 million people. The generosity of people willing to share the story of their diagnosis and the impact this has had on their lives, is both very moving and vital to raising awareness of the signs and symptoms of leukaemia.

I am extremely proud to be part of Leukaemia Care – a diverse community of patients, their families, carers, friends, healthcare professionals supporting them, together with fellow trustees, employees, volunteers, donors, and fundraisers. This list is by no means exhaustive and I would ask anyone reading this Report to get in touch and see how they can get involved.

What the past year has shown us is that, by working together and sharing our experiences, hopes and aspirations, we can continue to improve the lives of people affected by leukaemia and other blood cancers.

I would like to end by thanking all of our staff, who have worked tirelessly, in very difficult circumstances, to ensure that Leukaemia Care continues to operate effectively and is always there for those who look to us for help and support.

With warm wishes

Chris Matthews-Maxwell

(Chair of Trustees)

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees present their report and financial statements for the year ended 31 December 2020.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the Charity's memorandum and articles of association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Leukaemia Care is a national blood cancer support charity. We are dedicated to ensuring that anyone affected by blood cancer receives the right information, advice and support.

A diagnosis of a blood cancer can have a huge impact on someone emotionally, as well as physically. We understand that feelings of shock, anger and loneliness are all common at the time of diagnosis, during treatment and recovery and having someone to talk to, as well as the right information available can be a huge comfort.

We not only support patients, but carers and families too who can often carry a lot of the emotional strain when someone they love is diagnosed with a blood cancer.

We focus on the support that is needed now to help those affected by blood cancer cope during a diagnosis and beyond.

Purpose

The charity's objects are set out in its articles of association:

1. The relief of sickness and the promotion and protection of good health among persons suffering from Leukaemia and allied blood disorders.
2. The relief of need among families, carers and friends of persons suffering from leukaemia and allied blood disorders, and in particular those contemplating or suffering bereavement or who must contemplate the prospect of treatment where those needs are attributable to the affliction of leukaemia and allied blood disorders.

Our vision

Helping people live better with blood cancer.

Our mission

Improving lives through earlier diagnosis, access to effective treatments, information and support.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Our five strategic priorities

We save lives through earlier diagnosis

- We raise awareness of the signs and symptoms of leukaemia and work with healthcare professionals such as GPs, dentists and pharmacists to help them spot leukaemia.
- We help people to understand what leukaemia is and that it can affect anyone at any age.

We campaign for access to effective treatments

- We work with the NHS and other organisations to ensure patients can access the best possible treatment for them, and when they can't – we advocate on their behalf.

We believe people should get the right information when they need it

- We know that diagnosis and treatment can turn your world upside down – we empower people with accredited information, support from clinical nurse specialists and the opportunity to meet patients diagnosed with leukaemia.

We support healthcare professionals to help their patients

- We empower GPs and other healthcare professionals to spot leukaemia through awareness events and online learning.
- We provide nurses with tailored conferences, online learning and bursaries to enhance their knowledge of leukaemia and patient care.

We conduct research to improve patient experience

- We listen to patients, and using the evidence we gather, improve our services and focus our campaigning.

Public benefit

Our work delivers public benefit by providing information, advice and support to anyone affected by a leukaemia diagnosis; patients, family members, friends as well as employers and schools looking for advice on how best to support employees and students. This information and support helps people to live better with their leukaemia by reducing the isolation that can come with a blood cancer diagnosis, clarity on their treatment options and improving quality of life with strategies to reduce the impact of the side effects of treatment.

Our '#SpotLeukaemia' campaign reaches a wider audience equipping people with the awareness of the common signs and symptoms of leukaemia. This empowers them to speak with their GP if they have any concerns and increases the likelihood of earlier diagnosis and effective treatment.

Our training raises awareness of the signs and symptoms of leukaemia among GPs and other key healthcare professionals increasing the likelihood of earlier diagnosis and effective treatment. Our nurse training provides much needed low cost or free training on aspects of caring for blood cancer patients thus enhancing their care.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Grant making

Leukaemia Care has three grant making streams: Hospital Travel Fund, the Ann Ashley Leukaemia Counselling Fund and the Nurse Bursary Scheme. These contribute towards addressing the recommendations made in our Living with leukaemia reports which inform our strategic aims.

Hospital Travel Fund

To support people with the additional cost of traveling to hospital for treatment and monitoring appointments.

A maximum £200 grant is available to leukaemia patients that are currently undergoing treatment, chronic lymphocytic leukaemia (CLL) patients on 'watch and wait', or chronic myeloid leukaemia (CML) patients in the first year of treatment-free remission (TFR). Applicants can also be the parent, sibling, child or spouse of a patient as defined above. Grants can be used towards bus tickets, train tickets, fuel, car maintenance, parking and taxi fares. The fund operates monthly. There is no closing date, awards are distributed on a first-come, first-served basis until the fund is depleted each month.

The Ann Ashley Leukaemia Counselling Fund

We are committed to providing patients and their families with emotional and psychological support through their blood cancer diagnosis. To provide patients with a diagnosis of leukaemia, MDS or MPNs or a parent, sibling, child or spouse of a patient with a maximum of up to six sessions of counselling with a maximum award of £400. Counsellors must be registered with the British Association of Counselling and Psychotherapy (BACP), or the UK Council of Psychotherapy (UKCP). The fund opens at the beginning of each year and awards are distributed on a first-come, first-served basis until the fund is depleted for the year.

Nurse Bursary Scheme

Leukaemia Care is committed to enhancing patient care through supporting nurses caring for blood cancer patients. We provide bursaries towards post-graduate university study or professional short courses as well as attending relevant conferences and seminars, including Leukaemia Care nurse conferences. Bursaries are available from January each year and are distributed on a first-come, first-served basis until the fund is depleted for the year.

Volunteers

A huge thank you to our volunteers in 2020 – patients, carers and healthcare professionals who rose to the challenge of delivering services online or by phone. They were key in ensuring anyone affected by a leukaemia diagnosis received timely information and support during the pandemic. By sharing their personal experience and knowledge while shielding themselves or working on the COVID-19 frontline in healthcare, they went above and beyond to support others.

Our Buddy Support Service relies entirely on patients and carers volunteering their time to support other patients and carers who may be struggling with their diagnosis or feeling isolated because of it. The volunteers are DBS checked, trained and provided with ongoing support by our Buddy Co-ordinator who is a paid employee.

Our webinars and online training events rely largely on the generosity of healthcare professionals who volunteer their time as speakers – providing attendees with relevant and up to date information on leukaemia.

We are grateful to the many nurses who help to run our nationwide support groups ensuring patients do not become isolated because of their diagnosis. They are supported by our network of Regional Co-ordinators who provide practical, emotional and administrative support to the group.

Our medical and patient advisory panels provide Leukaemia Care with feedback on our strategy and activities ensuring our services remain relevant and timely. They also support with health technology appraisals, advice on advocacy requests from individual patients, content for articles, webinars and podcasts as well as reviewing patient information.

Each year people share and record their leukaemia stories as part of '#SpotLeukaemia' to raise awareness of the signs and symptoms. We recognise that people connect with stories and the people at the heart of them and each year they help us spread the '#SpotLeukaemia' message a little wider.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Our community fundraising volunteers place collection tins, hold supermarket collections, run events and join the cheer squad for the London Marathon. As well as raising funds, they raise awareness of leukaemia and the support we provide within their local communities. We recognise that 2020 was very difficult for them as many activities were put on hold.

Achievements and performance

Our response to the COVID-19 pandemic

In the weeks leading up to the national lockdown on the 23 March 2020, we put together an emergency response plan that prioritised the following

- the safety of our employees and the people we support
- ensuring patients and their families continue to receive support albeit modified to online or by phone
- safeguarding income wherever possible recognising that 2020 was likely to be very challenging for fundraising

From the 23 March, all employees were supported to work from home with only two colleagues coming into the office as necessary to co-ordinate tasks that could not be done from home.

We furloughed six employees on a full-time basis in March - all whose roles were directly impacted due to the cancellation of fundraising events, patient conferences or hospitals being limited to essential workers only. From November, we placed 18 employees on part-time furlough bringing back some who had been on full-time furlough to assist with patient support. With great regret, we made the role of Engagement Officer redundant as we could not foresee in person patient conferences restarting until at the earliest September 2022.

Teams worked hard to adapt services online with new Zoom support groups substituting for in person meetings and a series of webinars launched to keep patients and families up to date on developments with shielding, accessing treatment and dealing with the emotional effects of the pandemic. Our newly launched Welfare and Advocacy Service provided timely information and support to people worried about finances, employment rights and other issues.

Our helpline saw a significant drop in calls from newly diagnosed people and this made us determined to continue with our annual '#SpotLeukaemia' campaign during Blood Cancer Awareness Month in September. Unlike previous years that had roadshows and events in parliament, we ran an online only campaign that saw us launch World Leukemia Day on the 4th September 2020 in collaboration with other patient organisations worldwide. We recognized that raising awareness of the signs and symptoms of leukaemia was more important than ever during a pandemic and encouraging people to see their GP as early as possible was vital in improving outcomes.

We increased the frequency of communications with our beneficiaries and supporters launching our "Weekly Wrap" e-newsletter with a summary of key information for patients as well as light-hearted book and TV reviews and recipes.

Our planned deficit of £322,322 for 2020 involving a significant investment in patient services and London Marathon places from our reserves was rapidly looking to become even greater. The postponement of the London Marathon to 4 October 2020 and then as an elite race only was a significant blow.

However, we were able to mitigate the financial impact of the pandemic through a combination of reducing our expenditure and better than expected income from grants and trusts, pharmaceutical donations, legacies, and corporate fundraising. Planned expenditure was reduced by pausing all recruitment and using the furlough scheme alongside refunds on venue hire fees for patient conferences and support groups. International scientific meetings were postponed to 2021 or held online and travel expenses evaporated as support was delivered online instead. London Marathon expenditure of £170,000 was shifted to 2021 as runners' places were transferred to 2021 and beyond.

These changes enabled us to safeguard services and to prepare for a challenging year of fundraising in 2021 in anticipation of further lockdowns.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Our achievements

Our third “Living with Leukaemia” survey was postponed once again to 2021 due to the pandemic and we continue to use the findings from our two “Living with leukaemia” surveys run in 2017 and 2018 to inform our strategy alongside ongoing feedback from patients, their families and healthcare professionals.

Recruitment picked up in early 2020 prior to the pandemic, with the appointment of a Welfare and Advocacy Officer, a Campaigns Officer, an Advocacy Officer and a Hospital Support Worker at Worcestershire Royal Hospital in March. Our new colleagues had barely got to know us before the UK locked down on the 23 March and all employees became home workers. These were key appointments to providing a robust and holistic support service to patients and their families.

Patient Support: providing high quality information and emotional support

Our Advice Service comprising the helpline, email and WhatsApp handled 5,692 queries (3,003 queries in 2019). Our two nurses, both haematology clinical nurse specialists, provided much needed advice and emotional support throughout the pandemic and this complemented the information provided in our webinars and support groups. We saw a significant drop in calls from newly diagnosed patients and their families in the first three quarters of 2020, with these being replaced by COVID related queries. This made us even more determined to extend the reach of our annual '#SpotLeukaemia' campaign.

“This is my lifeline.”

“Thank you for answering all my questions, I feel much better now, I don't know what I would do if I didn't have you to call”.

Our Buddy Service provided one to one support to 77 patients (57 in 2019) on an ongoing basis by phone and email. All of our buddies are DBS checked and receive induction training.

“It was so good to speak to someone with the same illness. She was so helpful and gave me a link to join a WhatsApps group for support for people like me. Hearing her story gave me a lot of hope for the future and it really made my day.”

“Definitely 12 out of 10! [my buddy] is a star. She is very knowledgeable, very supportive and helpful. She is very talented and could easily be a counsellor should she want to be. The buddy scheme is an excellent idea and I find it invaluable to my wellbeing.”

Due to the pandemic, we postponed any in-person conferences until 2022. Instead, we launched a series of webinars addressing patient's immediate concerns around COVID-19 and their specific leukaemia. As the pandemic progressed, we looked at shielding and coming out of shielding, accessing your GP, vaccines, how to handle the psychological and emotional impact of the pandemic alongside specific updates for chronic and acute leukaemia patients as well as those with MPNs and hairy cell leukaemia. We held 23 webinars in 2020 some of which were in partnership with Lymphoma Action, and these would not have been possible without the generosity of healthcare professionals and patients donating their time to support others with their expertise. Average attendance at each webinar was 150 people.

“Valid, up to date and timely information is what I need to help me stay fit and well. This is what was provided by your latest webinar. Well done and thank you.”

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

We cancelled all in-person support groups from April onwards and replaced them where possible with Zoom online meetings. We supported 1,565 people across our 49 online support groups (1,303 in 2019), and our face-to-face support groups until lockdown. The meetings were a vital source of information, support from fellow patients and helped to reduce the isolation of shielding.

"You are the first people I have seen all week, other than my food delivery driver, thank you for the company."
CMML patient

"I walked away from the hospital with limited information, which then led me to the doom and gloom of the internet, meeting other patients and hearing their experiences has made me feel more positive." ET patient

The Ann Ashley Leukaemia Counselling Fund aimed to provide 70 individuals with up to six sessions with a counsellor of their choice (subject to registration with relevant professional bodies). Uptake continued to be less than anticipated due to people wishing to wait until they could see a counsellor face to face. We awarded 44 grants; nine people completed counselling and 14 were in progress at the time of this report. Twenty either deferred or cancelled their grant for a variety of reason such as preferring face to face counselling, health deteriorating and sadly three people died before they could start their sessions. However, those who gave feedback found it helpful.

"I am very pleased with my counsellor. She has helped me identify my anxiety and I am able to build on this myself."

In the second year of our Hospital Travel Fund we supported 250 people with a travel grant of £200. This was launched to ease the financial burden of traveling to hospital for treatment and monitoring appointments as well as supporting family members with the costs of visits. Through this fund, we were able to help a significant number of families with children undergoing treatment for leukaemia and wish to thank the many support workers and social workers in hospitals across the UK who raised awareness and supported people with their applications.

"Thank you so much. I am ever so grateful for this contribution towards our travel costs. It's a massive help!"

"Many, many thanks for this, as I know it will be a great help to the family" Young Lives vs. Cancer social worker.

In 2020, we continued to expand our information with four new booklets and reviewed 32 bringing our total number of publications to 41. These were Down's Syndrome and leukaemia, Donor-derived acute leukaemia and/or donor derived MDS, Mixed Phenotype Acute Leukaemia and CLL starting active treatment. We continue to signpost to our fellow blood cancer charities especially for lymphomas and myelomas. We distributed 15,360 (15,172 in 2019) hardcopy booklets mainly to hospitals. A further 8,000 booklets (4,403 in 2019) were downloaded from our website.

"I have read through the booklet and I think it's great. The amount of information is great and really wished we could have had something with this much information on JMML as we were told "do not google it" and there was nothing like this available at the time. It's really informative and will really help families out there that may need it."

To complement our patient information booklets, we produced 175 videos (60 in 2019) covering patient stories and ways to get involved but also edited our webinars which can be viewed on demand on our YouTube channel <https://www.youtube.com/leukaemiacare>. Our videos have been viewed 576,668 times across our social media outlets. A huge thank you to everyone who shared their story and expertise.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

We produced nine episodes of our podcast “Leukaemia Chatters” – which had 2,672 downloads (3,874 downloads in 2019). We decided to focus on our webinars instead during the pandemic which we felt would reach more people. The circulation of our quarterly magazine, Leukaemia Matters remained static at 6,456 with equal numbers subscribing to electronic and hardcopy editions.

Eight hospitals across the UK normally host Hospital Support Workers who work alongside healthcare professionals one day a week in haematology clinics and on wards providing information, practical and emotional support to patients and their families. These are at Heartlands Hospital (Birmingham), Good Hope Hospital (Sutton Coldfield), Solihull Hospital (Birmingham), St James (Leeds), Southampton, Worcestershire Royal Hospital and the Christie Hospital in Manchester. On lockdown, hospitals asked the support workers to stay away as clinics were reorganized to support as many people as possible remotely. Three of our Hospital Support Workers were furloughed with the remaining two redeployed across our support services. Our Leeds support worker briefly returned in September at the hospital’s request but stopped with the second lockdown.

Patient Advocacy: campaigning for access to treatment and services

Our newly appointed Advocacy Officer helped 194 (40 in 2019) people with a variety of issues the most popular being COVID related (vaccines and understanding shielding guidance). Other cases involved resolving communication issues with hospital teams, specialist referrals and seeking second opinions, access to IVF and dentistry for cancer patients alongside accessing clinical trials.

“Thank you so much for your prompt reply and for this information which is extremely helpful to us. This is much more than we could have expected, and I thank you for that.”

In March 2020, we launched our Welfare Advice Service in recognition of the significant financial challenges faced by patients and their families upon a blood cancer diagnosis. We supported 140 people mostly with accessing benefits but also helped with housing and homelessness, people facing discrimination at work on diagnosis, making grant applications for financial support, pension advice and challenging Personal Independence Allowance decisions.

“Having never claimed anything before and being overwhelmed by the whole benefits process this year, we have found ourselves in a horrible situation. She [LC advisor] has spent hours on the phone talking me through the PIP form application and typing up for me and then later again with the mandatory reconsideration. She has been so patient, understanding and so lovely with it. Whilst waiting for the results of everything [LC staff] check on me regularly on the progress of the application throughout.”

“My access to work has been awarded. Thank you for all your help, you have been brilliant. I would not have known where to start without your help.”

Leukaemia Care have committed to be actively involved in all relevant Health Technology Appraisals for leukaemia, to ensure that we work to obtain access for patients and represent their views when decisions that affect them are being made. We also get involved in other blood cancer related appraisals where there is an unmet clinical need and a need for patient input in the appraisal. The Patient Advocacy team was involved in six scoping meetings for NICE, two for the Scottish Medicines Consortium and the All Wales Medicines and Strategy Group but also contributed at different stages of the appraisal process including technical engagements and submissions.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Early diagnosis within primary care: supporting GPs

With COVID-19 affecting the public's confidence in seeking medical help, encouraging early diagnosis through our SpotLeukaemia campaign was more important than ever. Together with international patient groups, we launched World Leukemia Day on the 4 September reaching 19.3 million with the '#WorldLeukemiaDay' over the course of the campaign. Our '#SpotLeukaemia' reached over 10 million people alone.

We updated our e-learning course for GPs hosted by the Royal College of General Practitioners alongside running four training events reaching 471 GPs (400 in 2019).

Each year we reach out to people to share their experiences of being diagnosed with leukaemia to encourage others to become more aware of the signs and symptoms, and each year we are moved by the generosity of people willing to share often challenging experiences to help others. You can read all the stories on our website.

Haematology nurse education: specific and affordable training for nurses caring for blood cancer patients

Due to the reduction in our income and unlikely uptake during the COVID-19 pandemic, our nurse bursary programme was reduced from £10,000 to £5,000 with 10 awards being made.

Prior to lockdown, 22 nurses attended our nurse conference in Glasgow in March.

Alongside this, 292 nurses completed courses in our online Nurse Academy including our CNS course, CAR-T therapy, Treatment Free Remission and PCR testing, Minimal Residual disease and our newly launched end of life and acute leukaemia course.

"Excellent online learning package which will improve patient experience."

"Very informative. Enjoyed this course, my knowledge had increased which will help me to look after my patients having CAR-T therapy."

We will not be continuing with nurse bursaries in 2021, instead investing in content for our online Nurse Academy.

Raising funds to deliver patient services

Events and community fundraising was seriously impacted by the pandemic with the postponement of the London Marathon to non-elite runners until 2021, and the cancellation of Ride London, Great North Run and London Landmarks. However, despite fewer opportunities to run in mass participation events in 2020, lots of runners chose to take on virtual running events instead such as the virtual London Marathon.

Virtual fundraising involved online quizzes, a Christmas craft market, Christmas cards and face masks through crowd funding alongside a "Make it shine" event where people could donate and leave a message in memory or in support of a loved one.

In 2019, Leukaemia Care was chosen as one of three charities for the Telegraph Charity Christmas Appeal. Alongside the Silverline and Wooden Spoon, Leukaemia Care benefited not only from fundraising but also the opportunity to raise awareness of the impact of leukaemia and our work with a diverse readership. The Christmas campaign ran from November 2019 to January 2020. Up to December 2019, we received £56,929 from the Christmas Appeal which has been previously reported. In 2020, we received the remainder amounting to £124,738.

Legacies enable the charity to plan for the future, pilot new services and expand existing ones. Without the generosity of people who chose to remember Leukaemia Care in their will, this would not be possible. In 2020, we benefited from £268,497 from gifts in wills. We wish to honour the following people for their support for blood cancer patients and their families; Hilda Bollen, Jean Godebout, Caroline Baxter, Mavis Bird, Mollie Lake, Carol Pardoe, Diana May, Margaret Clark, Eleanor Braterman, Mrs T Butters, Graham Pannell, Olwyn Hammond, June Cooper, Violet Friend and Edna Grant.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

The charity works with the pharmaceutical industry to ensure that the interests of patients are considered when developing new drugs and treatments for patients. We received a total of £183,062.92 in funding from the following pharmaceutical companies in accordance with our Code of Practice (see website).

To ensure that we remain financially independent, limits are placed on all types of funding. We do not allow the total level of funding received from the pharmaceutical industry to exceed 25% of our total annual income. Nor do we allow the funding received from an individual company to exceed 10% of our total annual income.

Abbvie	£11,040 (£10,000 core funding and £1,040 honorarium)
Agios	£12,165 core funding
Amgen	£15,000 support services
Autolus	£5,000 core funding
Astellas	£15,000 patient support and awareness
Astra Zeneca	£400 honorarium
Astraze	£250 honorarium
Gilead	£10,000 emergency funding
Incyte	£30,000 core funding
Janssen	£20,270 (£20,000 core funding and £270 honorarium)
Jazz	£25,000 awareness and patient support
Novartis	£1,887.95 (£292.95 ASH video and £1,595 honorarium)
Pfizer	£10,000 support services
Servier Labs	£2,000 core funding
Takeda	£25,000 core funding

Financial review

The results for the year are set out in the financial statements commencing on page 25. The financial statements show incoming resources for the year of activities of £1,153,607 compared to incoming resources in 2019 of £1,235,966 (nine months). Trustees would like to thank all staff and volunteers for the continuing hard work and commitment that have made this possible.

Total reserves stand at £2,975,178 (2019: £2,887,745) of which £47,931 (2019: £45,785) was restricted in application and £1,334,103 (2019: £1,174,867) were designated by the trustees to match the tangible fixed assets of the charity and fund certain projects identified as being required in the immediate future. Those designated funds connected to tangible fixed assets relate predominantly to the freehold property and are likely, given current market conditions, to remain whilst the relevant charitable entity continues to own title to the same. Funds remaining for general use were £1,6593,144 (2019: £1,667,093).

In light of the issues created by the Covid-19 pandemic, the Trustees consider the results for the year to be satisfactory.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Risk assessment and management

The Trustees carry out an annual detailed review of the Charity's activities and produce a comprehensive three-year strategic plan which sets out the major opportunities for the delivery of patient support. The Trustees monitor progress against the strategic objectives set out in the plan quarterly, in addition to the annual review. As part of this process the Trustees have implemented a risk management strategy, which comprises:

- a comprehensive annual review to identify, where possible, the risks which the Charity may face during the forthcoming year;
- the establishment, where possible, of contingency plans to meet anticipated risk(s);
- the establishment of systems and procedures to mitigate such risks and the implementation of procedures to minimise any real or potential impact on the Charity should any such risk(s) materialise;
- the prioritisation of the Charity's activities both actual and planned;
- the preparation and monitoring of meaningful and timely financial and management information.

The strategic plan referred to above focuses on the delivery of care and support to persons affected by blood cancer. Successful implementation of the plan is dependent upon the Charity having the necessary resources available (financial and otherwise) and for the prudent and effective management of such resources.

Reserves Policy

The Trustees have forecast the level of free reserves (those funds not tied up in tangible fixed assets or categorised as designated or restricted funds) that the Charity will require to sustain its operations over the period when it is anticipated that there may be some reduction in income. Such reduction may lead to the curtailment or cancellation (temporarily or otherwise, depending on the specific nature of the income reduction) of projects detailed in the strategic plan (whether in progress or not yet commenced). The overriding concern of the Trustees at such a time will be the maintenance of the services that provide most benefit to patients.

Having regard to the foregoing, and with the assistance of professional advice and guidance, the Trustees consider that the most appropriate level of free reserves to be held by the Charity should be sufficient to cover between nine and twelve months of budgeted forecast expenditure.

Whilst the current level of income generated may prove sufficient to meet identified requirements, it is the Trustees' view that there should be sufficient free reserves available to provide financial flexibility, having regard to known and anticipated future expenditure and to provide contingency funding to meet any shortfall in income generation and/or any unplanned emergency expenditure which may be required.

The policy of the Trustees, therefore, is to closely monitor the financial and operational activities of the Charity and to continue to maintain free reserves within the parameters identified above.

Pensions

The charity will match employee contributions up to 7% of qualifying earnings to the government workplace scheme – NEST.

Investment Policy

The Trustee Board regularly monitors cash and investments against objectives and risk profile. The investment policy is reviewed annually, and recommendations made to Trustees. Day to day investment management is delegated to an authorized, professional investment advisor, regulated by the FCA.

Our investment policy aims to produce the best financial return within an acceptable level of risk. The investment objective for the long-term reserves is to generate a return in excess of inflation over the long term but also to be available at short notice to support the on going activities of Leukaemia Care.

The investment objective for the short-term reserves is to preserve the capital value with a minimum level of risk. Assets should be readily available to meet unanticipated cash flow requirements.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Our future plans for 2021 to 2023

We continue to work towards addressing the recommendations in our “Living with Leukaemia” reports published in September 2017 and 2018 by Leukaemia Care and regularly updating those, to ensure we and our external advocacy work remain evidence based. Alongside these we collect feedback from people using our services and frequently consult our medical and patient advisory panels.

We intend to continue to focus on leukaemia and associated blood cancers (including MDS and MPNs) and to signpost individuals to our fellow blood cancer charities as appropriate. We will continue to identify areas of collaboration through charity coalitions and individual partnerships.

We will also look to ensure that our services are diverse and accessible to all, considering factors such as: (1) different barriers to accessing information and support; (2) how appropriate they are based on age, gender, ethnicity, sexual orientation, religion and disability; and (3) how representative they are of the world around us, e.g., producing a diverse range of patient stories. This is an ongoing task, which will require us to improve our data collection and impact reporting to address this going forward.

With changes to the fundraising methods available to us, we have been required to adapt our services accordingly. The most notable is the ongoing impact of changes to the London Marathon, which equate to a total reduction in gross income of £836,182 compared to previous projections over the 3-year plan period.

While we rebuild our fundraising over time, we propose to part fund expenditure with investment from reserves of £392,112 over the period of the strategic plan. We expect fundraising to continue to be more challenging for the foreseeable future and especially in 2021, so we have identified ways to ensure that our services could be scalable if our income were to significantly change. We will also continue to review government support schemes and make use of them as appropriate.

With the ongoing COVID-19 pandemic and the ‘clinically extremely vulnerable’ status of many of our beneficiaries, we have assumed most of our services will continue in a digital format until at least September 2021. When appropriate, many will return in a hybrid format, making use of the increased demand for virtual support alongside our traditional in-person services. This also has a significant financial benefit, enabling us to continue delivering a greater range of services than might otherwise be possible.

Plans for 2021 to 2023 include:

- Expanding our network of buddies to 120
- Holding a CLL and CML national conference in 2022 alongside webinars on key topics.
- To award £50,000 in financial hardship grants in 2021 to provide patients and their families a reprieve from worrying about extra costs resulting from a diagnosis expanding the criteria beyond travel grants.
- Launching a campaign on the financial impact of leukaemia in 2021.
- Continuing to run the Spot Leukaemia campaign all year, but with a particular focus on Blood Cancer Awareness Month in September.
- Run awareness webinars on acute and chronic leukaemia, in partnership with regional Royal College of General Practitioner faculties.
- To offer our nurse learning content on a subscription basis at £5 per month which means we will continue to be able offer high-quality online resources to nurses at a low cost.
- Create nurse led forums with regular feedback from nurses to inform content.
- Launching a free wills service

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Structure, governance and management

Constitution

This is the first annual report of Leukaemia Care. Leukaemia Care was registered as a private company limited by guarantee on 28 March 2019 (Registered No: 11911752). It was then registered with the Charity Commission on 13 June 2019 (Registered No: 1183890) and with the Scottish Charity Regulator on 9th December 2019 (Registered No: SCO49802).

On 31 December 2019, all the assets and liabilities of the Leukaemia Care Society (Registered Charity No: 259483) were transferred to Leukaemia Care. All the activities and services delivered by the Leukaemia Care Society continue to be delivered by Leukaemia Care and patients, their families and healthcare professionals should notice no difference.

An EGM was held on the 29 July 2020 at which a resolution was passed to wind up the Leukaemia Care Society following the transfer of all assets and liabilities on the 31 December 2019. The Society has now been wound up and removed from the charity register.

Trustees and their role

The trustees are responsible for the governance and strategy of the charity. A minimum of five and a maximum of twelve trustees in office at any one time are required by the Articles of Association. At the first AGM held on the 16 December 2020, all trustees had to step down and be re-elected. At each subsequent AGM one-third of the trustees, must retire from office but may stand for re-election. Trustee's term of office is not restricted, and they receive no remuneration for their duties. They may claim reasonable expenses incurred such as travel to trustee meetings. The trustees meet four times a year (currently by Zoom) and delegate day-to-day running of the charity to the senior management team. In 2020, three of the four Trustee meetings were held by Zoom including the AGM.

There were nine Trustees as of 31 December 2020 who together bring a balanced mix of skills in governance, finance, business, healthcare (both primary and secondary) and administration to the Board. Almost half of our Board are patients and one third are medical professionals. Two new Trustees were appointed during the period of this report: Dharmesh Mehta and Robert Heppell.

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr C. R. G. Matthews Maxwell (Chair)	
Mr Albert Podesta (Vice-chair)	(Resigned 31 March 2020)
Mrs Wendy Davies (Treasurer)	
Mr Kristian Griffin	(Resigned 29 July 2020)
Dr Emmanouil Nikolousis	
Mr Matthew Fowler	(Resigned 17 May 2021)
Mrs Elizabeth Wilson (Vice Chair)	(Appointed 1 April 2020)
Dr B Compitus	(Resigned 15 June 2021)
Ms K Stallard	
Mr R Heppell	(Appointed 16 December 2020)
Mr D Mehta	(Appointed 16 December 2020)

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Recruitment, induction and training of Trustees

The Chair with support from their fellow Trustees and the CEO, identify the skills and insight required on the board to deliver the charity's strategy. A volunteer job specification is drafted and approved before being advertised as widely as possible. This includes Leukaemia Care's social media outlets, online recruitment sites, specialist publications targeting for example healthcare professionals as well as a direct approach to individuals identified as having the appropriate skill sets. Potential applicants are invited to submit a CV and if shortlisted for interview, will be interviewed by the Chair and another trustee. Successful applicants will be co-opted as trustees until their formal election at the next annual general meeting.

On appointment, the new Trustees attend an induction at our offices in Worcester (Government restrictions permitting during the pandemic) with the executive team and identify areas in which they may wish to take a special interest. They are provided with an induction pack including a copy of the constitution, recent trustee board minutes, accounts, financial reports, the charity's strategy as well as helpful publications such as the Charity Commissions "The essential trustee".

All Trustees are encouraged to attend Leukaemia Care's webinars for further insight into the challenges facing patients, their loved ones and the healthcare professionals that look after them, and how Leukaemia Care is addressing them.

Our approach to fundraising

Leukaemia Care is registered with the Fundraising Regulator and as such agrees that when fundraising will do so in accordance with the Fundraising Promise and such of the Code of Fundraising Practice as applies to our fundraising methods. We agree to promote the Fundraising Promise (<https://www.fundraisingregulator.org.uk/>) and to include the Registration Badge on our fundraising materials where practical.

We are committed to protecting vulnerable people and others from unreasonable intrusion on a person's privacy, unreasonably persistent approaches or undue pressure to give in the course of or in connection with fundraising for Leukaemia Care. As a result, the charity is signed up to receive suppressions under the Fundraising Preference Service and will actively promote this service to anyone enquiring directly to the charity about concerns with our fundraising ask.

In 2020, the charity received no suppression requests through the Fundraising Preference Service.

Leukaemia Care received 17 complaints relating to the discontinued charity bags: five regarding unwanted bags, seven regarding fly-tipping of bags and five covering a variety of other queries. All were reported to East London Textiles Limited who until September 2019 were contracted to deliver and collect charity textile recycling bags on our behalf.

Our complaints procedure can be found on our website <https://www.leukaemiacare.org.uk/about-us/>

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Senior management team

The Trustees delegate day-to-day operations of the charity to the executive team. In October, we welcomed Zack Pemberton-Whiteley as our new CEO and bid a fond farewell to Peter Mondon who retired after many years of serving the charity. Zack joined Leukaemia Care in 2014 as a Campaigns and Advocacy Officer and swiftly grew our advocacy, policy and campaigning functions allowing Leukaemia Care to play an active part in national and international patient coalitions. He launched our annual SpotLeukaemia campaign and prior to his appointment as CEO was Patient Advocacy Director at Leukaemia Care.

Chief Executive Officer	Peter Mondon (retired 31 December 2020)
Chief Executive Officer	Zack Pemberton-Whiteley (appointed 1 October 2020)
Chief Operating Officer and Deputy CEO	Monica Izmajlowic
Communications and Fundraising Director	Nicole Scully

Our Patrons

We are very grateful for the warm support of our patrons, Lady Penny Mountbatten and Beverley Worboys.

Our President and Vice-Presidents

Our Vice Presidents ably led by Dr Taylor represent our history as well as taking part in activities such as chairing our conferences, contributing via our medical advisory panels, raising awareness of leukaemia and fundraising.

President	Dr Richard Taylor
Vice Presidents	Ms. Sue Merchant
	Professor Claire Harrison
	Dr Robert Marcus
	Professor Andrew Pettitt
	Dr Noel E M Harker
	Professor Antonio Pagliuca
	Ms Sheila Hegarty
	Mr Jason Eliadis
	Mr Roland Maturi
	Mr Christopher Matthews-Maxwell
	Mr Peter Mondon
	Mr Anthony Gavin
	Mr Albert Podesta

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

Medical advisory panels

Our medical advisory panel together with our patient panel provide insight into our strategy development, as well as assisting the charity with identifying further opportunities to support patients and their loved ones. We are grateful for their feedback and wish to thank them for their time.

Acute lymphocytic leukaemia panel

Prof. David Marks
Prof. Adele Fielding
Dr. Anthony Moorman
Prof. Oliver Ottmann
Dr. Nick Morley
Dr. Sara Ghorashian
Dr. Deborah Yallop
Prof. Ajay Vora

Acute myeloid leukaemia panel

Dr. Manos Nikolousis
Prof. Mary Frances McMullin
Dr. Sahra Ali
Dr. Steve Knapper
Dr. Panagotis Kottaridis
Prof. Rachael Hough (SCT adolescent leukaemia)
Dr. David Taussig
Dr. Priyanka Mehta (AML & CML)
Dr. Panagiotis Kottaridis
Prof. Antonio Pagluica

Chronic lymphocytic leukaemia panel

Assoc. Prof. Anna Schuh
Dr. Ben Kennedy
Prof. Chris Fegan
Prof. Guy Pratt
Assoc. Prof. Francesco Forconi
Prof. Adrian Bloor,
Dr. Shankara Paneesha,
Dr. Alison McCaig,
Prof. George Follows,
Dr. Nilima Parry-Jones,
Dr. Piers Patten,
Dr. Chris Fox,
Dr. Renata Walewska,
Prof. Peter Hillmen,
Prof. John Gribben
Dr Sunil Lyengar

Chronic myeloid leukaemia panel

Dr. Dragana Milojkovic
Prof. Nick Cross
Prof. Jane Apperley
Prof. Stephen O'Brien
Prof. Mhairi Copeland
Prof. Adam Mead
Dr Jonathan Kell

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Other blood cancers panel

Prof. Claire Harrison (MPN)
Dr. Claire Dearden (HCL)
Dr. Sally Killick (MDS)
Dr. Robert Marcus (Lymphoma)
Simon Cheeseman (Pharmacist)
Prof. Judith Marsh (Aplastic anaemia, MDS)
Dr. Richard Kelly (Aplastic anaemia, MDS)
Prof David Bowen (MDS)
Dr Dima El-Shakari (LGLL, ALL, CLL)

GP advisory Panel

Dr. Rebecca Chellaswamy
Dr. Ruth Corbally
Dr. Elaine Hampton
Dr. Tom Kneale
Dr. Anish Kotecha
Dr. Lily Lamb
Dr. Rachael Marchant
Dr. Richard Roope
Dr. Lance Saker
Dr Sarah Smith (Searle)
Dr. Neil Smith
Dr. Sarah Taylor
Prof. David Weller

Nurse advisory panel

Sarah Blakey
Sarah Watmough
Jacqueline Stones
Joanna Stokes
Roxanne Spencer
Alison Pugh
Phyllis Paterson
Lianne Palmer
Aileen Nield
Klara Matulay
Laura Ledger
Joanna Large
Catherine Langton
Catherine Kunatsa
Helen Knight
Caroline Kerr
Michelle Kenyon
Tracy Gunter
Catherine Griffiths
Kirsty Crozier
Marife Colis
Matthew Fowler

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

Remuneration policy

Leukaemia Care is committed to paying our staff fairly and in a way to attract and retain the skills needed to deliver our vision and mission effectively.

When setting salaries for new roles or reviewing salaries for existing roles, we consider a range of factors. Leukaemia Care is committed to avoiding discrimination, including but not limited to the grounds of protected characteristics as set out in the Equality Act 2010.

When drafting this policy, Leukaemia Care was influenced by the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration).

The Board of Trustees are responsible for setting remuneration levels for the senior management team. This is currently identified as the CEO, COO and Communications and Fundraising Director. The CEO has the authority to agree salaries for all employees outside of the senior management team within the guidelines of this policy.

Leukaemia Care upholds a policy that the full-time equivalent ratio for remuneration between its highest paid member of staff and the median salary level will not exceed 3:1, and that remuneration will always meet all national pay standards, ensuring all staff are provided with a living wage.

Salaries are reviewed annually in March/April following annual appraisals and take effect from the January before. Staff are advised of any changes in writing stating the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health.

When setting remuneration levels for job roles within Leukaemia Care, we consider the following factors:

- Mission and strategic aims of the charity and its general day to day needs.
- Consistency of equivalent roles across the charity and how any decision might impact on the overall remuneration policy.
- Skills, experience, expertise, and competencies, and any significant changes in job descriptions or duties.
- Current strategic business plan and how this might affect current and/or future needs.
- Leukaemia Care's financial ability to pay.
- Available information on charitable sector pay levels, alongside that of other sectors.
- Available information on regional pay levels
- The nature of the wider employment offer the charity can make where pay is only part of the package and can include opportunities for personal development.
- The charity's track record in recruiting and retaining high-performing staff.
- The potential impact of any decision on the charity's reputation with beneficiaries, donors and the wider public.

Leukaemia Care is committed to transparency in pay and publishes its salary banding on all job descriptions. Progression within a band is dependent on performance assessed at the annual appraisal. Change to a different band requires a significant change in job description reflective of the responsibilities of that band. All salary changes must be approved in advance by the CEO.

As part of our commitment to transparency, information regarding the salary bandings will be made available to all Leukaemia Care staff. The salary bands apply to all roles, unless identified as requiring specific professional qualifications that fall outside this banding. Identified roles may follow other scales, such as the NHS salary scale.

LEUKAEMIA CARE

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

This includes a proposal to increase staff salaries each year in line with the cost of living (capped within the above bandings). Staff are also eligible for performance related reviews. All salary increases are capped within the bandings.

The remuneration policy is reviewed annually by Trustees, normally at their meeting in October.

Influenced by the 2014 NCVO inquiry referred to above, the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the charity's remuneration policy and approach to senior management pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to the Senior Management Team, in line with the accounting Statement of Recommended Practice 2019 for charities. Given the charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual salary of any individual member of staff, including that of the senior management team, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements). Staff/ pension costs: total organisational staff costs in 2020 were £720,136 (previous year: £493,900). Overall, our staff costs as a proportion of overall expenditure were 65% for 2020 an increase from 43% in 2019.

Related parties

The only related parties are the Trustees and those individuals connected with them including family members, business associates and other charities in which they are involved. Please refer to note 12 in the financial statements for detail.

Auditor

Kendall Wadley LLP were appointed first auditors to the charitable company. In accordance with the company's articles, a resolution proposing that Kendall Wadley LLP be reappointed as auditor of the company will be put at a General Meeting.

Disclosure of information to auditor

Each of the Trustees has confirmed that there is no information of which they are aware which is relevant to the audit, but of which the auditor is unaware. They have further confirmed that they have taken appropriate steps to identify such relevant information and to establish that the auditor is aware of such information.

The Trustees' report was approved by the Board of Trustees.

DocuSigned by:

Chris Matthews-Maxwell

6CF4719F0E4E433...

Mr C. R. G. Matthews Maxwell (Chair)

Trustee

Dated: 28 July 2021

LEUKAEMIA CARE

STATEMENT OF TRUSTEES' RESPONSIBILITIES

FOR THE YEAR ENDED 31 DECEMBER 2020

The Trustees, who are also the directors of Leukaemia Care for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF LEUKAEMIA CARE

Opinion

We have audited the financial statements of Leukaemia Care (the 'Charity') for the year ended 31 December 2020 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2020 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the Charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the Charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities and fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities including fraud and non-compliance with laws and regulations was as follows:

- an understanding of the risk assessment process (including the assessment of the risk of fraud) adopted by the Board is obtained and their attitude to risk ascertained
- an assessment of the susceptibility to material mis-statement of the financial statements as a result of management over-ride or fraud is made
- an review of the fundraising complaints register is undertaken and the matters arising assessed as to the existence of fraud and irregularities
- it is ensured that the engagement team have, collectively, the appropriate competence, capabilities and skills to be involved in the assignment, are fully briefed and understand the risks specific to the company

LEUKAEMIA CARE

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF LEUKAEMIA CARE

Audit response to risks identified

- processes to test the outcomes of our assessment include, a review of Board minutes, analytical review, the relevance and accuracy of significant accounting estimates, substantive testing of significant transactions, work to identify unusual or unexpected accounting entries including the testing of journal entries, information disclosed in the financial statements is traced to supporting documentation. In all instances it is acknowledged that material mis-statements that arise from fraud may involve deliberate concealment or collusion and are, therefore, by their very nature harder to detect than those arising from error.


- it is established if there have been any instances of non-compliance with applicable laws and regulations, where there are such breaches, a full understanding, including gathering of relevant documentation appertaining to the event is obtained and assessed

It should be noted that Auditing standards limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with part 4 of the Charities (Accounts and Reports) Regulations 2008 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

DocuSigned by:

058A9BD1D0D34B3...

Elizabeth Needham ACA CTA (VAT) (Senior Statutory Auditor)
for and on behalf of Kendall Wadley LLP

28 July 2021

Chartered Accountants
Statutory Auditor

Granta Lodge
71 Graham Road
Malvern
Worcestershire
WR14 2JS

Kendall Wadley LLP is eligible for appointment as auditor of the Charity by virtue of its eligibility for appointment as auditor of a company under of section 1212 of the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2020

Current financial year

	Notes	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Total 2019 £
<u>Income and endowments from:</u>					
Donations and legacies	3	615,967	148,723	764,690	698,510
Fundraising income	4	330,142	-	330,142	507,979
Investments	5	37,808	-	37,808	28,662
Other income	6	52,436	-	52,436	815
Total income		1,036,353	148,723	1,185,076	1,235,966
<u>Expenditure on:</u>					
Raising funds	7	277,077	-	277,077	292,494
Charitable activities	8	700,320	146,577	846,897	856,041
Total resources expended		977,397	146,577	1,123,974	1,148,535
Net gains/(losses) on investments	14	13,691	-	13,691	18,098
Net incoming resources		72,647	2,146	74,793	105,529
<u>Other recognised gains and losses</u>					
Revaluation of tangible fixed assets	16	12,640	-	12,640	9,480
Net movement in funds		85,287	2,146	87,433	115,009
Fund balances at 1 January 2020		2,841,960	45,785	2,887,745	2,772,736
Fund balances at 31 December 2020		2,927,247	47,931	2,975,178	2,887,745

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

STATEMENT OF FINANCIAL ACTIVITIES (CONTINUED) INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2020

Prior financial 9 month period

	Notes	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
<u>Income and endowments from:</u>				
Donations and legacies	3	438,745	259,765	698,510
Fundraising income	4	507,979	-	507,979
Investments	5	28,662	-	28,662
Other income	6	815	-	815
Total income		976,201	259,765	1,235,966
<u>Expenditure on:</u>				
Raising funds	7	292,494	-	292,494
Charitable activities	8	568,286	287,755	856,041
Total resources expended		860,780	287,755	1,148,535
Net gains/(losses) on investments	14	18,098	-	18,098
Net incoming resources		133,519	(27,990)	105,529
Other recognised gains and losses				
Revaluation of tangible fixed assets		9,480	-	9,480
Net movement in funds		142,999	(27,990)	115,009
Fund balances at 31 March 2019		2,698,961	73,775	2,772,736
Fund balances at 31 December 2019		2,841,960	45,785	2,887,745

The statement of financial activities includes all gains and losses recognised in the period.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

LEUKAEMIA CARE

BALANCE SHEET

AS AT 31 DECEMBER 2020

	Notes	2020		2019	
		£	£	£	£
Fixed assets					
Tangible assets	16		875,003		863,139
Investments	17		252,228		238,655
			1,127,231		1,101,794
Current assets					
Debtors	19	317,819		395,788	
Investments	20	400,000		600,000	
Cash at bank and in hand		1,205,514		909,841	
			1,923,333	1,905,629	
Creditors: amounts falling due within one year	21	(75,386)		(119,678)	
Net current assets			1,847,947	1,785,951	
Total assets less current liabilities			2,975,178	2,887,745	
Income funds					
Restricted funds	23		47,931		45,785
<u>Unrestricted funds</u>					
Designated funds	24	1,334,103		1,174,867	
General unrestricted funds		1,593,144		1,667,093	
			2,927,247	2,841,960	
			2,975,178	2,887,745	

The financial statements were approved by the Trustees on 28 July 2021

DocuSigned by:

Chris Matthews-Maxwell

Mr C. R. G. Matthews Maxwell (Chair)
Trustee

DocuSigned by:

Wendy Davies

Mrs Wendy Davies (Treasurer)
Trustee

Company Registration No. 11911752

LEUKAEMIA CARE

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	2020		2019	
		£	£	£	£
Cash flows from operating activities					
Cash generated from/(absorbed by) operations	27		84,650		(111,574)
Investing activities					
Purchase of tangible fixed assets		(26,904)		(7,855)	
Purchase of investments		(121,618)		(36,136)	
Proceeds on disposal of investments		125,988		32,699	
Other investment movements		(4,251)		3,499	
Investment income received		37,808		28,662	
Net cash generated from investing activities			11,023		20,869
Net cash used in financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			95,673		(90,705)
Cash and cash equivalents at beginning of year			1,509,841		1,600,546
Cash and cash equivalents at end of year			1,605,514		1,509,841
Relating to:					
Cash at bank and in hand			1,205,514		909,841
Short term deposits included in current asset investments			400,000		600,000

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

Charity information

Leukaemia Care is a private company limited by guarantee incorporated in England and Wales. The registered office is One Birch Court, Blackpole East, Worcester, WR3 8SG.

1.1 Accounting convention

The financial statements have been prepared in accordance with the Charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)". The Charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Basis of preparation and comparatives

The activities of the charity commenced on 1 January 2020 following the transfer of all assets, liabilities and activities from the unincorporated charity, Leukaemia Care Society (charity number 259483). In accordance with the provisions of the SORP and FRS102, the financial information is presented using the merger basis of accounting. Comparatives where shown relate to the activities undertaken by the former charity in the period 1 April 2019 to 31 December 2019 and are, therefore, not fully comparable.

1.3 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the Charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.4 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Designated funds comprise funds which have been set aside at the discretion of the Trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.5 Income

Income is recognised when the Charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the Charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies

(Continued)

Legacies are recognised on receipt or otherwise if the Charity has been notified of an impending distribution, the amount is known, and receipt is expected.

Event income is recognised as an incoming resource on receipt, as this is when it becomes measurable.

Investment income is included in the SOFA in the year in which it is receivable.

Voluntary income is recognised as an incoming resource when receivable, except insofar as when it is incapable of financial measurement.

Time spent by volunteers is recorded and valued as income at an hourly rate payable in the market place for the services provided. An equivalent amount is included as expenditure.

Government grants in connection with Covid-19 support are taken to the Statement of Financial Activities when receivable. For funds received under the Job Retention Scheme, the income is allocated to the respective activity areas in direct proportion to the staff cost to which the claim relates.

1.6 Expenditure

All expenditure is accounted for on an accruals basis, with the exception of expenditure directly attributable to forthcoming events. The income is recognised on receipt and so the expenditure is recognised at point of expense. Costs are allocated to a particular activity where the cost relates to that activity. Costs of generating funds comprise those costs directly attributable to raising funds through activities. Grants payable are recognised on an accruals basis. Salaries and central overhead costs are apportioned between costs of generating funds, charitable activities and governance costs based on estimate of staff time attributable to each.

1.7 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Freehold buildings	over 50 years
Computers and other equipment	over 3 or 4 years
Fixtures and fittings	over 10 years

Freehold land is not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

The charity has no specific value above which it capitalises assets. Assets are capitalised when they are held for long term use.

1.8 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies (Continued)

1.9 Impairment of fixed assets

At each reporting end date, the Charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.10 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.11 Financial instruments

The Charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Charity's balance sheet when the Charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

1.12 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the Charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

1 Accounting policies (Continued)

2 Critical accounting estimates and judgements

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

As described above, the trustees annually exercise judgement through consideration of the carrying value of the freehold buildings held by the charity. Adjustments are made through the Statement of Financial Activities for changes in value determined by that review process.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total	Unrestricted funds	Restricted funds	Total
	2020 £	2020 £	2020 £	2019 £	2019 £	2019 £
Donations and gifts	227,358	28,723	256,081	138,176	32,265	170,441
Legacies receivable	286,497	-	286,497	192,024	-	192,024
Corporate grants and donations	70,043	120,000	190,043	59,241	227,500	286,741
Donated goods and services	32,069	-	32,069	49,304	-	49,304
	<u>615,967</u>	<u>148,723</u>	<u>764,690</u>	<u>438,745</u>	<u>259,765</u>	<u>698,510</u>

4 Fundraising income

	Unrestricted funds	Unrestricted funds
	2020 £	2019 £
Fundraising events - all unrestricted	<u>330,142</u>	<u>507,979</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

5 Investments

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Rental income	25,900	17,500
Investment income	1,667	1,219
Interest receivable	10,241	9,943
	<u>37,808</u>	<u>28,662</u>
	<u><u>37,808</u></u>	<u><u>28,662</u></u>

6 Other income

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
Government Grants	51,735	-
Solar panels	701	815
	<u>52,436</u>	<u>815</u>
	<u><u>52,436</u></u>	<u><u>815</u></u>

The Government Grant is in relation to the Job Retention Scheme.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

7 Raising funds

	Unrestricted funds	Unrestricted funds
	2020	2019
	£	£
<u>Fundraising and publicity</u>		
Staging fundraising events	13,518	72,419
Advertising	4,107	18,472
Other fundraising costs	29,606	25,936
Staff costs	196,605	145,395
Depreciation and impairment	1,921	1,058
Investment management fees	1,785	1,280
Support costs (see note 10)	24,076	22,255
Governance costs (see note 10)	5,459	5,679
	<u>277,077</u>	<u>292,494</u>

The above expenditure relates to unrestricted fundraising.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

8 Charitable activities

	2020 £	2019 £
Staff costs	506,336	331,310
Depreciation and impairment	25,763	16,709
Patient Services costs	38,768	24,009
Conferences	5,692	37,758
Help Line costs	4,341	14,348
Leukaemia Matters/ Nursing Matters	11,091	19,541
Campaign costs	10,798	107,549
Other charitable activities	689	38,265
Nurse e-learning tool	22,342	27,069
Donated Help Line services	32,069	49,304
GP's e-learning tool	31,443	33,879
Other grants	50,000	50,000
Database costs	4,335	4,048
Patient Advocacy	1,257	-
Website costs	14,940	-
	<u>759,864</u>	<u>753,789</u>
Grant funding of activities (see note 9)	921	19,880
Share of support costs (see note 10)	73,374	69,123
Share of governance costs (see note 10)	12,738	13,249
	<u>846,897</u>	<u>856,041</u>
Analysis by fund		
Unrestricted funds	700,320	568,286
Restricted funds	146,577	287,755
	<u>846,897</u>	<u>856,041</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

9 Grants payable

Grants of £921 (Dec 2019 - £19,880) were paid to individuals, being bursaries to nurses as provided for in designated funds. Further grants of £50,000 (Dec 2019 - £50,000) were awarded to other individuals as part of the Hospital Travel programme.

10 Support costs

	Support costs	Governance costs	2020	Support costs	Governance costs	2019
	£	£	£	£	£	£
Staff costs	17,195	-	17,195	17,195	-	17,195
Other staff costs	10,278	-	10,278	3,172	-	3,172
Rent, rates and insurance	7,424	-	7,424	5,744	-	5,744
Heat and light	6,601	-	6,601	7,182	-	7,182
Repairs and renewals	7,878	-	7,878	3,973	-	3,973
Printing, postage and stationery	7,261	-	7,261	11,218	-	11,218
Telephone	10,105	-	10,105	3,344	-	3,344
Motor and other travel	6,538	-	6,538	8,157	-	8,157
Subscriptions	2,149	-	2,149	2,930	-	2,930
Other office costs	14,146	-	14,146	7,701	-	7,701
Website costs	-	-	-	15,166	-	15,166
Bank charges	2,085	-	2,085	421	-	421
Sundry Expenses	5,790	-	5,790	5,175	-	5,175
Audit fees	-	4,820	4,820	-	2,750	2,750
Legal and professional	-	10,674	10,674	-	15,055	15,055
Trustee and meeting expenses	-	2,703	2,703	-	1,123	1,123
	<u>97,450</u>	<u>18,197</u>	<u>115,647</u>	<u>91,378</u>	<u>18,928</u>	<u>110,306</u>
Analysed between						
Fundraising	24,076	5,459	29,535	22,255	5,679	27,934
Charitable activities	73,374	12,738	86,112	69,123	13,249	82,372
	<u>97,450</u>	<u>18,197</u>	<u>115,647</u>	<u>91,378</u>	<u>18,928</u>	<u>110,306</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

11 Auditor's remuneration

The analysis of auditor's remuneration is as follows:

Fees payable	2020	2019
	£	£
Audit of the annual accounts	4,820	2,750
	<u> </u>	<u> </u>

12 Trustees

The Charity reimburses expenses to Trustees and management committee members for travel, subsistence and telephone relating to charity business. The costs reimbursed to 3 (Dec 2019 :2) trustees for the current year were £2,619 (Dec 2019: £1,785).

None of the Trustees (or any persons connected with them) received any remuneration during the year.

The charity utilises the services of CK Chartered Accountants to prepare the payroll, W Davies, trustee, is a partner in this firm. The services are provided on an arms length basis and the amount paid during the year amounted to £1,881 (Dec 2019: £1,222).

All trustees are covered by an indemnity insurance policy costing £611 (2019: £750)

13 Employees

The average monthly number of employees during the year was:

	2020	2019
	Number	Number
Training and provision of care	19	16
Fundraising and publicity	9	8
Accounts and administration	4	4
	<u> </u>	<u> </u>
Total	32	28
	<u> </u>	<u> </u>

Employment costs

	2020	2019
	£	£
Wages and salaries	648,243	431,566
Social security costs	48,755	42,334
Other pension costs	23,138	20,000
	<u> </u>	<u> </u>
	720,136	493,900
	<u> </u>	<u> </u>

The remuneration of key management personnel through payroll and other fees is £162,544 (2019: £168,395).

There were no employees whose annual remuneration was £60,000 or more.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

14 Net gains on investments

	2020 £	2019 £
Revaluation of investments	6,161	14,163
Gains on sale of investments	7,530	3,935
	<u>13,691</u>	<u>18,098</u>

15 Taxation

There is no taxation payable during the year as the activities undertaken by Leukaemia Care fall within the charitable objectives of the charity.

16 Tangible fixed assets

	Freehold buildings £	Computers and other equipment £	Fixtures and fittings £	Total £
Cost				
At 1 January 2020	842,599	205,371	14,656	1,062,626
Additions	-	26,904	-	26,904
	<u>842,599</u>	<u>232,275</u>	<u>14,656</u>	<u>1,089,530</u>
Depreciation and impairment				
At 1 January 2020	-	191,497	7,987	199,484
Depreciation charged in the year	12,640	13,577	1,466	27,683
Revaluation	(12,640)	-	-	(12,640)
	<u>-</u>	<u>205,074</u>	<u>9,453</u>	<u>214,527</u>
Carrying amount				
At 31 December 2020	<u>842,599</u>	<u>27,201</u>	<u>5,203</u>	<u>875,003</u>
At 31 December 2019	<u>842,599</u>	<u>13,872</u>	<u>6,668</u>	<u>863,139</u>

The trustees consider that the value of the freehold property is not materially different from original cost and the computed depreciation charge for the year is accordingly reversed.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

17 Fixed asset investments

	Listed investments £	Cash in portfolio	Total £
Cost or valuation			
At 1 January 2020	236,575	2,080	238,655
Additions	121,618	(121,618)	-
Valuation changes	6,161	-	6,161
Other cash movements	(29)	(89)	(118)
Profit on disposal	7,530	-	7,530
Disposals	(126,032)	126,032	-
	<u>245,823</u>	<u>6,405</u>	<u>252,228</u>
Carrying amount			
At 31 December 2020	<u>245,823</u>	<u>6,405</u>	<u>252,228</u>
At 31 December 2019	<u>236,575</u>	<u>2,080</u>	<u>238,655</u>

18 Financial instruments

	2020 £	2019 £
Carrying amount of financial assets		
Instruments measured at fair value through profit or loss	<u>245,823</u>	<u>236,575</u>

19 Debtors

	2020 £	2019 £
Amounts falling due within one year:		
Trade debtors	9,839	91,954
Prepayments and accrued income	307,980	303,834
	<u>317,819</u>	<u>395,788</u>

20 Current asset investments

	2020 £	2019 £
Term deposits	<u>400,000</u>	<u>600,000</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

21 Creditors: amounts falling due within one year

	2020 £	2019 £
Other taxation and social security	13,057	13,487
Trade creditors	13,497	8,951
Other creditors	-	21,125
Accruals and deferred income	48,832	76,115
	<u>75,386</u>	<u>119,678</u>

22 Retirement benefit schemes

Defined contribution schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £23,138 (2019 - £20,000).

23 Restricted funds

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			Balance at 31 December 2020 £
	Balance at 1 April 2019 £	Incoming resources £	Resources expended £	Balance at 1 January 2020 £	Incoming resources £	Resources expended £	
The Lily Blaen Hope Fund	31,665	-	(1,400)	30,265	-	(5,837)	24,428
Information Booklets	-	27,628	(27,628)	-	32,400	(32,400)	-
GP e- learning Tool Nurse Advisor	-	33,924	(33,924)	-	5,935	(5,935)	-
Student/ Education Worcester Support Group	7,117	13,694	(20,811)	-	29,125	(29,125)	-
Glasgow Area	5,000	-	-	5,000	-	-	5,000
Kay Kendall Support Group West Midlands	420	-	(169)	251	-	-	251
Support Group - Durham	-	2,500	(1,175)	1,325	1,900	(3,225)	-
	6,198	-	(4,342)	1,856	-	(1,763)	93
	100	-	(75)	25	-	(25)	-
	324	-	(292)	32	-	(32)	-

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

23 Restricted funds	(Continued)						
Support Group - Taunton	-	500	(217)	283	-	(16)	267
Support Group - Scotland	-	7,000	(252)	6,748	-	(276)	6,472
Counselling Fund	-	7,650	(7,650)	-	5,440	(5,440)	-
Travel Grant	-	15,000	(15,000)	-	47,600	(47,600)	-
Support Group - Glasgow & Aberdeen	-	-	-	-	2,000	-	2,000
Support Group - South Shields	-	-	-	-	1,000	-	1,000
Support Group - Leicestershire	-	-	-	-	1,393	-	1,393
Patient Support - Worcestershire	-	-	-	-	2,500	(600)	1,900
Birmingham Patient Conference	-	-	-	-	500	-	500
Welfare & Advocacy Support	-	-	-	-	5,000	(4,373)	627
Belfast Hospital Support	-	-	-	-	2,000	-	2,000
Bristol Hospital Support	-	-	-	-	2,000	-	2,000
Staffing Costs	-	-	-	-	9,930	(9,930)	-
Nurse Conferences	852	4,955	(5,807)	-	-	-	-
Conferences	-	20,826	(20,826)	-	-	-	-
Care Helpline Costs	-	7,780	(7,780)	-	-	-	-
Support Groups	-	23,644	(23,644)	-	-	-	-
Nursing Matters	177	8,231	(8,408)	-	-	-	-
Ward Support	-	-	-	-	-	-	-
Goodhope	-	1,500	(1,500)	-	-	-	-
Nurse e-learning	11,281	15,788	(27,069)	-	-	-	-
Buddy Scheme	5,868	3,350	(9,218)	-	-	-	-

LEUKAEMIA CARE**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**
FOR THE YEAR ENDED 31 DECEMBER 2020**23 Restricted funds (Continued)**

P&C Conf - Cardiff	-	2,000	(2,000)	-	-	-	-
Support Families with children	4,400	-	(4,400)	-	-	-	-
Videos	-	57,500	(57,500)	-	-	-	-
Support Group - Cwbran	373	-	(373)	-	-	-	-
Radio 4 Appeal	-	6,295	(6,295)	-	-	-	-
	<u>73,775</u>	<u>259,765</u>	<u>(287,755)</u>	<u>45,785</u>	<u>148,723</u>	<u>(146,577)</u>	<u>47,931</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

23 Restricted funds

(Continued)

The Lily Blaen Hope Fund: this represents a legacy that was received to be used for activities in Scotland.

Information booklets: funds received to assist in the production of information booklets.

GP e-learning tool: this represents income received specifically for the GP's e-learning tool.

Nurse Advisor - in support of the Nurse Advisor services.

Student/Education - to raise awareness.

Worcester Support Group - to facilitate activities for the group.

Glasgow Area - funds to support services in the Glasgow area.

Kay Kendall - grant towards non-staff costs of helpline services

Support Group West Midlands - to facilitate activities for support groups in the area

Support Group Durham - to facilitate activities for the group.

Support Group Taunton - to facilitate activities for the group.

Support Group Scotland - to facilitate activities for the groups in Scotland.

Counselling Fund - to support the activity of offering counselling to patients and family members affected by leukaemia

Travel Grant - to support people with the additional cost of travelling to hospital for treatment and monitoring appointments.

Support Group Glasgow & Aberdeen - to facilitate activities for support groups in these areas

Support Group South Shields - to facilitate activities for support groups in these areas

Support Group Leicestershire - to facilitate activities for support groups in these areas

Patient Support Worcestershire - to facilitate activities for support groups in this area

Birmingham Patient Conference - to assist with the cost of patient conference in Birmingham

Welfare & Advocacy Support - in support of advocacy and welfare advise

Belfast Hospital Support - in support of the costs in providing ward support

Bristol Hospital Support - in support of the costs in providing ward support

Staffing Costs - to support the employment costs of the Welfare and Advocacy Officers

Nurse Conferences - to support with the costs of the Leukaemia Care run nurse conferences

Conferences - grants in support of conferences held in the year.

Care Helpline costs: this represents income received specifically to meet the costs of the Care line.

Support Groups - to facilitate activities for local support groups

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

23 Restricted funds

(Continued)

Nursing matters and nurse e-learning - funds to support the advancement of knowledge in the nursing profession.

Ward Support Goodhope - in support of the costs in providing ward support

Buddy Scheme - one to one support for patients with chronic lymphocytic leukaemia.

Patient Conference Cardiff - to assist with the cost of patient conference in Cardiff

Support families with children – this represents income received to specifically help children with Leukaemia

Videos - this represents income received specifically for the production of patient information videos

Support Group Cwbran - to facilitate activities for the group

Radio 4 Appeal - this represents donations from listeners to support and advise leukaemia patients as well help educate healthcare professionals about signs and symptoms of leukaemia.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

24 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

	Movement in funds							
	Balance at 1 April 2019	Resources expended	Transfers	Balance at 1 January 2020	Incoming resources	Resources expended	Transfers	Balance at 31 December 2020
	£	£	£	£	£	£	£	£
Fixed asset fund	863,572	-	(434)	863,138	11,862	-	3	875,003
Strategic implementation fund	634,308	(322,579)	-	311,729	547,661	(400,290)	-	459,100
	<u>1,497,880</u>	<u>(322,579)</u>	<u>(434)</u>	<u>1,174,867</u>	<u>559,523</u>	<u>(400,290)</u>	<u>3</u>	<u>1,334,103</u>

Fixed assets fund: The Trustees have agreed to assign all tangible fixed assets held with the exception of any which have restrictions imposed upon them to a general fixed asset designated fund. This was done to ensure that the Charity will have suitable levels of reserves to meet future depreciation costs relating to these fixed assets and to recognise the fact that future depreciation charges will not directly affect the net operating capital of the Charity.

Strategic Implementation Fund: funds to support the implementation of the three year strategy adopted by the Trustees on 28 November 2019.

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2020

25 Analysis of net assets between funds

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Unrestricted funds 2019 £	Restricted funds 2019 £	Total 2019 £
Fund balances at 31 December 2020 are represented by:						
Tangible assets	875,003	-	875,003	863,139	-	863,139
Investments	252,228	-	252,228	238,655	-	238,655
Current assets/ (liabilities)	1,800,016	47,931	1,847,947	1,740,166	45,785	1,785,951
	<u>2,927,247</u>	<u>47,931</u>	<u>2,975,178</u>	<u>2,841,960</u>	<u>45,785</u>	<u>2,887,745</u>

26 Operating lease commitments

At the reporting end date the Charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2020 £	2019 £
Within one year	1,325	3,766
Between two and five years	1,325	-
	<u>2,650</u>	<u>3,766</u>

LEUKAEMIA CARE

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2020

26 Operating lease commitments

(Continued)

Lessor

At the reporting end date the Charity had contracted with tenants for the following minimum lease payments:

	2020 £	2019 £
Within one year	12,950	25,900
Between two and five years	-	12,950
	<u>12,950</u>	<u>38,850</u>

27 Cash generated from operations

2020
£

2019
£

Surplus for the year	74,793	105,529
Adjustments for:		
Investment income recognised in statement of financial activities	(37,808)	(28,662)
Gain on disposal of investments	(7,530)	(3,935)
Fair value gains and losses on investments	(6,161)	(14,163)
Depreciation and impairment of tangible fixed assets	27,683	17,767
Movements in working capital:		
Decrease/(increase) in debtors	77,969	(232,016)
(Decrease)/increase in creditors	(44,296)	43,906
Cash generated from/(absorbed by) operations	<u>84,650</u>	<u>(111,574)</u>

28 Analysis of changes in net funds

The Charity had no debt during the year.